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Zusammenfassung	
Die  Herstellung  chiraler  Alkohole  als  Bausteine  für  die  Synthese  von  Pharmazeutika  und 
Feinchemikalien gewinnt an Bedeutung  in der  chemischen  Industrie. Biokatalytische Verfahren  zur 
Bereitstellung dieser Komponenten durch asymmetrische Reduktion von preiswerten Ketonen stellt 
eine  kompetitive  Syntheseroute  im  Hinblick  auf  Selektivität,  Produktivität,  Kosteneffizienz  und 
Nachhaltigkeit dar. Die Hauptherausforderungen zur Implementierung eines ökonomisch machbaren 
biokatalytischen  Prozesses  zur  Ketonreduktion  werden  hier  behandelt.  Einerseits  werden  die 
äußeren  Reaktionsbedingungen  so  verändert,  dass  die  Ressourcen  effizient  genutzt  werden  und 
hohe  Raum‐Zeit‐Ausbeuten  möglich  sind.  Andererseits  wird  das  Enzym,  welches  die  Reaktion 
katalysiert, mittels Proteinengineering so entwickelt, dass es den Prozesskenngrößen besser gerecht 
werden kann. 
Diese Thesis hat die Carbonylreduktase aus der Hefe Candida parapsilosis (CPCR2) zum Gegenstand, 
welche  in  der  Lage  ist  ein  breites  Spektrum  an  Ketonen  selektiv  zu  den  entsprechenden  chiralen 
Alkoholen  umzusetzen.  Zuallererst  musste  die  molekulare  Identität  der  CPCR2  geklärt  werden. 
Computergestützte  Modellierung  machte  die  Voraussage  von  Indikatorsubstraten  möglich,  die 
wiederum,  experimentell  verifiziert,  eine  Zuordnung  von  Sequenz und  Funktion  zweier  Isoenzyme 
(CPCR1 & CPCR2) ermöglichte. 
Die Verwendung von CPCR2  in einem neuartigen Reaktionskonzept  für die Produktion von chiralen 
Alkoholen  in  molaren  Mengen  durch  ein  apparativ  schlichtes  Verfahren  und  unkomplizierte 
Produktaufarbeitung wurde hier erstmals gezeigt. Die Entwicklung des sogenannten „Neat Substrate 
System“ oder „Reinsubstratsystem“, worin ausschließlich reine Substrate und der Ganzzellkatalysator 
verwendet werden, beinhaltete die Identifizierung der beeinflussenden Reaktionsparameter und der 
Optimierung. Zudem wurde dieses Konzept erweitert auf die Verwendung verschiedener Substrate, 
zwei  weiterer  Enzyme  zur  Ketonreduktion  und  eines  alternativen  Reaktionsmodus.  Das  „Neat 
Substrate  System“  ist  das  erste  Beispiel  für  eine  biokatalytische  Alkoholproduktion  in  einen 
Reaktionsmedium ohne jegliches zusätzliches Lösungsmittel. Die Vielseitigkeit und Effektivität dieses 
System, welches hier entwickelt wurde, macht eine breite Anwendung  in der organischen Synthese 
zur Herstellung chiraler Zwischenstufen möglich. 
Proteinengineering wurde  in den  letzten  Jahren  sehr erfolgreich verwendet um maßgeschneiderte 
Enzyme  für  industrielle  Prozesse  bereitzustellen.  Hierin  spielen  die  Verbesserung  von  Aktivität, 
Stabilität sowie Selektivität die Hauptrolle.  In dieser Thesis wird das Enzym CPCR2 zum ersten Mal 
einem  semi‐rationalen  Proteinengineering  unterzogen.  Die  Etablierung  eines  Proteinexpressions‐
verfahrens  sowie  Aktivitätstests  im  Microlitermassstab  sind  dafür  eine  Voraussetzung  um 
 
 
 
Mutantenbibliotheken  von  CPCR2  durchzumustern.  Die  zwei  Ziele  des  Engineering  waren  die 
Erweiterung  des  Substratspektrums,  sowie  die  Erhöhung  der  Enzmystabilität.  Ein  semi‐rationaler 
Ansatz führte dabei zu einer erheblichen Aktivitätssteigerung hinsichtlich der Umsetzung von methyl‐
substituierten Cyclohexanonen. Hierbei wurde eine CPCR2‐Variante  identifiziert mit einem Amino‐
säureaustausch an Position 119 von Leucin zu Methionin (CPCR2‐L119M), welche  im Vergleich zum 
Wildtyp eine siebenfache höhere Aktivität zu 2‐Methylcyclohexanon aufwies. Dieser experimentelle 
Befund  konnte  anhand  von  computergestützten  Simulationen  erklärt werden.  Für  CPCR2  konnte 
gezeigt werden, das strukturell konservative Austausche wohlmöglich besser geeignet sind um das 
Substratspektrum  zu  beeinflussen.  Die  Hypothese  liefert  einen  weiteren  Ansatzpunkt  für  die 
Interpretation von Struktur‐Funktions‐Beziehungen  in Enzymen und kann  zukünftige Strategien zur 
Erweiterung von Substratspektren voranbringen. 
Vorrausgehende  Untersuchungen  zur  Stabilität  von  CPCR2  zeigten  eine  starke  Inaktivierung  an 
wässrig‐organischen  Grenzflächen.  Für  den  Versuch  der  Enzymstabilisierung  durch  Protein‐
engineering  wurde  zuerst  ein  rein  rationaler  Ansatz  gewählt,  welcher  zu  der  Doppelmutante 
CPCR2‐A275N‐L276Q führte, die sowohl in Aktivität als auch in Stabilität verbessert war. Die Variante 
diente  als  Ausgangspunkt  für  eine  semi‐rationale  Optimierung  durch  einzelne  und  simultane 
Sättigungsmutagenese der Positionen 275 & 276. Die beste Variante CPCR2‐A275S‐L276Q zeigte eine 
Erhöhung der Aktivität um den Faktor 1,4, sowie eine Verbesserung der Thermoresistenz (ΔT50) um 
+5.2°C.  Zusätzlich  wurde  die  Grenzflächenstabilität  um  den  Faktor  1,6  erhöht.  Die  eingehende 
Analyse der Mutationen zeigte eine Kooperativität der Positionen 275 und 276, welche beide an der 
Interaktionsfläche  des  Dimers  bzw.  nahe  der  Bindungstasche  liegen.  Experimentelle  Daten  sowie 
computergestützte  Analysen  zeigten,  dass  die  Stabilisierung  hauptsächlich  durch  die  Position  275 
beeinflusst  wurde,  wohingegen  die  Aktivierung  maßgeblich  von  Position  276  verursacht  wurde. 
Strukturelle  Untersuchungen  eines  Homologiemodels  zeigten  zudem,  dass  die  stabilste 
Einzelmutante  CPCR2‐A275T  eine Wasserstoffbrücke  zwischen  den Monomeren  ausbildet, welche 
die erhöhte  Stabilität erklärt. Der Einfluss  von Position 276  konnte  insoweit  rationalisiert werden, 
dass  die Aminosäuren  an  dieser  Positionen  in  direktem  Kontakt  zum  Substratmolekül  stehen  und 
somit die Aktivität modulieren können. 
In dieser Arbeit wurde die Zuordnung von Sequenz zu Funktion für die Identifizierung von CPCR1 und 
CPCR2 erreicht. Des Weiteren wurde ein neuartiges Reaktionskonzept, das „Neat Substrate System“, 
entwickelt  und  erweitert  für  mögliche  breite  Anwendung.  Außerdem  wurden  mittels  Protein‐
engineering  Varianten  von  CPCR2  erzeugt  mit  erweitertem  Substratspektrum,  sowie  deutlich 
erhöhter Stabilität und Aktivität.   
  
 
Summary 
Biocatalytic manufacturing of chiral alcohols as building blocks for the synthesis of pharmaceuticals 
and fine chemicals is of growing relevance in the chemical industry. The biocatalytic route to provide 
these compounds by asymmetric reduction of cheap ketones constitutes a competitive synthesis 
route with respect to selectivity, productivity, cost-effectiveness and sustainability. Major challenges 
to establish economically feasible biocatalytic processes are addressed; on the one hand by reaction 
engineering facilitating efficient use of the resources and high space-time yields and on the other 
hand by protein engineering to supply appropriate enzymes to meet the process benchmarks. 
In this thesis, the characterization of a promising carbonyl reductase from the yeast Candida 
parapsilosis (CPCR2), which is able to selectively reduce various ketones to the corresponding 
alcohols, is presented. Molecular modeling permitted the prediction of indicator substrates and 
experimental verification enabled the assignment of sequence to function of two CPCR isoenzymes 
(CPCR1 & CPCR2). Applying CPCR2, a novel concept for producing chiral alcohols in molar amounts 
via an easy operation mode and straightforward work-up is introduced. Throughout the devolvement 
of this so-called “neat substrate system”, which is composed of pure substrates and the whole cell 
catalyst, the key reaction parameters were elucidated and optimized. Moreover, the concept was 
further expanded towards different substrates, other ketone reducing enzymes and alternative 
operation modes. The “neat substrate system” demonstrates the first example for efficient 
biocatalytic alcohol production in a reaction medium lacking any bulk solvent. The versatility and 
efficiency of this system, developed here, might leverage this technique to become widely applicable. 
Protein engineering has become a powerful tool for tailoring enzymes to meet certain requirements 
like increased activity, stability or selectivity. In this thesis, CPCR2 was subjected to semi-rational 
protein engineering for the first time. The establishment of an appropriate protein expression 
procedure and a NADH-depletion activity assay in microliter formate enabled screening of CPCR2 
variant libraries. The main engineering goals were the enlargement of the substrate spectrum and 
stabilization of the enzyme. 
A semi-rational approach led to substantial activity increase towards cyclohexanone substrates by 
exchange of leucine to methionine located in the substrate binding pocket (CPCR2-L119M). In 
particular, kcat for the reduction of 2-methyl cyclohexanone was increased more than 7-fold. The 
effect was explained on the molecular level by in silico substrate docking. The overall findings led to 
the assumption that more conservative amino acid substitutions might be more appropriate for 
altering the substrate scope of CPCR2. This may guide future strategies to modify the substrate 
acceptance of this enzyme class. 
  
 
Former studies on CPCR2 revealed severe inactivation at water-organic interfaces, which limits the 
application of the enzyme in biphasic systems. Previous attempts to stabilize the enzyme by rational 
protein engineering led to the double mutant CPCR2-(A275N, L276Q) showed increased stability as 
well as activity. This variant was adopted as a starting point for semi-rational optimization. 
Simultaneous site saturation and screening of these two positions revealed variants with improved 
activity and stability superior to the previous variant. The best variant found was 
CPCR2-(A275S, L276Q) exhibiting 1.4-fold higher activity, a ΔT50 of +5.2 °C in thermoresistance and 
1.6-fold increased interfacial stability. Analysis of the single mutations suggested cooperativity of the 
amino acids at position 275 and 276, which are located at the dimer interface and close to the 
binding pocket. Experimental data as well as computational analysis indicated a contribution to 
stability by position 275 and an impact on activity by position 276. Structural investigation of the 
model predicted the establishment of an inter-subunit hydrogen bond by threonine at position 275 
being responsible for stabilization and direct interactions of residue 276 with the substrate 
modulating activity. 
Taken together, a sequence to function assignment was achieved for identification of CPCR1 and 
CPCR2. A novel concept for biocatalytic alcohol manufacture, the “neat substrate system”, was 
developed and expanded to possible broad applications. CPCR2 was subjected to protein engineering 
yielding new variants with enlarged substrate scope, increased activity and stability.  
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1. General Introduction 
1.1. Biocatalysis in Organic Synthesis 
Biocatalysis is one of the main pillars of applied biotechnology, defined by the European Federation 
of Biotechnology as the “integration of natural sciences and engineering sciences in order to achieve 
the application of organisms, cells, parts thereof and molecular analogs for products and services”.[1] 
In this thesis, the focus is laid on biocatalysis with regard to application in white/industrial 
biotechnology to produce value-added compounds mainly applying biotransformation involving only 
one or few synthetic steps. 
1.1.1. Importance of Biocatalysis in Industry in the 21th Century 
Biocatalysis is used by mankind since 6000 years for preparation of food and drinks; at the outset 
without knowing about the microorganisms facilitating these useful conversions like ethanol 
production from sugars during brewing. Traditionally, biocatalysis played a crucial role in the food 
sector but started to gain significance around hundred years ago in other areas like the laundry, pulp 
and leather industry. Fundamental discoveries led to the understanding that microorganisms and the 
enzymes therein are the catalysts accelerating the chemical reactions. With the advent of 
recombinant DNA technology in the late 1980s´ as well as the advancements in protein chemistry 
and reaction engineering, biocatalysis became a valuable tool in organic synthesis. Some processes 
employing enzymes have been established in multi-ton scale e.g. for the production of sweeteners, 
vitamins, amino acids or acrylamide (see Table 1). The number of industrial processes with 
biocatalysis involved is rapidly increasing especially in the fields of biofuels, biomaterials and active 
pharmaceutical intermediates. 
Table 1 Selected large-scale biotransformations (not whole cells), adapted from 
[2]
. 
Scale (t a
-1
) Product Enzyme Application Company 
>1,000,000 high-fructose corn syrup glucose isomerase sweetener in drinks various 
>100,000 lactose-free milk lactase food & drinks various 
>10,000 acrylamide nitrilase polymer industry Nitto Co. 
>10,000 cocao butter lipase Food industry Fuji Oil 
 
In 2003, McKinsey & Co. predicted that by 2010, industrial biotechnology will account for 10 % of the 
sales within the chemical industry, amounting to 125 billion US$.[3] This value was almost met with 
121 billion US$ and sales are estimated to reach up to 675 billion US$ in 2020.[4] This development is 
also reflected by the doubling of biocatalytic processes implemented in industry, wherein 150 
processes were counted in 2005[5] and 300 processes are reported in 2010.[6] Biocatalysis is especially 
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suited for drug synthesis and in this multi-billion dollar market actually 10 % of the total drug 
synthesis depend on enzymatic steps as announced in 2009.[7] 
1.1.2. Advantages and Drawbacks of Biocatalysis 
Nowadays, not only economic drivers foster the substitution of established chemical processes but 
also political and ecologic issues are taken into account. At best, a process has to be efficient and 
sustainable at the same time and biocatalysis can contribute to this overall goal in a substantial 
manner due to its inherent characteristics. One development is the use of non-fossil carbon sources 
for the production of bulk chemicals and fuel components to be less dependent on the depleting oil 
sources. Especially the recycling of cheap waste material by biocatalysis lowers the cost of raw 
materials.[8] The application of bio-based starting material directly counteracts the use of toxic 
chemicals and reduces emission of greenhouse gases and waste water.[8] Another environmental 
aspect is that biocatalysts themselves are biodegradable.[9] 
Compared to classical chemical catalysis, biocatalysis usually operates at mild reaction conditions 
such as ambient pressure and temperature as well as mostly in aqueous buffer systems. These 
features increase the safety at the working place, decrease energy costs and unwanted side-
reactions.[9] Additionally, enzymes are very efficient catalyst accelerating reaction exceeding factor 
1015 at loads of usually 0.1–1 % and total turnover numbers up to 105.[9] 
A key feature of biocatalysis is its chemo-, regio- and stereoselectivity, which are usually superior to 
chemical catalysis. Especially in pharmaceutical industry enantiomeric purity of the products is most 
important and 80 % of all active components are chiral.[10] Biocatalysis, furthermore, provides 
excellent product qualities.[10-11] The innate chemoselectivity of enzymes makes the use of intensive 
protection-group chemistry obsolete, reducing the number of reaction steps and waste 
production.[11] 
Recent developments aim at the implementation of biocatalytic processes in multi-step reactions 
since enzymes are typically compatible and these arrangements enforce productivity and reduce 
inhibition phenomena.[8] Also combinations of chemo- and biocatalytic steps in one pot are 
established to increase yields and simplify the reaction sequences.[8, 12] 
Even though biocatalysis is endowed with several advantageous features compared to chemical 
catalysis the choice for a biocatalytic route in organic synthesis is often impaired. This is because 
many reservations are voiced including limited substrate specificity and general catalyst availability, 
instability and inhibition as well as low productivity and dependency on expensive cofactors.[2, 9] 
Furthermore, enzymes are most active in aqueous environments and water is in many cases the least 
suitable solvent or agent in organic chemistry since water is nucleophilic and acts as acid or base.[9] 
Also most organic compounds are only poorly soluble in water.[9] 
General Introduction 
 
3 
 
However, recent scientific developments in the field of protein engineering have facilitated the 
tailoring of enzyme properties towards specific process requirements. Many examples show the 
application of powerful techniques such as directed evolution, rational design and combinations 
thereof to provide suitable catalysts for industrial application.[6, 10, 12-13] Herein, substantial 
improvements in activity, selectivity and process stability have been achieved. Process engineering 
helped overcoming inactivation and inhibition phenomena by design of appropriate reactors or 
catalyst immobilization, which dramatically increased space-time yields and catalyst stability.[8] The 
dependence on expensive auxiliary compounds such as nicotinamide cofactor was tackled by 
recycling and is efficiently applied on industrial scale.[14] 
Current trends in biocatalysis are expected to emerge from the fields of metabolic engineering and 
synthetic biology. Metabolic engineering aims at optimization of enzymatic, transport and regulatory 
functions of a production microorganism to provide high value-added products from cheap feed 
stocks. In synthetic biology, for example, microorganisms with a minimal synthetic genome are 
generated with customized gene expression abilities for an application. 
1.1.3. Biocatalysis for the Production of Chiral Compounds 
In recent years, chiral chemicals for pharmaceuticals, agrochemicals and food ingredients are more 
and more manufactured via biocatalysis.[15] Most of the industrial relevant processes involve 
introduction of chiral centers to product molecules.[16] The importance of enantiopurity in this multi-
billion dollar market is further fueled by the Food & Drug Administration (FDA). Due to the critical 
role of enantiomeric purity of drugs in selectivity and toxicity, the FDA demands additional 
toxicological studies on all drug components that comprise more than 1 % of the total agent (docket 
No. 97D-0448).[2] Most important compounds are chiral alcohols, amine, carboxylic acids and 
epoxides.[13b] 
1.2. Chiral Alcohols through Biocatalysis 
1.2.1. Chemical versus Biocatalytic Synthesis of Chiral Alcohols 
Asymmetric reduction of simple prochiral ketones, such as 2-butanone or 3-butyn-2-one, to the 
corresponding chiral alcohols is still a lively research area. In 2001, the Nobel Prize in Chemistry was 
awarded for development of Rhodium/Ruthenium catalysts for this purpose to K. B. Sharpless, W. S. 
Knowles and R. Noyori. Industrial processes in ton scale have been established employing this type of 
catalysts.[10] 
The Rhodium/Ruthenium catalysts constitute a breakthrough in homogeneous catalysis towards 
chiral alcohols; however, the technology is hampered by the rather expensive, rare and toxic 
transition metals.[18] Additionally, the complex chiral ligands are difficult to produce and cannot be 
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reused. Furthermore, enantioselectivity of most chemical hydrogenation methods is only moderate 
for simple dialkyl ketones or diketones.[19] Progress was made by using organic H-donor instead of 
molecular hydrogen, since this is comparably expensive and explosive.[10] Chiral modified borane 
compounds can deliver a broad variety of enantiopure alcohols, but large amounts of borane are 
difficult to handle.[10] 
Nowadays classical chemical synthetic approaches are in competition with biocatalytic processes due 
to the numerous advantages of biocatalysis stated earlier. Especially in the field for the preparation 
of enantiopure alcohols, the selectivity of enzymes coupled with the benign reaction mode have the 
potential to outperform chemical catalysts.[2, 17] 
1.2.2. Biocatalytic Routes to Chiral Alcohols 
The demand for production processes of chiral alcohol is enormous, since in five years 57 patents 
have been filed using biocatalysis for this purpose.[16] Chiral alcohols can be accessed by different 
pathways using various precursor molecules and enzymes (see Figure 1). 
 
Figure 1 Examples for different biocatalytic routes for the production of chiral alcohols. The substrate 
structures are depicted, which result in chiral alcohols when transformed by the respective enzyme class (EC 
= Enzyme Commission number) indicated. Adapted from 
[20]
. 
 
Hydrolases (EC 3) play the most important role in industrial processes today.[21] Very prominent 
among these are lipases performing kinetic racemate resolution by stereoselective esterification and 
hydrolysis. Here, an acyl donor is connected to only one of the stereoisomers of the racemic alcohol. 
The ester and the remaining alcohol can be separated by distillation. The enantiopure esterified 
enantiomer can be recovered by ester hydrolysis. Furthermore, lipases offer a broad substrate 
spectrum, are commercially available and operate in organic solvents, which provides high solubility 
of organic substrate and product.[9] Additionally, other hydrolases such as phosphatases and 
sulfatases are described to yield chiral alcohols.[20] However, the maximum possible yield of kinetic 
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resolution is 50 % and enantiomeric excess of the product is reduced with conversion higher than 50 
%.[9] Recently, an interesting approach combining a lipase for racemate resolution and a Ruthenium 
catalyst for racemization of the unwanted enantiomer was realized.[22] 
Chiral hydroxyketones can be obtained by lyases (EC 4) such as benzaldehyde lyase, pyruvate 
decarboxylase and deoxyriboaldolase or hydroxylnitrile lyases.[20] In this reaction a new carbon-
carbon bond is established between two aldehydes and chiral hydroxyketones are produced. 
Among the oxidoreductases (EC 1), alcohol dehydrogenases (ADHs) or carbonyl reductases play the 
most important role. To access chiral alcohols asymmetric reduction of prochiral ketones to the 
corresponding alcohols is performed. The main advantage compared to kinetic resolution by lipases  
is that the theoretical yield can be 100 %. Furthermore, no auxiliary compounds (e.g. acyl donor) are 
required rendering this process efficient with regard to atom economy.[23] However, a major 
drawback is that ADHs almost exclusively depend on the expensive nicotinamide cofactor in 
stoichiometric amounts. The solution to this is cofactor recycling, which is outline in chapter 1.3.2. 
As ketone reduction is reversible, asymmetric oxidation of alcohols can also be used to kinetically 
resolve a racemic mixture but yields can again not exceed 50 %. Nevertheless, a combination of 
enzymes exhibiting different cofactor preference and opposite enantioselectivity was applied in a 
one-pot reaction to give 100 % enantiopure alcohol from the racemate.[24] Also stereoinversion was 
reported wherein microorganisms resolve racemic mixtures to only one enantiomer (see Figure 2).[9] 
Furthermore, ADHs are not as tolerant to organic solvents as lipases, but many of them are 
commercially available tendering the two possible stereoselectivities. 
 
Figure 2 Deracemization of secondary alcohol via microbial stereoinversion applying two enzymes of opposite 
enantioselectivity. Taken from 
[9]
. 
A second enzyme class performing oxidoreductions are monooxygenases, which are able to 
incorporate hydroxyl functions into non-activated alkyl chains yielding chiral alcohols.[25] However, 
larger scale applications of this enzyme class are lacking. 
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1.3. Asymmetric Reduction of Prochiral Ketones by Biocatalysis 
1.3.1. General Aspects 
The interconversion of ketones to the corresponding alcohols and vice versa is the most common 
redox reaction in organic chemistry.[18] Compared to the other biocatalytic methods to prepare chiral 
alcohols, asymmetric reduction of prochiral ketones with NAD(P)H-dependent alcohol 
dehydrogenases -also termed carbonyl reductases- (E.C. 1.1.1.1) is distinctly attractive. This is due to 
the cheap prochiral ketonic starting material and the theoretically yield of 100 % of enantiopure 
alcohol (see Scheme 1). The introduction of chirality in to non-chiral compounds is generally 
connected to a high increase of value. The high value-added product from asymmetric ketone 
reduction is the driving force for the development of new biocatalytic production processes. This 
technique is now considered as fully complementary to chemical methods for large-scale 
pharmaceutical manufacturing.[17] 
 
Scheme 1 Interconversion of a ketone to the corresponding alcohol with NAD(P)H as cofactor catalyzed by alcohol 
dehydrogenase (EC 1.1.1.1). R and R` indicate different substitutions of the molecule. The asterisk designates a chiral 
carbon atom.
 
Since the early days of biotechnology, whole cell microorganisms, such as Saccharomyces cerevisiae, 
were used to reduce carbonyl compounds enantioselectively in industrial scale due to the easy 
process handling, cheap raw materials and in vivo cofactor recycling.[10] However, an economic 
fermentation process usually requires substrate concentrations >30 g L-1 and easy product 
downstream processing, which is not always feasible.[10] 
Shortcomings in aqueous biocatalysis like low solubility of the organic substrate and product 
molecules are tackled by process engineering such as aqueous-organic two-phase setups, 
monophasic aqueous-organic mixtures or enzyme-membrane and packed-bed reactors.[16-17] Most 
importantly, these processes were proven to be scalable for industrial application.[13b] Recently, “one-
pot” syntheses of multi-step process involving biocatalytic asymmetric reduction were shown to 
work.[14b, 17] Such developments are desirable since time, effort and solvent can be saved. 
Oxidation of alcohols by ADHs is rare, since this destroys stereocenters and can easily be achieved by 
classical chemical methods. However, aldehydes are notoriously instable in conventional chemical 
oxidation conditions; hence, some biocatalytic methods have been developed to produce aldehydes 
from the corresponding primary alcohols.[26] 
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1.3.2. Cofactor Regeneration 
The economic drawback that costly nicotinamide cofactors (NAD(P)H) are needed in stoichiometric 
amount was overcome by several strategies to regenerate the cofactor in situ.[14b] Herein, two main 
approaches appear also in industrial scale, namely the substrate-coupled and the enzyme-coupled 
cofactor regeneration (see Figure 3). 
In the substrate-coupled approach, a single ADH oxidizes an auxiliary cheap alcohol (H-donor), mostly 
isopropanol, while reducing NAD(P)+ to NAD(P)H (see Figure 3, left).[18] The same ADH also carries out 
the stereoselective reduction reaction. Herein, the H-donor must be in excess to shift the equilibrium 
to the product side, which can result in substrate-inhibition or biocatalyst inactivation.[18] However, 
there are solvent-tolerant enzymes and cells, which can deal with up to 80 and 50 % (v/v) of 
isopropanol, respectively.[27] In principle, the reaction can also be run in the oxidation direction with 
an excess of acetone. However, biocatalysts have been shown to be susceptible to acetone 
inactivation at higher concentrations.[28] 
 
Figure 3 Cofactor regeneration systems for alcohol dehydrogenases. Left: Substrate-coupled mode with a single enzyme 
catalyzing substrate reduction and auxiliary substrate oxidation. Right: Enzyme-coupled mode wherein enzyme A 
reduces the substrate and a second enzyme (B) takes over the part of auxiliary substrate oxidation. Taken from 
[9]
. 
 
In the enzyme-coupled approach one enzyme has the reducing the other the oxidizing part (see 
Figure 3, right). With different substrates and activities the performance and equilibrium of these 
systems can be triggered. A prominent method is the use of dehydrogenases oxidizing formate, 
glucose and glucose-6-phosphate for cofactor reduction.[9] The oxidized species are in the following 
eliminated from the equilibrium promoting alcohol formation. Additionally, phosphite and other 
ADHs have been exploited for cofactor regeneration as well.[9] Alternatively, hydrogenases were 
shown to utilize molecular hydrogen for regeneration of nicotinamide cofactors.[7, 9] 
For recycling of oxidized nicotinamide cofactors either glutamate dehydrogenase or nicotinamide 
oxidase can be utilized.[9] Electrochemical and photochemical regeneration methods have been 
proven to work too, but are not as efficient as enzymatic methods.[7, 9] 
1.3.3. Whole Cells vs. Isolated Enzymes 
The choice of the appropriate biocatalyst form (whole cells or isolated enzyme) to produce the 
desired product depends on the most economic operation mode of the manufacturing process. 
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Herein, the two options whole cells and isolated enzyme have distinct advantages and disadvantages, 
which will be discussed in the next paragraph. 
Generally, whole cells have the big advantage that they are easy to produce and that tedious and 
expensive enzyme purification is not necessary.[26a] For an efficient process the biocatalytic activity 
may be enhanced by overexpression of the enzyme of interest. The type of reaction treated here 
requires nicotinamide cofactors; whole cells provide this expensive component from their intrinsic 
cofactor pool and can even regenerate it effectively in situ. Compared to isolated enzymes whole cell 
catalysts exhibit considerably higher process stability since the enzymes are operated in a native-like 
environment. A disadvantage of whole cells is that other host enzymes may cause side reactions and 
reduce the final yield and especially enantiomeric excess of the product. Furthermore, substrates and 
products have to cross the membrane barrier, which constitutes a mass-transfer barrier. 
Recently, so-called “designer bugs” have been generated to overcome limitations of whole cell 
biocatalysis such as side-reactions and insufficient cofactor regeneration. Side products were 
eliminated by knocking out genes coding for competing enzymes and cofactor regeneration was 
enhanced by overexpression of cofactor regenerating enzymes in the same microorganism.[14b] 
Additionally, efficient “cell factories” might be generated by metabolic engineering to carry out 
highly optimized biotransformations or multi-enzyme synthesis of high value product.[26a] 
The application of isolated enzymes bears the advantage of higher productivity and less side 
reactions. The major drawback is; however, that the cofactor has to be added externally to drive the 
reaction. The cofactor as well as the enzymes may exhibit limited stabilities under process conditions. 
Immobilization of both was shown to improve stabilities, but reduce enzyme activity. Additionally, 
the enzymes have to be purified, which is tedious and costly. Nowadays, commercial enzyme 
preparations consist mostly of crude cell lysate containing the desired enzyme in an enriched, 
sometimes partially purified form, which reduces the production costs. Nevertheless, in such semi-
pure preparations side reactions may occur caused by protein impurities. 
1.3.4. Large-Scale Production of Chiral Alcohols 
Implementation of an enzymatic process is determined by certain performance parameters in order 
to be competitive to chemical processes. Herein, an optimal biocatalyst converts >99 % of substrate 
at a concentration >100 g L-1 in less than 24 h with the product having >99.5 % ee and a catalyst load 
of <5 g L-1.[17, 29] In 134 industrial-scale biotransformations (>100 kg) for fine chemicals (not 
pharmaceuticals) average performance parameters were found to be 78 % yield, 108 g L-1 product 
concentration and 372 g L-1 d volumetric productivity.[2] These parameters indicate how challenging 
industrial biocatalysis is and where to go when new processes or biocatalysts are designed for 
industrial applications. In general, the biocatalyst itself has to be optimized to meet these 
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requirements and/or the process has to be adapted by process engineering. The methods for enzyme 
optimization will be outlined in chapter 1.6. 
In Table 2, large-scale industrial processes for the asymmetric production of chiral alcohols are 
summarized together with important performance parameters such as substrate concentration, 
conversion, yield and reaction scale. Entries in Table 2 are sorted on the basis of reaction scale 
starting with a multi-ton process down to few kilograms. It may be noted that substrate loading is 
mostly higher than 100 g L-1, enantiomeric excess (ee) is higher than 94 % and yields are higher than 
80 %, which is close to the above mentioned parameters for industrial processes. 
Interestingly, non-recombinant whole cell microorganisms are employed for multi-kg (see Table 2, 
entries 7-9) as well as multi-ton (see Table 2, entries 1) preparation of highly pure enantiomeric 
alcohols. Herein, the molecular identity of the enzyme or enzymes performing the reaction is 
generally not known. 
Table 2 Biocatalytic asymmetric reduction of C=O compounds in industrial scale (>1kg). 
Entry Catalyst Product 
Substrate 
(g L
-1
) 
ee 
(%) 
Conversion/ 
Yield (%) 
Reaction 
Scale 
[kg] 
Source 
1 Neuospora crassa 
S S
OO
OH
 
- >98 -/>85 multi ton [21] 
2 Engineered CR Cl
O
OOH
 
160 >99.5 -/92 1104 [30] 
3 Engineered CR 
Ar1
OH
Ar2  
100 99.9 -/85-90 >200 [31] 
4 Engineered CR 
S
OH
 150 >99 >95 200 
[32] 
5 CR from screening 
O
OH
O
O  
100 >99 -/>96 80 [33] 
6 
CR from Candida 
parapsilosis 
OH
 
100 98.4 68/- 10 [34] 
7 Candida sorbophila 
N
OH
N R
H
O
 
60 >99.8 >99/82.5 13.9 [21] 
8 
Zygosaccharo-myces 
rouxii 
O
O OH  
40 >99.9 -/96 11.5 [21] 
9 
Geotrichium 
candium 
Cl
O
OOH
 
10 99 -/95 7.1 [21] 
10 
CR from Candida 
parapsilosis 
OH
OH  
100 94 -/15.5 3.1 [35] 
11 
ADH from 
Rhodococcus 
erythropolis 
OH
Cl  
156 >99.8 94/91 1.56 [36] 
 
The product of the largest scale is manufactured by Zeneca Life Sciences Molecules with several tons 
serving as an intermediate in the synthesis of a carbonic anhydrase inhibitor Trusopt® (see Table 2, 
entry 1).[21] Very important building blocks are (S)-4-chloro-3-hydroxybutanoic acid esters (see Table 2 
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entries 2 & 9) produced in scales >1000 kg. This chiral alcohol is the key intermediate for an 
anticholesterol agent. The final drug inhibits hydroxymethyl glutaryl (HMG) CoA.[15b] Another multi kg 
process performs asymmetric reduction of a bulky ketone via an engineered carbonyl reductase 
providing a chiral intermediate for Montelukast sodium (Singulair®) a leukotriene receptor antagonist 
developed by Merck (see Table 2, entry 3).[31] (R)-Tetrahydrothiophene-3-ol (see Table 2, entry 4) is a 
key component in Sulopenem®, a potent antibacterial, a prodrug, which is being developed by 
Pfizer.[32] 
Carbonyl reductases are developed on academic and industrial level to match the requirements for 
efficient manufacturing. Such enzyme candidates are investigated in preparative scale under process-
like conditions. Table 3 demonstrates selected examples for asymmetric reduction of prochiral 
ketones for important chiral products on preparative scale (<1 kg). Some of these enzymatic 
processes exhibit interesting features making them attractive for industrial use. Especially high 
substrate loads were enhanced to values higher than 600 g L-1 (see Table 3, entries 6 & 7). As 
benchmark substrates important chiral intermediates like the 4-chloro-3-hydroxybutanoic acid esters 
are used to validate these processes (see Table 3, entries 3, 5 & 7). 
Table 3 Biocatalytic asymmetric reduction in preparative scale (<1 kg). 
Entry Catalyst Product 
Substrate 
(g L
-1
) 
ee 
(%) 
Conversion/ 
Yield (%) 
Reaction 
Scale [g] 
Source 
1 
ADH from 
Lactobacillus kefir O
OOH
 
290 99 78/- 797 [37] 
2 
ADH from 
Leifsonia sp. 
OH
OH  
50 99 99/99 250 [38] 
3 
ADH from 
Candida 
magnoliae 
Cl
OH
OOH
 
450 >99 -/89 22.5 [39] 
4 
CR from 
Saccharomyces 
cerevisiae 
CHO2Me
Cl OH
 
178 >99 99/89 15 [40] 
5 
ADH from 
Sporobolomyces 
salmonicolor 
Cl
O
OOH
 
300 91.7 94.1/- 14.1 [41] 
6 
FabG from 
Bacillus sp. 
ECU0013 
O
OH
O  
620 >99 99/91 5.6 [42] 
7 
CR from 
Streptomyces 
coelicolor 
Cl
O
OOH
 
600 >99 -/93 grams [43] 
8 
Acinetobacter 
calcoaceicus O OEt
OH OH O
 
10 99 -/92 - [21] 
9 
Staphylococcus 
epidermis 
OH
OH
O  
35.6 99 91/- - [21] 
10 
ADH-A from 
Rhodococcus ruber 
OH
 
120 >99 90/- - [44] 
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Also difficult substrates like the small prochiral ketone 4-hydroxy-2-butanone (see Table 3, entry 2) or 
bulky ketones like 6-benzyloxy-3,5-dioxo-hexanoic acid ethyl ester (see Table 3, entry 8) are 
converted in enantioselective manner. The latter reduction yields two stereocenters applying a 
whole cell catalyst and this enantiopure diol produced by Bristol-Myers Squibb serves as an 
intermediate for the synthesis of an anticholestrol drug.[21] Inhibitors of angiotensin-converting 
enzyme (ACE) all require a (S)-homophenylalanine moiety, which can efficiently be provided by 
reduction of the corresponding ketones as shown in Table 3 (entries 6 and 9). The ACE inhibitors such 
as Enalapril, Lisinopril, Cilapril and Benazepril are widely used as antihypertensive drugs and in the 
therapy for congestive heart failure. Another interesting product is methyl (R)-o-chloromandelate 
(see Table 3, entry 8), which is a key compound for the manufacture of Clopidogrel a platelet 
aggregation inhibiting drug.[40] The process parameters look very promising for large-scale 
production. 
Taken together, almost all processes on industrial or preparative scale produce intermediates for 
pharmaceuticals rendering this market as most important driving force for the development of new 
processes involving carbonyl reductases. 
1.3.5. Alcohol Dehydrogenases in Non-conventional Media 
Biocatalysts are naturally designed to work in dilute aqueous solutions; however, it is known since 
the pioneering work of Klibanov et al. that enzymes can also perform in nearly anhydrous 
environments such as pure organic solvent.[45] The term non-conventional media summarizes all 
reaction media different from pure aqueous buffers including mono- or biphasic mixtures of organic 
solvents, ionic liquids, gas and solid phases or supercritical fluids.[46] Under certain circumstances 
enzymes are active in all of these media, which drastically increases the scope of their application in 
organic synthesis. 
For ADHs the use of organic solvents as reaction medium is advantageous since organic substrate 
molecules can be dissolved in higher amounts in comparison to aqueous buffers. Additionally, water-
labile compounds can be converted in anhydrous environments. Herein, aqueous organic biphasic 
systems using water-immiscible solvents as second phase are useful since the organic phase serves as 
substrate reservoir and facilitates product extraction from the aqueous phase simplifying 
downstream processing. Furthermore, the enzyme and the cofactor remain in the aqueous phase, 
where they are protected from possible inhibition or inactivation of organic molecules. 
Also monophasic mixtures of water-miscible organic solvents with buffer is advantageous, since high 
concentrations of an auxiliary alcohol or ketone may be used to achieve efficient substrate-coupled 
cofactor regeneration (see Figure 3, left). Taking organic solvents as the only reaction medium for 
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asymmetric reduction a process can be envisaged wherein the ketone substrate is solubilized in pure 
isopropanol as auxiliary substrate omitting any other solvent. 
In 1986, the ADH from horse liver (HLADH) was the first ADH operated in pure organic solvent. The 
enzyme was suspended in isopropyl ether co-precipitated with NAD+ on glass beads.[47] The dry 
enzyme showed 25 % of its activity in the organic solvent when compared to the activity in aqueous 
buffer. [47] Later on, the HLADH performance was studied in different organic solvents and different 
pretreatments. It was found that the pH in the solution prior to freeze drying plays an important role 
and that catalytic activity in organic solvent, which increased with the amount of water added.[48] 
From this and other studies the conclusion was drawn that the absence of water reduced 
conformational flexibility and hence reduced activity.[48-49] On the other hand, stability was increase 
and bioimprinting was promoted.[48-49] Other ADHs also exhibit catalytic activity in water-immiscible 
organic solvents, like ADH from Thermoanaerobacter brockii (TbADH) and Rhodococcus erythropolis 
(ReADH), whereas the ADH from bakers´ yeast (YADH) was not active in any of the tested solvents.[50] 
Operation of ADHs is aqueous organic biphasic systems was also realized with HLADH, TbADH and 
Lactobacillus brevis (LbADH) and all three enzymes showed good stabilities in the system tested 
depending on the functionality of the organic solvent applied.[51] Gröger et al. demonstrated that 
ReADH can perform asymmetric reduction of ketones in biphasic systems composed of heptane or 
hexane with enzyme-coupled cofactor regeneration.[52] Interestingly, electrochemical cofactor 
regeneration applying a rhodium complex was achieved in a buffer-octane biphasic system 
employing an ADH from Thermus sp.[53] 
High tolerance to 80 % (v/v) isopropanol and 50 % (v/v) acetone was demonstrated for ADH-A from 
Rhodococcus ruber rendering this enzyme valuable for application with substrate-coupled cofactor 
regeneration for both, the reduction and the oxidation direction.[27b] Investigation of the crystal 
structure showed the presence of ten salt bridges at the dimer interface, possibly being responsible 
for the high stability in the tested solvents.[54] Similarly, Thermoanaerobacter ethanolicus secondary 
ADH showed low inactivation when mixed with 30 % (v/v) isopropanol or 10 % (v/v) acetone.[55] 
Activation upon addition of water-miscible organic solvents was observed for ADH from Aeropyrum 
pernix depending on the kind and concentration of solvent.[56] The same was observed for ADH from 
Paracoccus pantotrophus DSM 11072 where operation in 15 % (v/v) DMSO increased conversion by 
twofold.[57] 
The application of organic solvents with alcohol dehydrogenases has effects on stability and activity 
depending on the nature of organic solvent employed. Additionally, it was observed that 
stereoselectivity is affected in monophasic mixtures of buffer and organic solvent. For TbADH it was 
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found that increasing amounts of organic solvent decrease the stereoselectivity, whereas the 
opposite effect was observed for ADH from Thermoanaerobacter sp. Ket4B1.[58] For ADH from 
Thermoanaerobacter ethanolicus stereoselectivity seemed to be even tunable dependent on the 
solvent applied; however, there was no correlation found between the physicochemical properties of 
the solvent and ee.[55] Similar observations were made for carbonyl reductase from Sporobolomyces 
salmonicolor and ADH from Lactobacillus brevis.[59] 
Another prominent non-conventional medium for biocatalysis are ionic liquids (ILs), which are salts in 
the liquid state with low melting points and virtually no vapor pressure. ILs applied in biocatalysis are 
liquid at room temperature and feature reusability, non-flammability and compatibility with enzymes 
and microorganisms.[60] 
LbADH was the first ADH operated in ionic liquids in 2004.[51b] The biphasic system composed of IL 
and buffer was superior to a MTBE-buffer system due to more favorable partition coefficients of 
substrates and products. Application of water-immiscible ILs with ReADH substantially increased 
productivity and simplified product isolation.[61] In this work, the same ADH was used together with a 
glucose dehydrogenase for cofactor regenerating with a large number of water-miscible and 
immiscible ILs.[61] Also whole cells were employed for asymmetric ketone reduction in ILs. For 
example, E. coli whole cells with overexpressed LbADH and formate dehydrogenase from Candida 
boidinii were tested with various water-immiscible ILs giving up to 180 g L-1 d-1 (R)-octanone in a 
continuous process.[62] An effect on stereoselectivity for ketone reduction with cells of bakers´ yeast 
was observed wherein the (R)-alcohol was obtained (70.4 % ee) with benzene or ethyl ether but 
addition of an IL yielded the (S)-alcohol, however with moderate selectivity (27.7 % ee).[63] 
The concept using a gaseous phase as substrate carrier and a solid phase as catalyst carrier was 
employed for ADHs as well. The main arguments to use such gas-solid system are the increased 
catalyst stabilities as well as easy supply with hardly water-soluble substrates. In 1986, HLADH was 
used, co-immobilized with NADH, as solid phase converting several aldehydes supplied via the gas 
phase.[64] The same group also showed applicability of thermostable ADH from Sulfolobus solfataricus 
in this system.[65] For LbADH a 40-fold stabilization in gas-solid system could be achieved by adding 
sucrose to the enzyme preparation after discovering that process stability is governed by enzyme 
rather than cofactor inactivation.[66] It was found that dried whole cells of Saccharomyces cerevisiae 
can be used in gas-solid systems to transform ethanol and hexanal and that the relative humidity, 
expressed as water activity (aw) triggers activity and stability.
[67] 
Asymmetric reduction of several ketones with a crude enzyme preparation of Geotrichium candium 
was performed in buffer overlaid with supercritical carbon dioxide (CO2).
[68] Herein, enzyme 
inactivation caused by pH drop upon CO2 dissolution in the aqueous phase was overcome by 
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buffering with bicarbonate. This system is characterized by a simple workup since the alcohol 
product could be recovered from the supercritical fluid by lowering the pressure to ambient 
conditions. 
Taken together, a huge number of ADHs have been employed in various non-conventional media 
showing reasonable performance by taking advantage of the various benefits like increased substrate 
and cosubstrate concentrations, catalyst stabilization, simple product work-up or tunable 
selectivities. However, usually activity is decreased when non-conventional media are used and 
selectivity might be negatively affected. Many of the observed effects are not easy to rationalize; 
hence more research has to be carried out to address the open questions.  
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1.4. Biochemical Properties of Alcohol Dehydrogenases  
1.4.1.  Classification of NAD(P)H-dependent Alcohol Dehydrogenases 
The enzyme class 1 according to the nomenclature of the Enzyme Commission (EC) is termed 
oxidoreductases, which contains enzymes enhancing the rate of electron transfer reactions. Class 
EC 1.1.1.1, in particular, targets electron transfer to carbon atoms with hydroxyl functions (alcohols) 
with NAD(P)+ as electron acceptor; the last number refers to the serial number of the enzyme name 
in its class.[69] The members of this class catalyze the reversible oxidation of alcohols to the 
corresponding aldehydes or ketones (see Scheme 1). Alcohol dehydrogenases (ADHs) or 
synonymously ketoreductases have been classified EC 1.1.1.1 and are part of a large and diverse 
protein superfamily. Herein, medium-chain (MDR) and short-chain dehydrogenase/reductase (SDR) 
superfamilies have the most members. A third superfamily is the family of “iron-activated” long chain 
dehydrogenases/reductases (LDR).[50] 
ADHs may also be categorized according to their stereoselectivity using the delivery of the two 
diastereotopic hydrogens of the cofactor as criterion (see Figure 4, right). If the pro-S hydride is 
transferred, the enzyme is classified group A if the pro-R is delivered it is denoted group B enzyme. 
ADHs are ubiquitous in all kingdoms of life and play various roles in detoxification and metabolism, 
among them most famously ethanol fermentation. They can accept a wide variety of substrates like 
branched and non-branched as well as cyclic alcohols. Many organisms comprise several very similar 
ADH isoenzymes each adapted to its physiological function. Historically, the ADH1 from bakers´ yeast 
(YADH1) was the first enzyme of this class described in 1937.[70] In the early sixties, the ADH from 
horse liver (HLADH) was isolated and characterized structurally as well as biochemically.[71] 
Additionally, many aspects about ADH enzyme kinetics as well as structure function relationships 
were elucidated with HLADH or YADH1 serving as a general model enzymes for ADHs.[72] 
These two famous enzymes belong to the MDR superfamily with 10888 members, wherein the 
enzymes are categorized according to the amino acid chain length of 350 residues.[73] Furthermore, 
this superfamily consists of homodimeric (like HLADH) or homotetrameric (like YADH1) proteins, 
which mostly contain zinc in the active center.[73] 
1.4.2. Catalytic Mechanism and Enantioselectivity 
The catalytic mechanism of alcohol dehydrogenase is characterized by a two electron process, 
wherein these get transferred in form of a hydride (H-). In the suggested ordered bi-bi mechanism, 
first NAD(P)+ binds tightly to a specific binding site followed by the substrate. The alcohol substrate is 
coordinated by a divalent zinc atom in the active site stabilizing the alcohol oxygen and concurrently 
acidifying the hydroxyl proton. A catalytic histidine is activated by protonation via a base to withdraw 
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a proton from the nicotine amide ribose. The proton relay system involves also a negatively charged 
threonine (or serine), which abstracts the proton from the actual substrate after it got deprotonated 
by itself through NAD+ (see Figure 4, left). Finally, a hydride is transferred from the alkoxide ion to the 
NAD+ leading to a NADH and a carboxyl compound.[74] However, the final mechanism with detailed 
insights of structure-function relationships and protein dynamics is still not fully elucidated even 
though studies using advanced quantum mechanics were undertaken.[75] Recently, a comprehensive 
model for a "tunneling ready state" was developed to explain the hydrogen transfer.[76] 
 
Figure 4 Mechanism and enantioselectivity of alcohol dehydrogenases. Left: Mechanistic hydride transfer from an 
alcohol substrate to NAD
+
 in horse liver ADH.
[77]
 Right: The four possibilities to generate chiral alcohol from a prochiral 
ketone in ADHs; the pro-R (HR) or pro-S (HS) hydride attacks from si- or re-face of the ketone. Adapted from 
[7]
. 
The stereoselectivity is determined by the transfer of the hydride and the orientation of the 
substrate. For the reduction reaction the hydride from the NAD(P)H attacks either the si-face or the 
re-face of the planar carbonyl substrate. On the other hand, the enzyme transfers the pro-R (HR) or 
the (HS) hydride from the cofactor to the substrate, which is enzyme-dependent (see Figure 4, right). 
This results in four stereochemical patterns for a possible outcome of this reaction.[7] For example, 
when the pro-R hydride is transferred to the si-face of the substrate the (R)-product results 
(Prelogs´rule). So far, an ADH performing pro-S hydride transfer to the re-face of the substrate has 
not been reported. 
Most commercially available ADHs deliver the pro-R hydride to the si-face and are so-called Prelog-
ADHs yielding usually (S)-alcohol from the corresponding ketones.[9, 78] Conversely, anti-Prelog ADH 
deliver mostly (R)-alcohols. Generally, ADHs are classified due to the chiral configuration of the 
products using (R)- and (S)-nomenclature according to the Cahn-Ingold-Prelog rules. However, in 
some cases a so-called (S)-specific ADH may yield the (R)-alcohols, since the substituents at the chiral 
center can reverse the assignment of the priorities. For example, an ADH reduces acetophenone to 
(S)-1-phenylethanol but a chlorine substitution at the α-position (α-chloro acetophenone) will yield 
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2-chloro (R)-1-phenylethanol. Therefore, it is more accurate to designate the specificity of an alcohol 
dehydrogenase according to Prelogs´ specificity rules in Fig. 4 rather than to the nomenclature of the 
products.  
In principle, the substrate could bind in the opposite manner (exchange of R and R´ in Fig. 4) into the 
active site of an ADH. By this, the outcome of the reduction would yield the opposite 
stereoselectivity. This is often observed for almost symmetrical ketone substrates, such as 2-
butanone, as these fit in both orientations into the active site. Hence, both enantiomers results as 
products and the ee is low. In some rare cases, the enantiopreference of some ADHs strongly be 
influenced by the substrate geometry.[9] 
1.4.3. Structural Motifs & Substrate Specificity 
The overall sequence identity of ADHs is often not very high (<30 %); however, they exhibit an overall 
conserved fold with characteristic structural motifs. Generally, the polypeptide chain is divided in the 
N-terminal catalytic and the C-terminal cofactor-binding domain.[79] In the following, horse liver 
alcohol dehydrogenase (HLADH) is taken as model enzyme and amino acid numbering is according to 
this enzyme (structural model see Figure 5, left). 
Since all ADHs are dependent on NAD(P) cofactors a conserved fold for cofactor binding is present 
called Rossmann-fold (see Figure 5, right).[80] It consists of five to six β-strands in parallel 
arrangement, flanked by α-helices. In this fold, three βα-pairs make up one of the two motifs (β1-α1-
β2-α2-β3, β4-α4-β5-α5-β6), which are connected by a α-helix (α3).
[81] Each of the two (βα)3 motifs binds 
one mononucleotide of the cofactor. Within this secondary structure motif, a conserved glycine-rich 
region is found (GX1-2GXXG) necessary to bind the phosphate of the cofactor. Other amino acid 
residues (Phe-319, Ala-317, His-51, Ile-269 and Val-292) make hydrogen bonds to stabilize the 
cofactor. 
 
Figure 5 Overall structure of a dimeric alcohol dehydrogenase and the Rossmann-fold. Left: Structural model of HLADH as 
a dimer in complex with NADH and pentafluorbenzylalcohol. The zinc ions are dark blue spheres and the dimer interface 
is between the green and the brown strands and helices.
[79]
 Right: Topology diagram of the Rossmann-fold; cylinders 
represent α-helices and arrows denote β-strands. Dashed lines indicate elements of secondary fold below the plane of 
fold.
[81]
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In HLADH, a catalytic Zn2+ is coordinated in tetrahedral fashion by two cysteine resides (Cys46, 
Cys174) and a histidine (His67). One coordination site is occupied by a water molecule and can be 
replaced for the oxygen of the substrate molecule (see Figure 6, left).[79] This coordination promotes 
catalysis and is therefore termed catalytic zinc. A second Zn2+ may be found in mammalian (or 
eukaryotic) ADHs as structural zinc coordinated by four cysteines (Cys97, Cys100, Cys103 & Cys111) 
(see Figure 6, right). The role of this zinc is attributed mainly to maintain the tertiary/quaternary 
structure of the enzyme.[82] 
 
Figure 6 Catalytic and structural zinc in HLADH. Left: Binding of pentafluorobenzylalcohol and NADH in an active 
conformation with coordinated zinc ion.
[79]
 Right: Geometry of the structural zinc site from simulations, all cysteines are 
considered to be deprotonated.
[83]
 
Substrate recognition and binding is facilitated by many amino acids in the active site from the 
catalytic as well as from the cofactor-binding domain. Most importantly, a serine (Ser48) in HLADH is 
in hydrogen-bonding distance to the oxygen atom of the substrate. The flanking parts of the 
substrate are protruding into the binding pocket of the enzyme lined by several non-conserved 
amino acids, which shape the architecture with respect to available space and affinity.[84] For zinc-
containing MDRs generally two separate substrate binding pockets of different size are found (see 
Figure 7, left). The available space determines the orientation how a prochiral substrate can bind and 
the orientation defines the enantiopreference of the conversion.[84] 
Figure 7 General architecture of an alcohol dehydrogenase and overview of substrate spectrum of commonly used 
alcohol dehydrogenases. Left: Active site of alcohol dehydrogenase from Thermoanaerobacter ethanolicus in space-filling 
representation based on PDB#1YKF. NADP
+
 and Zn
2+
are in white, amino acid residues are in gray.
[85]
 Right: Preferred sizes 
of ketone and aldehyde structures accepted by alcohol dehydrogenases.
[9]
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The substrate spectrum is a very important feature for the synthetic applicability of alcohol 
dehydrogenases. From the most commonly used alcohol dehydrogenases YADH exhibits a very 
narrow substrate spectrum accepting only aldehydes and methyl ketones.[9] In contrast, HLADH has a 
very broad substrate range, especially suited for cyclic moieties; however, only weakly accepting 
open-chain ketones.[9] This gap is filled by a variety of ADHs from mesophilic and thermophilic 
microorganisms (see Figure 7, right).[9] 
1.4.4. Limitations of Using Alcohol Dehydrogenases in Industrial Applications 
Industrial applications aim at stable processes with robust, simple and sustainable operation and 
product recovery as well as an efficient use of the resources.[8] This holds also true for biocatalytic 
ketone reduction for chiral alcohol manufacture. The questions arises what prevents this route to 
become the standard method of choice in organic synthesis. 
The drawback of the cofactor dependency of ADHs is largely solved by recycling and applied on 
industrial scale with methods outlined in 1.3.2. The availability of ADHs was much improved in the 
last years by screening and protein engineering campaigns.[7] However, the known ADHs are not 
suitable for every application due to limitations in activity, selectivity and very often stability. 
Good basal activity and selectivity on non-natural substrates are important to reach high space-time 
yields but more important is process or operational stability.[2] These critical parameters might be 
approached by reaction engineering to provide an optimal environment for the catalyst. Nowadays, 
the advancements in molecular biology, protein chemistry and screening methods make it possible 
to tailor the enzyme to the process requirements by applying enzyme engineering methods. The 
latter will be described in more detail in chapter 1.6. 
The engineering of activity and specificity is studied since a long time applying model enzymes such 
as YADH.[86] General concepts how substrate acceptance is triggered are developed due to the 
“localized” nature. However, very large substrate molecules with two bulky substituents flanking the 
carbonyl function remain challenging targets. The same holds true for very small ketones such as 2-
butanone, since many enzyme cannot distinguish between methyl and ethyl-group, which results in 
low stereoselectivity (compare 1.4.2). Furthermore, the stereoselective reduction of more than one 
carbonyl group leading to 2n possible stereoisomers is difficult (n = number of carbonyl groups). 
The engineering of stability on the protein level comprises a more demanding problem, because 
stabilization mechanisms are only poorly understood on the molecular level and many amino acids 
may be involved. Hence, rational single amino acid exchanges do usually not results in fundamental 
stabilization rendering this issue a “non-localized” engineering problem. Here, mostly traditional 
immobilization methods are applied or whole cells are used in industrial processes. Nevertheless, 
engineering of protein stability is still emerging due to the ever growing progress in protein 
engineering techniques. 
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1.5. Carbonyl Reductase from Candida parapsilosis, a Powerful Catalyst 
with a Moving History 
1.5.1. Discovery and Impact 
The carbonyl reductase from Candida parapsilosis DSM 70125 (CPCR) is regarded as a very valuable 
tool in synthetic applications. Since the discovery in 1992 by Peters et al. this enzyme attracted much 
attention due to its enzymatic features and is labeled with an exciting development.[87] 
Back in 1992, exploitation of strain collections and environmental samples were the major sources 
for new biocatalytic activities. During a screening campaign with four ketoesters and two ketoacids 
with 36 bacterial and 29 yeast strains, Candida parapsilosis DSM 70125 cell free extract exhibited 
highest activities with NADH on ketoesters.[88] Nowadays, two enzyme preparations labeled “CPCR” 
are traded by Codexis® and X-zyme® underlining the importance of the enzyme. Nevertheless, the 
molecular identity of the original CPCR discovered by Peters was never fully clarified. This will be 
done in this thesis.  
1.5.2. Substrate Scope and Selectivity 
In the following, the enzyme responsible for this activity was purified from Candida crude cell extract 
and biochemically characterized.[89] The preparation showed conversion of a broad variety of ketone 
compounds, especially ketoesters, aliphatic, cyclic and aromatic ketones as well as aliphatic 
aldehydes and ketoacetals (compare Table 7).[89b] Also propargylic alcohols were shown in a later 
work to be produced effectively.[90] Most interestingly, also the small 2-butanone was reduced to 
(S)-2-butanol with highest selectivity.[91] This large substrate scope together with the generally high 
enantioselectivity (ee >95 % Prelog product) and tolerance towards 10 % (v/v) isopropanol rendered 
the CPCR a promising catalyst for synthetic applications (see 1.5.5).[89b]  
 
Figure 8 Proposed model of the substrate binding pocket of Candida parapsilosis carbonyl reductase and stereochemical 
pattern of hydride transfer (pro-R to re-face) indicating Prelog´s specificity. Taken from 
[89a]
. 
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These promising features were the reason for further investigation of the mechanism and kinetics, 
herein the first model of the architecture of the substrate binding pocket was proposed.[89a] A 
screening of many structurally different substrates allowed deducing the shape of the active site. It 
was suggested that a small pocket accommodating mostly methyl and ethyl groups is located next to 
a large pocket fitting larger groups such as aromatic or branched alkyl groups (see Figure 8).[89a] In the 
same study, an ordered bi-bi-mechanism and evidence for Prelog´s specificity (pro-R hydride 
transferred to re-face, Figure 8) were described as known for many other ADHs (see 1.4.2 and 
1.4.3).[78, 89a] Stereoselectivity for CPCR was tested for many substrates and turned out to obey 
Prelog´s rule as proposed with ee-values always exceeding 94 % (compare Table 7, entries 1-10). 
However, CPCR was found to have also some limitations in substrate scope as ketoacids in general, 
formaldehyde, α-chloroacetophenone and propiophenone were no substrates for CPCR.[89b] 
Furthermore, stereoselectivity for reduction of 3-butyn-2-one was only 49 % ee S.[90] 
1.5.3. Temperature, pH Optimum and Stability 
The purified enzyme prepared from Candida lysate was fully characterized and the optimal 
conditionns for reduction and oxidation were determined.[89b] The values for temperature optimum 
are in a range typical for enzymes from mesophilic microorganisms (see Table 4).[50] Also pH optimum 
for oxidation is expected to be more in the alkaline regime as the one for reduction (see Table 4). 
Table 4 Temperature and pH optimum for CPCR preparation. 
Temperature Optimum pH Optimum Source 
Reduction Oxidation Reduction Oxidation  
39-40°C 50–52°C 7.5-8.5 9-10 
[89b]
 
CPCR is fairly stable at ambient temperature when stored in buffer (see Table 5, entry 3) and remains 
stable for several weeks at lower temperatures and long-term storage conditions (see Table 5, entry 
1 & 2). Operation of non-immobilized Codexis®-CPCR in an emulsion membrane reactor exhibited 
extraordinary high half-life time of 1488 hours, which is explained by the low concentrations of 
substrate and production promoting operational enzyme stability (Table 5, entry 4).[92] This 
demonstrates well how reaction engineering can assist the stabilization of biocatalysts in generating 
more appropriate operation conditions. Furthermore, a recombinant CPCR in purified form was 
operated in an aqueous-organic biphasic system with varying organic phases. In this, CPCR was 
severely inactivated by the presence of the interphase (see Table 5, entries 5-6). This feature limits 
the applicability of free CPCR in two-phase systems, which are frequently applied for asymmetric 
ketones reductions.[93] However, CPCR purified from Candida lysate encapsulated in poly vinyl alcohol 
beads showed reasonable stability in pure hexane proving that immobilization is an efficient tool for 
CPCR stabilization (see Table 5, entry 7).[94] 
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Table 5 Stability of CPCR preparations under different conditions. 
Entry Condition Half life time [h] Source 
1 25 % glycerol, -20°C >984 
[89b]
 
2 temperature (4°C) 990 
[95]
 
3 temperature (25°C) 115.5 
[96]
 
4 emulsion membrane reactor (25°C) 1488 
[92]
 
5 cyclohexane interphase (25°C) 4.0 
[97]
 
6 heptane interphase (25°C) 17.7 
[97]
 
7 immobilized in hexane (25°C) 63.7 
[94]
 
As mentioned before, the stability of a catalyst under operation conditions is one of the most 
important parameters for process development. Therefore, characteristics like thermostability and 
solvent stability can be valuable measures for possible application in a process since they may 
correlate with operational stability. 
1.5.4. Comparison to Other Carbonyl Reductases from Candida spp. 
The Candida genus is exploited since a long time as a source for oxidoreductases and provides a 
biocatalytic platform for practical applications and academic insights.[98] Especially, strains 
categorized as parapsilosis species show interesting reducing activities. For instance, whole cells 
perform selective imine reduction[99] or effective stereoinversion of racemic 2-octanol[100] indicating 
the presence of several alcohol dehydrogenases/carbonyl reductases. With this knowledge, it is not 
surprising that in the literature many entries about carbonyl reductases isolated from Candida type 
strains are found. 
Table 6 Recombinant carbonyl reductases from various Candida parapsilosis type strains compered to CPCR. 
Entry Type strain 
Enzyme 
name 
Uniprot 
accession 
Protein 
length 
Cofactor 
Stereo-
specificity 
Source 
1 DSM 70125 CPCR - - NADH Prelog 
[89b]
 
2 IFO 1396 CpSADH BAA24528.1 336 NADH Prelog 
[101]
 
3 CCTCC M203011 rCR ABP38340.1 336 NADH Prelog 
[102]
 
4 CCTCC M203011 CpADH ABG57118.1 279 NADPH anti-Prelog 
[103]
 
5 IFO 0708  CPR-C1 BAD01652.1 299 NADPH Prelog [104] 
6 IFO 0708 CPR-C2 BAD01653.1 307 NADPH Prelog [104] 
 
A carbonyl reductase from Candida parapsilosis IFO1396 was described by the Japanese company 
Daciel and denoted CpSADH.[105] The according nucleotide sequence was described and the enzyme 
was expressed in E. coli (see Table 6, entry 2).[101] Furthermore, recombinant alcohol dehydrogenase 
from Candida parapsilosis CCTCC M203011 was shown to resolve racemate of 1-phenyl-1,2-
ethanediol (see Table 6, entry 3).[102, 106] Analysis of the latter two carbonyl reductases revealed that 
they are identical except one amino acid. Structural information is not available and only low 
sequence identity (<35 %) is found in the protein data bank (PDB) with ADHs mainly from 
thermophilic hosts or the archaea kindom. 
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The DNA sequence of CpSADH is also present in the genome of Candida parapsilosis strain CDC317. 
The transcriptome was fully sequenced and translated proteins were automatically annotated.[107] 
Within the fully sequenced genome automated annotation revealed 20 members of the zinc-binding 
dehydrogenases family (PF00107), which are vastly overlapping with the 21 members found 
belonging to the alcohol dehydrogenase GroES-like protein family (PF08240).[107] Partial coding 
sequences identical to CPCR (42-274) were discovered in Candida parapsilosis strains T30451, 452 
and 480. [107] However, activity of the according enzymes was never reported. 
Additionally, also a short-chain alcohol dehydrogenase has been isolated from Candida parapsilosis 
CCTCC M203011 exhibiting anti-Prelog specificity (see Table 6, entry 3).[103] For this enzyme, a crystal 
structure is available (PDB: 3CTM).[108] Furthermore, two polyketone reductases were simultaneously 
found in Candida parapsilosis IFO 0708 converting ketopantoyl lactone to D-(−)-Pantoyl lactone with 
NADPH as cofactor (see Table 6, entries 5 & 6).[104] 
Table 7 Applications of CPCR in preparative scale and in different reaction setups. FDH is formate dehydrogenase from 
Candida boidinii for regeneration of the NADH cofactor. EMR is enzyme membrane reactor for retention of the 
biocatalyst. PVA stands for polyvinyl alcohol. 
Entry Biocatalyst Product 
Yield 
[%] 
ee 
[%] 
Reactor, 
scale 
Cofactor 
recycling 
Substrate 
[mmol L
-1
] 
Sour
ce 
1 
Purified from 
Candida 
extract 
Ethyl-(S)-3-
hydroxybutanote 
- 
98.5 
S 
5 mL aqueous FDH 100 [89b] 
2 
Purified from 
Candida 
extract 
(S)-1-(2-naphtyl)-
ethanol 
70 
99.5 
S 
30-200 mL 
aqueous, 
cyclodextrin 
FDH 50 [109] 
3 
Candida 
extract 
Lactate aldehyde 
dimethyl acetal 
92 
100 
S 
100 mL 
aqueous 
FDH 200 [110] 
4 
Candida 
extract 
Various hydroxyl 
ester 
>83 
>95 
S 
100 mL 
aqueous 
FDH 30–200 [91a] 
5 
Candida 
extract 
(S)-1-
phenylethanol 
61 
94 
S 
100 mL 
aqueous 
5 % (v/v) 
2-pro-
panol 
50 [91a] 
6 
Commercial 
CPCR (X-
Zyme) 
(S)-2-octanol 99.5 
97 
S 
EMR, 
continuous 
FDH 7 
(21 g L-1 d-1) 
[92] 
7 
Commercial 
CPCR (X-
Zyme) 
(S)-2-octanol 99.5 
97 
S 
Emulsion 
reactor, 
continuous 
FDH 68 
(11 g L-1 d-1) 
[92] 
8 
Purified from 
Candida 
extract 
(S)-2-butanol 60 
100 
S 
Micro-
emulsion 
FDH 670 [91b] 
9 
Purified from 
recombinant 
E. coli 
(S)-1-
phenylethanol 
25 
99 
S 
Biphasic, 
continuous 
10 % (v/v) 
isopro-
panol 
100 [96] 
10 
recombinant 
E. coli whole 
cells 
(S)-2-butanol - - 
Encapsulated 
cells 
2.8 % 
(v/v) iso-
propanol 
40 [111] 
11 
Purified from 
Candida 
extract 
(S)-1-
phenylethanol 
- - 
PVA beads, 
hexane 
FDH, 5 % 
(v/v) iso-
propanol 
150 [94] 
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1.5.5. Synthetic and Preparative Applications of CPCR Preparations 
Due to afore the mentioned features of CPCR, the enzyme was used for several synthetic applications 
in preparative scale and also for validation of reactor concepts for asymmetric ketone reduction 
involving strategies to increase the substrates load and cofactor regeneration (see Table 7). Table 7 
demonstrates the versatility of CPCR with respect to applicability in various reactor types and 
operation modes (see Table7, entries 6-9) as well as tolerance to additives (see Table 7, entry 2, 5, 9 
and 10) and immobilization (see Table 7, entry 11). However, E. coli whole cells with CPCR 
overexpressed do not withstand encapsulation in polyelectrolyte multilayer systems (see Table 7, 
entry 10).[111] 
For all applications stereoselectivity exceeded 94 % and yields were generally high, which speaks for 
the robustness of the catalyst under operation conditions and indicates the absence of inhibition 
phenomena. 
1.5.6. Patent Situation 
The detected carbonyl reducing activity in cell-free lysate of Candida parapsilosis DSM 70125 
discovered by Peters et al. was filed for patenting in 1992 (see Table 8, entry 1-2). The responsible 
carbonyl reductase protein was purified and characterized but the amino acid or nucleotide 
sequence was not identified.[87] Most interestingly, a work group from the company Daciel patented 
the DNA and amino acid sequence of a carbonyl reductase recovered from Candida parapsilosis type 
strain IFO1396 exhibiting similar reducing activities (see Table 8, entry 3-5).[112] However, biochemical 
data from the enzyme described by Peters et al. were at odds with data reported in the patent and 
corresponding publications.[89b, 101] In Table 8 only patents covering the activity or amino acid 
sequence of the protein are covered. 
Table 8 Patents published for reductive activities of Candida parapsilosis. 
Entry Inventors 
Date 
(priority) 
Date 
(published) 
Application Patent no. Source 
1 Kula, Peters 1992/03/12 1993/09/16 
New ketonic ester reductase, its 
preparation and use for enzymatic 
redox reactions 
WO 
93/18138 
[87]
 
2 Kula, Peters 1993/03/05 1996/06/04 
Ketoester reductase for conversion 
of keto acids esters to optically 
active hydroxy esters 
US 
5,523,223 
[113]
 
3 
Kojima, Yama-
moto, Kawada, 
Matsuyama 
1996/09/12 1998/06/09 
Method for producing ketone or 
aldehyde using an alcohol dehydro-
genase of Candida parapsilosis 
US 
5,763,236 
[105]
 
4 
Kojima, Yama-
moto, Kawada, 
Matsuyama 
1993/09/24 2004/11/24 
ADH, DNA encoding its, preparation 
& method of preparing optically 
active alcohols 
EP 
0645453 
[112]
 
5 
Kojima, Yama-
moto, Kawada, 
Matsuyama 
1997/06/11 2001/06/03 
Stereospecific ADH isolated from 
Candida parapsilosis, amino acid 
and DNA sequences thereof, and 
method of preparation thereof 
US 
6,255,092 
[114]
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1.6. Enzyme Engineering for Improving Enzyme Performance 
1.6.1. General Concepts for Enzyme Improvement 
Enzymes with interesting activity do rarely match all requirements for application in commercially 
viable processes such as sufficient specific activity and selectivity on the desired substrates as well as 
reasonable operational stability and absence of inhibition phenomena.[2, 115] However, advancements 
in enzyme engineering and screening technologies demonstrate many astonishing examples where 
enzyme properties were improved up to several thousand folds (see Table 9, entries 3, 6, 7 & 10). 
These success stories also increased the understanding of structure-function relationships in 
biocatalysts. 
There are two different strategies of enzyme engineering Rational Protein Design & Directed 
Evolution both exhibiting advantages and disadvantages. Recent developments enforce the 
combination of both techniques as well as more data-driven approaches due to the accumulation of 
sophisticated information in extensive data bases.[6, 115] The general methodology in protein 
engineering involves the selection of changes (rational or random), the introduction of these changes 
(mutagenesis) and their evaluation (screening or selection). 
Table 9 Selected examples of recent achievements in protein engineering towards improvement of various properties 
with random, rational and combined methods. 
Entry Protein Property Improvement Mutations Method Source 
1 
gluco corticoid 
receptor 
stability & 
solubility 
ΔTm= 8°C, 26x more 
soluble protein 
4 random 
[116]
 
2 
glucose 
dehydrogenase 
ketoreductase 
activity & stability 
7-13x more active, 
higher substrate 
resistance 
- random 
[30, 117]
 
3 ketoreductase activity >3000x 19 random 
[31]
 
4 
imidazoleglycerol-
phosphate synthase 
de novo function 
Kemp elimination, 
kcat = 1.375 s
-1
 
>9 rational 
[118]
 
5 ketosteroid isomerase de novo function 
Diels-Alderase 
kcat = 0.036 s
-1
; 
14 rational 
[119]
 
6 
glucose 
dehydrogenases 
half-life >10
6
 2-3 rational 
[120]
 
7 transaminase 
substrate 
specificity 
27000x higher 
activity 
27 combined 
[121]
 
8 enoate reductase enantioselectivity 
>98 (S) & (R)-
selectivity 
2 combined 
[122]
 
9 ketoreductases enantioselectivity 63 to 99.4 % ee 10 combined 
[32]
 
10 
cyanohydrin 
dehalogenase 
activity 4000x 35 combined 
[123]
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1.6.2. Rational Protein Design & Computational Methods 
In rational protein design amino acid changes are introduced on the basis of structural information 
such as X-ray structures, NMR data or homology models of the enzyme of interest. With this 
methodology problems of well understood enzyme properties like substrate acceptance or selectivity 
can be targeted and a priori hypotheses on the expected effects have to be made. Here, only few 
amino acid exchanges are generated resulting in small number of possible variants to test for an 
improvement in the targeted property. The necessity of structural information and a basic 
understanding of the property to improve clearly constitute a drawback but the small screening 
effort exhibits the major advantage. Moreover, with this approach it is rather unlikely to find the best 
possible variant since the understanding of protein function and dynamics is only limited and 
synergistic effects are poorly understood and often cannot be predicted. For example, substitutions 
affecting activity may be scattered throughout the whole protein and not only located at the active 
site. The reasons for that are in general hard to rationalize. 
For single amino acid exchanges simple methods based on polymerase chain reaction (PCR) are 
applied using a primer pair containing the nucleotide triplet coding for the desired amino acid. Semi-
rational approaches would be performed similarly by site-saturation, where all nineteen possible 
amino acids are substituted to identify the most appropriate by screening. Larger library sizes are 
obtained by simultaneous multiple site-saturation giving access to possible synergistic effects. A 
powerful tool for probing the sequence space is the combinatorial active-site saturation test (CAST) 
after careful selection of target residues. With CAST the substrate specificity of a lipase was changed 
saturating 3 amino acids.[124] In principle, the size of (multiple) site-saturation libraries can be 
reduced by using reduced sets of codon like NNK (32 codons for 20 amino acids) or NDT (12 codons 
for 12 amino acids). These libraries are referred to as “smart libraries” since they exhibit a desired 
amino acid diversity with a significantly smaller diversity on the DNA level compared to completely 
degenerated codons with NNN (64 codons for 20 amino acids). 
Lately, tremendous advances in protein engineering have emerged through computational methods. 
Rational computational design greatly decreases the need for probing randomized sequence space, 
rendering the route to novel biocatalyst much more efficient. Herein, SCHEMA, ProSAR and ROSETTA 
are the most prominent tools.[115] SCHEMA is a computational methodology, wherein the amount of 
protein disruption upon DNA recombination is scored. Screening is focused on the chimeras with less 
structural disruption resulting in functionality enriched diversity. ProSAR stands for Protein Sequence 
Activity Relationships a statistical approach, which finds the contribution of amino acid substitutions 
to an improvement out of a large number of variants.[123] Previously collected DNA sequence and 
enzyme activity data from different mutants is applied to ProSAR as a training set and beneficial 
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mutations are fixed for subsequent rounds of mutation. Variants contain an average of ten mutations 
and the final candidate may contain even more substitutions. An impressive example is a halohydrin 
dehalogenase with 35 substitutions with 4000-fold improved activity (see Table 9, entry 10).[123] 
ROSETTA represents a fully rational approach creating novel biocatalysts by fitting a theoretically 
designed active site (”theozyme”) in to stable protein backbone. Herein, different active site designs, 
are suggested and composed on the basis of quantum mechanics for a desired reaction.[125] ROSETTA 
in conjunction with the theozyme approach has been proven to be very successful in design of de 
novo catalysts with new functions (see Table 9, entries 4 & 5).  
1.6.3. Directed Evolution 
In contrast to rational protein design, directed evolution does not require structural information 
since nucleotide substitutions are incorporated randomly into a targeted DNA sequence. Multiple 
rounds of genetic diversity generation and gene recombination (step 1) combined with functional 
screening or selection are carried out to identify improved variants (step 2, see Figure 9). Improved 
variants are used for the next cycle of mutagenesis and screening/selection mimicking the natural 
process of Darwinian evolution (step 3). The iterative nature of this approach results in stepwise 
improvements and may lead to substantial overall improvements of the desired enzyme property 
after several rounds. This strategy produces a vast number of possible variants in diversity 
generation. For example, a ten amino acid peptide can yield theoretically 2010 (ca. 1013) combinations 
for a complete randomization. Consequently, screening or selecting all possible variants of an 
average enzyme is impossible, which constitutes the main limitation of this strategy.  
 
Figure 9 Scheme of the three steps in a directed evolution experiment. Taken from 
[126]
. 
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The strategy of stepwise accumulation of random beneficial mutations is powerful to elucidate new 
positions and substitutions for improving enzyme properties, also referred to as “hot spots”. This 
methodology can lead to tremendous improvement of enzyme properties like stability and solubility 
(see Table 9, entry 1 & 3) as well as catalytic activity (see Table 9, entry 2 & 3). Incorporation of 
random mutations can lead to enzyme destabilization or complete loss of activity due to misfolding. 
Therefore, the choice of the template, which can bear many mutations is desired. Evolving for 
stability first to make the enzyme fit for subsequent mutations is an approved strategy as well as 
exploiting neutrally drifted mutations or starting from a consensus sequence.[115, 127] 
The probably most applied and robust method for random mutagenesis is error-prone (ep) PCR, in 
which usually one to three nucleotides are altered per gene. Besides, high-error rate epPCR with 27 
nucleotide exchanges on the average also yielded functional enzymes with novel properties.[128] 
However, epPCR is strongly biased in the mutational pattern since transition mutations (A↔G, 
C↔T) are highly favored and only single nucleotide exchanges are performed.[129] This results in only 
an average of 6 of the 20 possible amino acid substitutions on the protein level because 
transversions and/or consecutive  mutations are rare events.[127] However, there are developments 
to circumvent these limitations by advanced techniques such as Sequence Saturation Mutagenesis 
(SeSaM).[130] 
Another frequently used method to generate genetic diversity is gene shuffling, where DNA 
fragments from different parent genes are recombined in vitro.[131] Herein, a certain degree of 
minimum homology is required, which limits applicability only to related genes. The main advantage; 
however, is that only functional parts are shuffled yielding a higher fraction of active variants in 
contrast to epPCR. 
1.6.4. Selection and Screening for Improved Variants 
The experimental test system for evaluation of improved variants generated in rational or random 
fashion is the most vital part for a protein engineering campaign. Most appropriately, these systems 
should at best mimic the final operation conditions or properties of improvement, because “You get 
what you screen for”.[132] Moreover, a physical connection between the gene (genotype), the protein 
it encodes (phenotype) and the test signal has always to be maintained. Basically, a test system 
should be as sensitive and reproducible as possible, otherwise positive variants might get lost due to 
high variations in the assay. Hence, an activity related standard deviation established with wild type 
activity under test conditions is an important quality parameter for assay validation; usually numbers 
<15 % are regarded as suitable. The number of false positives and false negative should be negligibly 
low. 
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Herein, two main routes can be described; one is (in vivo & in vitro) selection and the other is 
screening. Unlike screening, where individual (also the inactive) clones are analyzed, selection targets 
the whole gene pool and only active clones are selected. Applying a selection setup very large 
libraries (1012-13 variants) may be tested.[127] However, in vivo selection is limited by transformation 
efficiencies, which generally do not exceed 1010 transformants.[133] In in vivo selection the 
establishment of a reliable, low noise complementation system is difficult. The latter systems mostly 
dependent on the survival or growth of host organisms and the selection pressure may surpassed 
leading to many false positives. Furthermore, reduced membrane permeability constitutes a mass 
transfer barrier for assay compounds, which can be challenging.[134] In vitro selection is not 
dependent on transformation or mass transfer limitations; additionally, harsher non-physiological 
selection pressures can be applied than for living cells. Powerful systems like phage display, ribosome 
display, cell surface display and in vitro compartmentalization have been developed and validated to 
find improved proteins.[134] 
High-throughput screening (HTS) is generally more tedious than selection and library sizes of only 
105-7 are the average because each clone, also inactive ones, are tested.[115] In screening, theoretically 
every enzymatic reaction can be used as long the substrate or product can be directly or indirectly 
detected. Simple, qualitative assays with high throughput rely on color, fluorescence or halo 
formation on agar plates. Other more advanced methods to separate active from inactive clones in a 
HTS manner use microfluidics or flow cytometry, wherein >1010 variants can be tested.[135] The latter 
techniques can be exploited as pre-screen to consider only the active portion of clones for closer 
examination. Quantitative assays like UV-Vis and fluorescent spectroscopy or gas and high 
performance liquid chromatography are more appropriate to screen in detail for improved 
properties. Commonly, multititer plates in 96-well- or 384-well-formates are applied for 
spectrophotometric assays. 
Further developments of efficient selection and screening methods are emerging rapidly. The rather 
philosophical question whether it is the better strategy to go for higher sample throughput to test 
larger libraries or to design smarter libraries, which can be screened with much less effort remains to 
be answered. 
1.6.5. Enzyme Engineering of Alcohol Dehydrogenases 
Since horse liver alcohol dehydrogenase (HLADH) was one of the first oligomeric enzymes in 1973 
with amino acid sequence and crystal structure available, many structure–guided mutagenesis 
studies were performed to alter the properties of this enzyme.[136] From the late 1980s´ onwards, 
ADH1 from bakers´ yeast (YADH) was also mutated intensively because it was one of the most 
employed catalysts for synthetic applications. For this, a structural model of YADH was derived from 
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HLADH, since the crystal structure of YADH was solved first in 1994; however, at low resolution of 
3.2 Å.[137] Advances on the field of protein structure determination resulted in a rapid increase in 
available highly accurate ADH crystal structures for mutational analyses. Hence, a structure at 2.44 Å 
resolution is available now for YADH in the protein data bank with the ID 2HCY. Additionally, 
computational simulations such as molecular modeling gave insights into the mechanisms of 
catalysis, cofactor specificity, stability, selectivity and substrate acceptance promoting rational 
approaches to tailor enzyme properties.[76, 79, 83, 138] 
Substrate Specificity and Activity 
Site-directed mutagenesis experiments targeting the substrate binding pocket broadened the narrow 
substrate range of YADH (compare Figure 7, right) by exchanges from large to small amino acids.[86, 
139] The same approach was followed for ADH from Thermoanaerobacter ethanolicus[140] and human 
liver ADH isoenzyme β1β1
[141] leading to the general hypothesis, that the acceptance of substrates is 
largely dependent on the architecture of the substrate binding pocket. If the pocket is widened, 
larger substrates fit better and vice versa. 
Furthermore, apart from rational also random mutagenesis or combined approaches succeed in 
altering the activity profile of ADHs. For example, activity of a carbonyl reductase and glucose 
dehydrogenase was increased 7- and 13-fold, respectively by several generations of DNA shuffling 
(see Table 9, entry 2).[30] For the (R)-selective ADH from Lactobacillus kefir a platform technology has 
been developed by Codexis to tailor activity and selectivity to the desired needs and several patents 
have been filed for the evolved variants used in various synthetic applications.[13a] 
For AdhA from Pyrococcus furiosus random exchanges of amino acids, which are not in direct contact 
with the substrate, showed acceptance of larger substrates.[142] Furthermore, a glyceraldehyde 
dehydrogenase was engineered to convert 2-hydroxybutanone 26-fold more efficient than the wild 
type after DNA shuffling and site-directed mutagenesis.[143] 
Enantioselectivity 
High enantioselectivity is a very important feature of ADHs and enantiomeric excesses found are 
usually >95 % for natural substrates. Most known ADHs exhibit Prelogs´ specificity (see chapter 
1.4.2). In order to increase or invert the stereoselectivity mostly rational approaches are used, since 
the orientation of the substrate has to be carefully tuned to give the desired product. Site-directed 
single point mutations showed inversion of stereoselectivity for substituted aromatic ketones of 
ADHs from Sporobolomyces salmonicolor[59a, 144] and Thermoanaerbacter ethanolicus[140b]. Short-chain 
carbonyl reductase from Candida parapsilosis showed reversed enantiopreference with 1 – 3 site-
directed substitutions[145], whereas an aldo-keto reductase from Penicillium citrium was evolved via 
epPCR and saturation mutagenesis to increase enantioselectivity.[146] The most astonishing example 
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for engineering this enantioselectivity is reported for a carbonyl reductase developed by Codexis 
where the ee of a non-natural substrate was increased from 63 to 93 %.[32] In eight rounds of random 
mutagenesis and application of ProSAR (see chapter 1.6.2) also activity and stability could be 
improved substantially by introducing 10 mutations.[32] 
Cofactor Preference 
ADHs are dependent on either NADH or NADPH, wherein NADPH is more expensive and less stable 
rendering this cofactor less attractive for application.[147] Therefore, it is desired to change the 
cofactor preference from NADPH to NADH by rational protein engineering. Generally, the cofactor 
binding site is altered in a way that the adenyl ribose 2’-phosphate group of NADP, which is not 
present in NADH, cannot bind anymore. This has been achieved for ADH from Lactobacillus brevis, 
wherein an exchange from glycine to aspartate led to steric hindrance and charge repulsion of 
NADPH in the cofactor binding domain.[148] However, this change compromised activity but further 
engineering yielded fourfold increase activity with NADH with an additional point mutation.[149] An 
ADH from Saccharomyces cerevisiae was mutated in the cofactor binding site, which resulted in 
mixed cofactor acceptance.[150] Site-directed mutagenesis has been used to introduce eight amino 
acid substitutions into Candida magnolia reductase S1 to completely overcome NADPH dependency 
and switch to NADH as preferred cofactor.[151] A substitution to the negatively charged asparagine in 
the cofactor binding site has a repulsive effect for the adenosine 2´-phosphate anion of NADPH. 
Notably, cofactor preference of glucose dehydrogenase from Haloferax mediterranei was switched 
from NADPH to NADH by a single amino acid substitution broadening its applicability for cofactor 
regeneration.[152] 
Conversely, cofactor preference of formate dehydrogenases was converted to NADPH rather than 
NADH rendering it a suitable catalyst for enzyme-coupled regeneration of both cofactors in industrial 
applications (see chapter 1.3.2.).[153] 
Stability 
Catalyst stability can be measured in different ways like thermo- , pH- or solvent stability, but for 
synthetic application the overall process stability under operational conditions is most important.[2] 
Nevertheless, protein stability is most commonly connected to a rigid protein fold and stabilization 
against thermal inactivation oftentimes also protects against denaturants like organic solvents or 
detergents. Rigidification by removal of flexible loops as well as introduction of stabilizing molecular 
connections such as hydrogen bonds, disulfide bonds and salt bridges can be achieved by rational 
protein design. However, the effects of the latter alterations are generally not so easy to predict 
since exact spatially arrangement of the interaction partners is required. 
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Another rational approach follows the strategy of rigidification by reducing the entropy of the 
unfolded state by introduction of prolines or removal of glycines.[154] By this, a thermostable alcohol 
dehydrogenase from Clostridium beijerinckii has been generated by introducing a proline. This single 
substitution gained substantial increase in thermal resistance.[155] (R)-selective ADH from 
Lactobacillus kefir was engineered by Codexis to meet certain characteristics predetermined by the 
process.[31] In Penicillium citrium β-ketoester reductase a single amino acid substitution identified by 
combination of random followed by saturation mutagenesis increased thermostability.[146] A similar 
approach was followed for phenylacetaldehyde reductase from Rhodococcus sp. ST-10 where 
increase resistance in the presence of isopropanol was achieved, which is advantageous for 
substrate-coupled cofactor regeneration.[156] Conversely, Adha from Pyrococcus furiosus partly lost its 
inherent thermostability upon directed evolution towards acceptance of new substrates.[142] The 
same effect was observed with amino acid exchange W95L in ADH from thermophile Solfolobus 
solfataricus disrupting an aromatic cluster responsible for stability.[157] 
Other Properties & Recent Developments 
Alcohol dehydrogenases and carbonyl reductases are distinguished by their directional preference in 
catalysis. The underlying reasons were elucidated for a mannitol-2-dehydrogenase and a “one-way” 
carbonyl reductase was generated by active-site redesign.[158] 
Recent achievements in engineering of alcohol dehydrogenases are inferring multi-parameter 
optimization to meet all requirements for an economic relevant industrial process. In this, factors like 
substrate loading, reaction time, biocatalyst loading as well activity and selectivity are considered.[30, 
159] Implications on process engineering are occurring for example when reduced catalyst load 
facilitates easier downstream processing. In turn, biocatalyst improvements are measured as overall 
gain in process productivity and not as increase in a single property. 
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1.7. Aim of This Thesis 
Biocatalysis became a well-established alternative to classical chemical routes to manufacture a huge 
variety of products in economical and sustainable manner. However, it is far from being the standard 
choice. Therefore, the development towards greener production processes applying biocatalysts has 
to be promoted by meeting the requirements for industrial applications. To achieve this, engineering 
of the reaction or the biocatalyst has to be performed to optimize the overall system. From the 
gained results, fundamental knowledge can be extracted to create a basic understanding to meet 
upcoming challenges in optimization procedures. 
In this thesis, the model enzyme carbonyl reductase Candida parapsilosis (CPCR) is employed for 
asymmetric reduction of ketones. The resulting chiral alcohols comprise key intermediates in the 
synthesis of diverse important drugs and fine chemicals. CPCR was found previously to exhibit 
interesting reducing activity; however, the activity could not be assigned to a definite enzyme. The 
Candida native host contains two isoenzymes of CPCR, which appeared to have very similar 
biochemical proprieties. The identity of CPCR1 and CPCR2 is clarified here by combining tools of 
classical biochemical and modern computational chemistry. The broad substrate spectrum observed 
is now allocated to CPCR2. 
With this promising enzyme at hand, a reaction system for efficient ketone reduction is strived for. 
So far, the current biocatalytic reduction systems suffer from low substrate loadings, limited process 
stability of the catalyst or tedious work up procedures. These constraints are addressed in this thesis. 
Furthermore, it is aimed to characterize the reaction system with respect to its limitations and 
broaden the applicability to other ketone reducing enzymes. 
CPCR2 is particularly powerful with regard to substrate spectrum and stereoselectivity; however, 
some substrates are only poorly accepted. Moreover, the CPCR2 undergoes fast inactivation at 
aqueous-organic interphases in biphasic reaction systems. These drawbacks are tackled by means of 
protein engineering, wherein the enzyme is altered by introduction of mutations. The findings 
deduced from broadening the substrate scope and interfacial stabilization build the basis for further 
improvement of CPCR2 and other enzymes of this class. 
To this end, this work is supposed to provide a new powerful reaction system for efficient 
biocatalytic ketone reduction as well as a CPCR2 enzyme with substantially improved properties. 
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2. Experimental 
2.1. Molecular Biology Techniques 
2.1.1. Used Strains and Plasmids 
 
E. coli DH5α or 10G  [(supE44 ΔlacU169 Φ80 lacZΔM15) hsdR17 recA1 gyrA96 thi-1 relA1)] 
 
E. coli BL21(DE3)  [F- ompT gal dcm lon hsdSB (rB- mB-) λ(DE3 [lacI lacUV5-T7 gege 1 
ind1 sam7 nin5])] 
pET-22b(+) Novagen (Cat. No. 69744-3) 
 
 
Figure 1 Vector map of pET22b(+) vector from Novagen (Cat. No. 69744-3) 
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2.1.2. Design of CPCR2 Gene Construct 
For protein engineering of carbonyl reductase from Candida parapsilosis DSM 70125 (CPCR2), the 
gene with Genbank accession number AB010636 was taken as a template. A DNA construct was 
newly designed and synthesized with E. coli codon usage by GeneArt (Invitrogen, Darmstadt) using 
the provided standard algorithm. Adaption of codon usage was carried out to minimize the 
probability of expression mutants. For example, when codons commonly used by Candida are rare in 
E. coli expression might be reduced or even terminated. In the newly designed recombinant CPCR2 
gene construct, rare codons are replaced by codons frequently used in E. coli. These may account for 
optimal expression and silent mutations introduced by protein engineering techniques will not lead 
to increased expression levels. Higher expression levels of the identical protein are directly reflected 
in activity-based screening assays yielding false positives. 
For efficient cloning, recognition sites for endonucleases NdeI at the C-terminus and NotI at the N-
terminus were incorporated (see black boxes in Figure 2). Two stop codons are positioned right in 
front of the NotI restriction site to terminate protein synthesis (see Figure 2, grey box). For possible 
subcloning, HindIII and BamHI sites were introduced between functional elements of the DNA 
constructs. The resulting gene fragments are compatible with pET22b(+) vector (Novagen) and can by 
cloned in frame using DNA ligation (see Figure 1). 
Three elements were attached to the C-terminal end of the 336 amino acid sequence of CPCR2 (see 
Figure 2). C-terminal extensions are preferred over N-terminal ones, since protein folding starts from 
the N-terminus. Hence, C-terminal extensions interfere less with native folding of the target protein. 
 
Figure 2 Design of the wtCPCR2 construct. 
 
For convenient and mild purification of the protein, an affinity tag of eight amino acids was fused 
(see Figure 2, ocher box). The motif WSHPQFEK binds with high selectivity to the column matrix, and 
facilitates one-step purification by elution with desthiobiotin (IBA BioTAGnology, Göttingen) (see also 
2.2.4). A decamer of alanines is placed upstream of the strep tag (see Figure 2, green box), which is 
prone to form a stiff α-helix and serves a spacer peptide. The structural motif provides mobility to 
the strep-tag thereby reducing the probability that it is inaccessible for purification. Furthermore, a 
recognition site for the commercially available protease from tobacco etch virus (TEV) is positioned 
subsequent to the terminal amino acid of CPCR2 (see Figure 2, red box). The protease recognizes the 
peptide sequence ENLYFQG and cleaves between Q and G. In case, the C-terminal extension 
negatively affects CPCR2 properties, the extension could be eliminated upon TEV protease 
treatment. 
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2.1.3. Generation of Site-specific CPCR2 Mutants 
In this work, amino acid exchanges were introduced at specific sites in the protein using a method 
based on polymerase chain reaction (PCR). In this, the primer contains the nucleotides coding for the 
desired mutation whereas the flanking parts of the primer sequence are fully commentary to the 
template DNA. A high-fidelity DNA polymerase amplifies the whole plasmid construct and the final 
PCR product contains the mutation(s) at the desired position since the synthetic primer was 
integrated. The principle is known and commercialized as QuikChange® method (Stratagene). 
The example in Figure 3 depicts an exchange from leucine (Leu, green box) to asparagine (Asn, red 
box) with a primer carrying an AAC nucleotide codon, whereas the template DNA exhibits a CTG-
codon. 
Figure 3 Principle of a single amino acid exchange using the QuikChange® method. 
To obtain only mutated DNA from PCR, template DNA with wild type codon has to be removed 
efficiently. For this, the DNA restriction enzyme DpnI is applied, since it cleaves only template DNA 
from microbial origin. For instance, DNA from E. coli is specifically methylated to mark it as host DNA 
and DpnI works only on the template DNA leaving non-methylated PCR-products intact. 
The design of the primer results in two oligonucelotides, which are fully complementary to each 
other and are prone to annealing, which gives primer dimers. Thus, PCR will result in reduced yield 
since the primer dimers cannot be used for elongation. Hence, a two-step protocol was applied 
wherein at first the two primers are elongated separately and are mixed afterwards.[1] 
2.1.4. Construction of CPCR2 Site-saturation Libraries 
For protein engineering not only site-specific single amino acid exchanges are performed but also 
site-saturation in, which all 19 alternative amino acids occur. For this semi-rational approach the 
QuikChange® method with primers having degenerated codons are employed. The maximum 
degeneracy for an amino acid would be NNN, where N stands for all four nucleotides giving 43 = 64 
possible triplet codons. The NNN codons cover all 20 amino acids as well as the three stop codons. 
However, reduced codon degeneracy e.g. NNS (S stands for G & C) also covers the full set of amino 
acids but only one stop codon with 32 variations. It has been shown that a minimal set of twelve 
chemically different amino acids encoded by NDT codon (D = G, A & T) can lead to similar results than 
using NNN codon but with screening much less variants.[2] For a site-saturation experiment the codon 
degeneracy strongly affects the effort in screening. 
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The quality of a library may be analyzed with respect to the wild type gene unintentionally present. 
This is usually done be DNA sequencing of few clones to check efficient mutagensis and removal of 
wild type DNA after PCR. High content of wild type DNA lowers the quality of the library and more 
clones have to be analyzed to cover all possible variants. 
To assure that all possible variants are present in the library after PCR and transformation, a library 
of certain size has to be generated. With a set completeness (usually >95 %), the library size depends 
on the number of codons and the degeneracy applied in the experiment. For example, a site-
saturation library for a single amino acid with codon degeneracy NNN comprises 64 possible variants. 
For a library with desired 100 % completeness, statistically a three times excess of variants (64 x 3 = 
192 clones) represents the full set of variants with 95 % probability.[2] 
Codon degeneracy NNS (32 possible codons) requires only 96 clones to match the same statistical 
parameters. When the number of codons increases the number of possible variations rise 
exponentially, e.g. two amino acids with NNS codon, 322 = 1024 variants are possible and at least 
3066 variants have to be screened. Hence, addition of only one amino acid increases the screening 
effort by the factor of 33. Therefore, the design of a site-saturation experiment has to be carried out 
with care. A comprehensive online-tool provides the possible codon degeneracies as well as the 
statistics and minimum number of variants to screen for.[3] 
2.1.5. Transformation of Plasmid Constructs to E. coli 
To introduce recombinant plasmid DNA generated by restriction and ligation (compare 2.1.2) or 
QuikChange® (compare 2.1.3 & 2.1.4) to the expression host E. coli two methods were applied. 
Heat shock transformation was carried out with E. coli previously made competent according to 
Inoue[4] or Sambrook & Russell[5]. After conferring competence, E. coli was able to take up plasmid 
DNA upon heat treatment. 
For higher transformation efficiencies, e.g. for library construction, usually electroporation was 
applied with commercial E. coli cells (E. cloni® BL21(DE3) Express, Lucigen). Transformation was done 
according to the manufacturers’ manual. If the number of transformants was too low, commercial 
“ultra-competent” cells were used (E. cloni® 10G, Lucigen). Then plasmids were recovered and re-
transformed to the expression host. In all cases ampicillin at 100 µg mL-1 was used as antibiotic as the 
gene for ampicillin resistance is provided by pET22b(+) (see Figure 1). 
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2.2. Protein Chemistry Techniques 
2.2.1. CPCR2 Protein Expression in Flask Scale 
CPCR2 was cloned into pET22b(+)-vector and transformed to E. coli BL21(DE3). The vector contains a 
promotor for a RNA-polymerase from the phage T7. The gene for T7-RNA polymerase is encoded in 
the genome of E. coli (DE3)-strains and is under the control of the lac-promotor. Upon induction with 
isopropylthiogalactoside (IPTG), T7-RNA polymerase is expressed by the E. coli protein synthesis 
machinery. The polymerase binds to its promotor on the plasmid and generates mRNA of the gene 
encoded downstream. The repressor of the lac-promotor (lac I) is encoded not only on the E. coli 
genome but also on the plasmid, ensuring a minimum basal expression of the recombinant gene 
since the T7-promotor also contains a binding site for lac I (lac o). The tight control of expression 
together with the high expression levels induced by the strong T7 promotor render this system very 
powerful for heterologous protein expression. 
A CPCR2 construct used in former projects consisted of the gene with original Candida codon usage 
cloned in to pET26 vector.[6] This construct was successfully applied in E. coli JM109(DE3) at 30 °C 
expression temperature and 1 mol L-1 IPTG to produce soluble and active CPCR2. For the newly 
designed CPCR2 construct; however, expression conditions were changed. To obtain soluble CPCR2, 
the expression temperature had to be lowered to 15 °C and 0.1 mol L-1 IPTG were added. It can be 
assumed that higher expression temperatures led to excessive production of CPCR2 beyond the 
folding capacities of the E. coli resulting in formation of inclusion bodies. Reduced expression 
temperatures slow down the whole metabolism as well as protein expression allowing CPCR2 to fold 
properly. 
CPCR2 expression in flask scale was carried out in TB medium (24 g L-1 yeast extract, 12 g L-1 tryptone, 
4 g L-1 gylercol, 0.1 mol L-1M KPi pH 7.0) with a ratio of medium to flask volume of at least 1:5. As 
inoculum, 2 % (v/v) of an overnight culture in LB medium (5 g L-1 yeast extract, 10 g L-1 tryptone, 
10 g L-1 NaCl) were added. The culture was incubated at 37 °C and 250 rpm until an optical density at 
600 nm of 0.6 was reached indicating the early exponential growth phase. Then, 0.1 mol L-1 IPTG was 
put in and the temperature was shifted down to 15 °C. CPCR2 expression was usually carried out 
overnight but never longer than 18 hours. 
2.2.2. CPCR2 Protein Expression in Fermenter 
For production of larger amounts of CPCR2, high-cell density fermentation in 2 liter was carried out. 
For this a BIOSTAT®Bplus (Sartorius) was applied. In principle, all parameters such as medium, 
temperature and IPTG concentration were identical to flask expressions. Though, TB medium was 
supplemented with 30 g L-1 glycerol to serve as carbon source and promote cell growth to high 
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densities. Ammonia (30 % (w/v)) had the function of pH regulation agent as well as nitrogen source. 
Oxygen saturation was set to 30 %, relative to air. 
Fermentation was initiated by inoculation with 5-6 % (v/v) of a pre-culture and cell proliferation was 
assessed by measuring optical cell density at regular time intervals. A stable fermentation was 
achieved by keeping the oxygen saturation level constant by controlling stirrer speed. In the early 
exponential phase (usually OD600 8-10) expression was induced with 0.1 mol L
-1 IPTG. After the 
temperature shift to 15 °C, cell growth was further monitored and activity of CPCR2 was determined 
(for activity assay see section 2.2.6). After 8-10 hours, fermentation was terminated and cells were 
harvested. 
2.2.3. CPCR2 Protein Expression in 96-well Multititer Plates 
As for flask and fermenter expression, the principle parameters for expression in 150 µL scale in 96-
well plates were similar. The standard procedure is depicted in Figure 4. 
Figure 4 Standard operation procedure for CPCR2 expression in multititer plate 
The starting point is the master plate, a storage culture in a microtiter plate, containing the library of 
clones mixed with 25 % (v/v) glycerol. From this, a pre-culture was inoculated and grown overnight at 
37 °C in a flat bottom plate. The main culture was inoculated with 10 µL of the pre-culture in a V-
bottom plate. Ideally, this culture has only little deviation in growth across the plate (<10 %) since 
stationary growth phase should be reached. The initial growth phase in TB medium at 37 °C takes 
one hour and was followed by the expression phase of 6-8 hours at 15 °C after addition of 0.1 mol L-1 
IPTG. Expression was terminated by harvest of the cells through centrifugation. Cell pellets with 
overexpressed CPCR2 were stored at -20 °C after medium removal. 
To obtain lowest growth deviation throughout the microtiter plate, inoculation was carried out using 
a multichannel pipet. Furthermore, plates were tightly sealed with tape to prohibit influx of oxygen 
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promoting bacterial growth on the edges of the plate. For accurate evaluation of screening results 
controls were added to each plate. One control was the parent protein (e.g. wild type CPCR2) to 
compare the features of the variants with the basal values. Furthermore, a negative control usually 
carrying empty vector was integrated to check whether E. coli lysate interferes with detection assay. 
These controls appeared at least three times per plate and at best equally distributed across the 
plate (e.g. 2x corner, 1x center of the plate) to have an estimate on the significance of the values. 
2.2.4. Cell Lysis & CPCR2 Protein Purification 
Fresh or frozen cell pellets from flask culture or fermentation were lysed enzymatically and 
mechanically by adding lysis buffer (0.05 mol L-1 NaPi, 0.3 mol L
-1 NaCl, 1 g L-1 lysozyme) in a ratio1:4. 
At first cells were resuspended in lysis buffer and incubated for 1 h at 37 °C to weaken the E. coli cells 
walls by lysozyme. Afterwards, the slurry was subjected to ultra-sonication to break the cells and 
release CPCR2 into the medium. Here, an ultrasonic homogenizator (MS73/UW 200 with generator 
Sonopuls HD 200, Bandelin) at 40 % amplitude and 40 cycles was used. The treatment was done for 
1 minute for three times with intermittent cooling steps on ice. Cell debris was collected by 
centrifuging with 2820x g for 10 minutes at 4 °C. The cleared lysate was applied for strep-tag protein 
purification. 
For strep-tag purification in small scale (up to 5 mL lysate), gravity columns with 1 mL bed volume 
were applied, whereas for larger scales high-capacity columns for fast liquid protein chromatography 
(FPLC) were utilized. For all purifications commercial columns and chemicals were used supplied by 
IBA BioTAGnology (IBA BioTAGnology GmbH, Göttingen). Proteins comprising a strep-tag bind with 
high selectivity (Kd = 1 µmol L
-1) to immobilized Strep-Tactin, an engineered streptavidin and can be 
eluted efficiently by addition of 2.5 mmol L-1 desthiobiotin. Up to 100 nmol L-1 highly pure protein can 
be recovered. Conveniently, no gradient of eluent has to be applied and eluent concentration in the 
final sample is fairly low. Hence, this method is easy to handle, mild and the purified protein is readily 
usable. 
For FPLC strep-tag purification, parameters for appropriate CPCR2 purification were established. 
Here, an ÄKTA Prime (GE Healthcare) was applied equipped with a Strep-Tactin®Superflow® cartridge 
with 5 mL capacity (IBA BioTAGnology GmbH, Göttingen). For purification procedure, wash buffer 
(0.3 mol L-1 NaCl, 0.1 mol L-1 Tris pH 8.0) and elution buffer (0.025 mol L-1 desthiobiotin, 
0.3 mol L-1 NaCl, 0.1 mol L-1 Tris pH 8.0) were prepared, degassed and chilled to 4 °C. Prior application 
of cleared cell lysate, the system was equilibrated with wash buffer until a stable baseline was 
reached. Cell lysate was pumped with 4 mL min-1 and the column was rinsed with wash buffer with 
until the original baseline value was obtained (usually 4-5 column volumes). After washing, elution 
buffer was pumped by the FPLC device and fractions were collected. Pure CPCR2 protein was eluted 
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after one column volume plus dead volume of the system (ca. 1-2 mL). Flow rates and fraction sizes 
were adjusted according to back pressure requirements and grade of separation desired. 
2.2.5. Cell Lysis in 96-well Plate-scale 
For cell lysis in 96-well plate, a new protocol was established since ultra-sonication could not be 
carried out. The standard operation procedure for effective cell lysis in microtiter scale to release 
CPCR2 is Figure 5. 
Figure 5 Standard operation procedure for cell lysis of CPCR2 in microtiter plate scale 
Wells with frozen pellets were filled with 150 µL lysis buffer (0.3 mol L-1 NaCl, 0.05 mol L-1 NaPi, 
pH 8.0) containing 5 g L-1 lysozyme for enzymatic rupture of the outer E. coli membrane. 
Resuspending and additional mechanical lysis was facilitated by pipetting 100 times 100 µL volume 
with a pipetting tool specially designed to aspire 96 times with one action (liquidator96®, 
Steinbrenner GmbH, Wiesbaden). After incubation of one hour at 37 °C cell lysis was completed and 
cell debris was collected by centrifugation. The cleared lysate was the kept on ice and applied to 
microtiter plate screening. 
2.2.6. NADH-depletion Assay for Activity Determination in Cuvette-scale 
Volumetric activity of CPCR2 was determined by initial rate measurements using an NADH depletion 
assay. During reduction of a ketone substrate the cofactor NADH is converted in an equimolar 
fashion wherein NADH absorbs light at 340 nm and NAD+ does not. Consequently, the consumption 
of NADH is proportional to the accumulation of product accessible through the molar extinction 
coefficient of cofactor εNADH. Hence, NADH depletion over time can directly be linked to the 
enzymatic unit [U], which is defined as the amount of enzyme generating 1 µmol of product 
produced per minute. The relation of decrease in absorbance and enzymatic activity is given in 
Equation 1 known as Lambert-Beer Law. 
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Equation 1: Calculation of volumetric activity of CPCR2 in NADH depletion assay. 
In a standard NADH depletion assay for CPCR2 in 1mL scale, acetophenone served as a model 
substrate for ketone reduction and was used in 5 mmol L-1 concentration in assay buffer (0.1 mol L-1 
triethanolamine (TEA), pH 8.0). Generally, 10 µL enzyme solution was added and the reaction was 
initiated by 10 µL 30 mmol L-1 NADH (final concentration 0.3 mmol L-1 NADH). The decrease in 
absorption at 340 nm was monitored over 2 minutes. CPCR2 solution has to be diluted appropriately 
to give a linear decrease in initial rate measurement. Most reliable values are obtained when 
ΔAbs/Δt are ranging between 0.5-0.05 min-1. The coefficient for linear regression R2 was always 
>0.95 indicating a high probability of linear correlation of the measured values. 
In this setup, volumetric CPCR2 activity was calculated by combining the constant factors (Vtotal = 1 
mL, Venzyme = 10 µL, d = 1 cm, εNADH = 6,220 mol
-1 L cm-1) to one value of 16.078 µmol. This value was 
simply multiplied with the obtained slope and corrected for the dilution giving the volumetric activity 
of CPCR2 in enzymatic units. Reference measurements were carried out omitting substrate to 
evaluate whether NADH is consumed by mechanisms except ketone reduction by CPCR2. 
For normalization to specific CPCR2 activity, total protein concentrations of purified CPCR2 
preparations were determined using Bradford assay. In this colorimetric assay, the dye Coomassie 
Brilliant blue G250 interacts with proteins and shifts the absorption maximum of the dye to 595 nm. 
Here, calibration curves using 20 µL of bovine albumin serum standard from 0-1 mg mL-1 in 980 µL 
Bradford reagent were prepared fresh. CPCR2 enzyme solutions were diluted accordingly to fit in the 
linear range of the standard curve. To obtain specific CPCR2 activity, volumetric activity [U mL-1] was 
divided by measured protein concentration of the sample mgProtein mL
-1 giving U mgProtein
-1. Since in 
the Bradford assay, the total protein concentration is determined, purity of CPCR2 has be checked 
carefully by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) described 
elsewhere.[5] 
2.2.7. NADH-depletion Assay for Activity Determination in Microtiter Plate 
The principle of activity determination of CPCR2 in multitier plate formate remains the same as 
outlined in section 2.2.6; however, the assay had to be down-scaled for 250 µL volume, smaller path 
length and CPCR2 activities found after expression and cell lysis in microtiter plate. 
enzymeNADH
total
vol
Vd
FV
t
Abs
A
Avol =  volumetric enzyme activity  [U mL
-1
] 
ΔAbs/Δt = linear slope of absorption over time [min
-1
] 
Vtotal =  total assay volume  [mL] 
F =  dilution factor [-] 
εNADH =  molar extinction coefficient  [mol
-1
 L cm
-1
] 
d =  path length  [cm] 
Venzyme = volume of enzyme solution  [mL] 
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For library screening, 50 µL of enzyme solution was mixed with 150 µL substrate in assay buffer 
(8.33 mmol L-1 acetophenone, 0.1 mol L-1 TEA, pH 8.0) in a flat bottom plate made of polystyrene. The 
reaction was initiated by addition of 50 µL 5 mmol L-1 NADH in assay buffer and proper mixing. 
Bubbles occurring during mixing were burst applying a heat gun. 
Absorption at 340 nm was recorded for 5 minutes using a multititer plate reader Infinite® M1000 
equipped with the according software i-control 1.6 (Tecan Ltd.). The assay was validated using a plate 
containing wild type CPCR2 and empty vector controls. This analysis revealed that virtually no 
background activity from E. coli proteins consuming NADH was present. Furthermore, standard 
deviation in activity for the whole procedure starting from the master plate via CPCR2 expression and 
cell lysis was <15 %, which is considered sufficient to screen libraries for improved variants.[7] 
2.2.8. Inactivation Assays for CPCR2 
CPCR2 is prone to inactivation in the presence of aqueous-organic interphases as reported earlier.[8] 
Hence, there is a demand for improvement of CPCR2 stability to make the enzyme more suitable for 
possible industrial applications. Therefore, one goal of this thesis was the general stabilization of 
CPCR2 using methods of protein engineering. To analyze stability improvement of CPCR2 variants, 
appropriate inactivation assays had to be developed and transferred to microtiter plate formate for 
screening. 
For library screening, CPCR2 in E. coli cell-free lysate was exposed to elevated temperature and 
detergent for inactivation to identify variants with higher residual activity than wtCPCR2. These 
variants are, in turn, supposed to be more stable. For this, suitable conditions with respect to 
incubation time, applied temperature and detergent, as well as concentrations and volumes of assay 
components have to be discovered. Generally, parameters found suitable for screening can also be 
useful for subsequent characterization of improved purified CPCR2 variants. 
2.2.8.1. Inactivation by Temperature 
Since thermostability often correlates with organic solvent stability, the behavior of wtCPCR2 at 
elevated temperatures was investigated. More precisely, the T50-value was determined as the 
temperature at, which 50 % of the initial enzyme activity is lost upon thermal incubation at constant 
time. Inactivation of CPCR2 lysates was tested after 20 minutes incubation in a range of 30-70 °C. A 
typical inactivation profile for an enzyme is depicted in Figure 6. In this profile the T50-vlaue is the 
transition midpoint of the curve. Equation 2 shows the underlying mathematical model describing 
thermal enzyme inactivation. 
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Equation 2 Mathematical model for determination of the T50-value. Letter a is a fitting parameter. 
A temperature close to T50 can be applied for thermal inactivation in screening, because changes in 
thermal resistance are most prominent in this regime of the curve (see Figure 6). Hence, subtle 
improvements in T50 will be reflected in strong changes in residual activity, which can be identified by 
screening. 
 
Figure 6 Typical inactivation profile of an enzyme to determine T50-value. Taken from 
[9]
. 
For CPCR2 variants identified by screening, T50-values were determined for purified enzyme and 
compared to wtCPCR2 as a stability parameter. 
2.2.8.2. Inactivation by Detergents 
As potent inactivating agents for enzymes, detergents are well known. That is why four different 
detergent classes were tested to identify the most appropriate candidate for inactivation of CPCR2 
for screening. TritonX100 as non-ionic, sodium dodecyl sulfate (SDS) as negatively charged, cetyl 
trimethyl ammonium bromide (CTAB) as positively charged and 3-[(3-Cholramidopropyl)dimethyl-
ammonio]-1-propanesulfonate (CHAPS) as zwitterionic detergent were tested with crude lysate of 
wtCPCR2. Properties and applied concentrations are listed in Table 1. 
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Table 1 Properties and applied concentrations of selected detergents for CPCR22 inactivation. Critical micelle 
concentrations (cmc) were retrieved from booklet Calbiochem® Detergents. 
Entry Detergent Type 
cmc 
[mmol L
-1
] 
Tested concentrations 
[mmol L
-1
] 
1 TritonX100 non-ionic 0.2-0.9 0.5 1 
2 SDS anionic 7-10 0.5 2 
3 CTAB cationic 1 0.5 5 
4 CHAPS zwitterionic 6-10 2 20 
 
For the inactivation assay, 10 units of CPCR2 in crude E. coli extract were mixed in final volume of 2 
mL with detergent in assay buffer (0.1 mol L-1 TEA, pH 8.0) at 30 °C and 100 rpm stirring. Enzymatic 
activity was assayed at regular time intervals using the cuvette-scale activity assay. Measurements 
were carried out in duplicates. 
SDS was found to inactivate CPCR2 within minutes for CPCR2 concentrations >1 mmol L-1. Hence, for 
the inactivation assay in multitier plate SDS was selected. Convenient SDS concentration and 
incubation time were established to inactivate wtCPCR2 activity in 96-well plates by 50 %. Library 
screening for improved detergent stability was performed under these conditions. 
2.2.8.3. Inactivation by Organic Solvents 
As fundamental drawback of CPCR2, low interfacial was identified previously.[8] To alleviate this 
disadvantage, stabilization of CPCR2 towards elevated temperature and a detergent is undertaken, 
since stabilities were shown to correlate. Screening with water-immiscible solvents directly would be 
an adequate approach to find variants with improved interfacial stability; however, this was not 
perused due to practical reasons. For instance, inactivation of CPCR2 at an interface in crude E. coli is 
not convenient due to evaporation of solvent, dissolution of plastic equipment and extended 
incubation times. Therefore, temperature and detergent incubation were selected due to better 
handling in screening. 
Nevertheless, purified CPCR2 variants were tested in the presence of an aqueous-organic interphase. 
For the analysis of interfacial stability, cyclohexanone as second was applied. Herein, 2-3 mL of 
solvent-saturated buffer (0.1 mol L-1 TEA, pH 8.0) was mixed with purified CPCR2 enzyme at 
100 mg mL-1 in standard glass vials. The aqueous phase was overlaid with the same amount of buffer-
saturated cyclohexanone. The setup was incubated at room temperature and 100 rpm stirring. 
Residual activity was assayed at regular time intervals by application of the cuvette-scale activity 
assay. 
In this, a first order decay of enzyme activity was assumed to describe the decrease in CPCR2 activity. 
The mathematical model describing the decrease of CPCR2 activity is presented in Equation 3. 
Usually, enzyme stabilities are compared by the half-life time (t1/2). This is the time, when 50 % of the 
initial enzyme activity (At = 0.5) is lost and can be derived from Equation 3: t1/2 = 0.693/k. 
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Equation 3 Mathematical model to describe the decrease of CPCR2 activity. A0 is initial activity, At is residual activity after 
the time t, k is the deactivation constant. 
Improved CPCR2 variants identified by screening were purified and tested in this system to elucidate 
whether interfacial stability and thermostability correlate. 
 
2.2.9. Screening Strategy for Identification of More Stable CPCR2 Variants 
Improved variants of CPCR2, generated by protein engineering, can be identified by comparing initial 
activity with residual activities after treatment with SDS and temperature. However, for libraries 
containing various CPCR2 variants growth behavior and expression levels may vary, which results in 
high deviation in the activity assay wherein volumetric activity is detected. To eliminate false 
negatives and false positives, activity ratios rather than absolute values are considered for 
comparison. The overall screening strategy is depicted in Figure 7. 
 
Figure 7 Screening strategy to find CPCR2 variants with increased activity and stability. 
2.3. CPCR2 Biotransformations 
2.3.1. Biotransformation with Purified CPCR2 Enzyme 
Biotransformations with purified CPCR2 enzyme were carried out to obtain chiral in alcohol in 
analytical amounts to determine conversion and enantiomeric excess. For this, CPCR2 was purified as 
described in 2.2.4 and used with up to 30 U in the experimental setups in 25-50 mL scale. Usually, 
1 mmol L-1 dithiothreitol as reducing agent and 1-5 mmol L-1 NADH as cofactor were added. Organic 
substrates were solubilized in isopropanol, the latter serving as cosubstrate for enzyme-coupled 
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cofactor regeneration. This mixture was added to assay buffer (0.1 mol L-1 TEA, pH 8.0) with final 
concentration of 2.5-5 % (v/v) isopropanol. The setup was stirred at 200 rpm for 24 hours at 30 °C. 
Conversion was monitored by taking regular samples and extracting organic compounds with 
dichloromethane or ethylacetate. The dried organic portion was analyzed by gas chromatography. 
Identification of compound peaks was performed with authentic commercial standards. For some 
compounds, derivatization was necessary to obtain reasonable separation. Conversions were 
calculated by taking the peak areas of substrate and product into account (see Equation 4). 
Substrateoduct
oduct
areaarea
area
conversion
Pr
Pr[%]  
Equation 4 Calculation of conversion on the basis of peak areas deduced from gas chromatography 
Enantiomeric as well as diastereomeric excess (ee & de) was determined by comparing the peak 
areas obtained for the products. The ee & de is always calculated for the stereoisomer in excess (see 
Equation 5). 
erstereoisomexcessnonerstereoisomexcess
erstereoisomexcess
areaarea
area
deee [%]/  
Equation 5 Calculation of enantiomeric and diastereomeric excess on the basis of peak areas deduced from gas 
chromatography 
2.3.2. Biotransformation with Whole Cells with CPCR2-overexpressed 
For analytical scale, E. coli cells with overexpressed CPCR2 were used for asymmetric reduction in 
aqueous buffer. In this, 1 g wet E. coli whole cells were resuspended in 25 mL buffer (0.1 mol L-1 KPi, 
pH 6.8). As second phase methyl tert-butyl ether (MTBE) was used containing the organic substrates 
and serving as extraction phase for the products. For cofactor regeneration, isopropanol (5 % (v/v) or 
glucose (5 g L-1) were used. Samples of the organic phase were directly applied to gas 
chromatography to calculate conversion and ee with Equation 4 and Equation 5, respectively. 
2.3.3. Biotransformation in Neat Substrates 
Asymmetric ketone reduction was carried out with E. coli cells containing overexpressed CPCR2 in 
neat organic substrates. Additionally, alcohol dehydrogenases from Lactobacillus brevis (LbADH) and 
Rhodococcus erythropolis (ReADH) overexpressed in E. coli were investigated in this system. For this, 
the cells have to be completely dried, which is facilitated by lyophilization. This was carried out for at 
least 48 hours in a lyophilizer (Alpha 1-2 LD plus, Christ ) at default settings. The organic substrates 
for biotransformation were dried with molecular sieves for at least 48 hours. 
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Table 2 Composition of saturated salt solutions and water activity at 30 °C, taken from 
[10]
. 
salt Salt amount [g] Water [mL] aw [%] 
Potassium Acetate K(CH3COO) 200 65 22.4 
Magnesium Nitrate Mg(NO3)2 200 30 51.4 
Sodium Chloride NaCl 200 60 75.4 
Potassium Chloride KCl 200 80 83.6 
Potassium Nitrate KNO3 200 75 92.3 
Water activity (aw) was established by equilibrating dry substrates and dry E. coli whole cells in the 
presence of saturated slat solutions via the vapor phase. Certain salts with fixed humidity points (aw-
values) at a certain temperature according to Greenspan were used.[10] Saturated salt solutions of 
fixed aw were composed according to Table 2. 
For equilibration to fixed aw-values portions of the compositions from Table 2 were placed in a 
100 mL screw cap bottle and a container plus stirrer bar with dry substrates or cells was pressed into 
the excess solid salt (see Figure 8). The sealing was air-tight to prevent evaporation of the substrate 
solutions or influx of humidity from the environment. 
 
Figure 8 Setup for equilibration to fixed aw-values of substrate solutions and cells with saturated salt solutions 
For complete equilibration, substrate solutions and cells were incubated in this setup for at least 
48 hours at 30 °C. Liquid substrates were stirred at 200 rpm and solid cells were mixed applying a 
spatula. 
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2.4. Computational Methods 
2.4.1. DNA & Protein Design and Sequence Analysis 
For design of DNA constructs and primers as well as analysis of DNA-sequencing results, the software 
packages ApE© plasmid editor version 2.0.15 (by M. Wayne Davis) and BioEdit version 7.0.9 (by Tom 
Hall) were applied. Structural analysis of enzymes was done with PyMol software version 0.99rc6 
(DeLano Scientific). 
2.4.2. DNA & Protein Alignments 
For comparison of DNA and protein sequences, alignments were generated using the standard 
multiple sequence alignment tool CLUSTAL W imbedded in BioEdit.[11] Searching DNA and protein 
sequences in online databases was performed using basic local alignment search tool (BLAST) with 
default settings.[12] Structural alignments were performed using PyMol version 0.99rc6 (DeLano 
Scientific). 
2.4.3. Data Analysis and Fitting 
Data analysis was performed using Mircosoft Professional Plus 2010 Excel® with a built-in software 
Solver. Additionally, data fitting software SimFit (version 6.2, release 2) was utilized.[13] 
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3 Results & Discussion 
3.1 Who´s who? – Allocation of Carbonyl Reductase Isoenzymes from 
Candida parapsilosis by Combination of Bio- and Computational 
Chemistry 
3.1.1 Abstract 
The identification of a single enzyme responsible for an interesting catalytic property remains 
challenging especially when isoenzymes are present in the host organism. In this work, we show the 
allocation of two carbonyl reductase isoenzymes from Candida parapsilosis (CPCR1 & CPCR2) by a 
rational combination of classical biochemical methods and computational chemistry. By building 
homology models and comparison of the substrate binding pockets, distinctive indicator substrates 
were predicted and tested with the single enzyme candidates. Herein, a previously described 
carbonyl reducing activity on structurally diverse substrates detected in Candida parapsilosis lysate 
could be undoubtedly assigned to only one of the enzymes (CPCR2). Likewise, a complementary 
substrate scope of the two carbonyl reductases could be excluded 
3.1.2 Introduction 
Years ago, carbonyl reductase from Candida parapsilosis (CPCR; E.C.1.1.1.1) was described as a 
suitable catalyst for the asymmetric reduction of various carbonyl compounds, such as aliphatic and 
aromatic ketones and diketones, keto acids, esters, and amides (see Scheme 1).[1] Apart from the 
large substrate range and high stereoselectivity, it is characterized by high stability in the presence of 
low molecular weight alcohols, such as isopropanol[2], and a preference for NADH as cofactor instead 
of the more expensive and less stable NADPH associated with many other alcohol 
dehydrogenases.[1a] As a result, regeneration of the essential cofactor can be achieved either by 
providing isopropanol as co-substrate[1a, 1b, 3] or by use of established co-catalysts such as formate 
dehydrogenase (FDH; 1.2.1.2) from C. boidinii.[4] All these features imply a special utility of CPCR for 
organic synthesis. 
Nevertheless, application in research as well as industrial production is only limited today. This can 
probably be explained by the uncertainties regarding the biocatalyst’s identity and thus its precise 
and reproducible synthetic use: Two preparations are currently commercially available, isolated 
either from the native production strain C. parapsilosis (Codexis, USA), or from Escherichia coli as 
recombinant host organism (X-zyme, Germany). However, the preparations reveal clear differences 
in their biochemical features and do not match those of the data defining the original target 
enzyme.[1a, 5] 
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Scheme 1 Sample compounds from the substrate range of carbonyl reductase from Candida parapsilosis DSMZ 70125 
This study describes the elucidation of the molecular identity of CPCR isoenzymes by the 
interdisciplinary approach of combining classical biochemical methods and methods from 
computational chemistry. It involves a stepwise identification of two possible enzyme candidates 
with their amino acid sequences, the establishment of active site molecular models with subsequent 
application to the prediction of substrate binding patterns and a final discrimination of enzymes by 
experimental investigation of activity towards selected indicator substrates. 
3.1.3 Experimental 
If not stated otherwise all buffer salts, media ingredients, and chemicals were of highest available 
quality and used without further purification. 
3.1.3.1 Preparation of CPCR from C. parapsilosis 
According to the protocol of Peters et al.[1a] C. parapsilosis DSMZ 70125 was cultivated in shake flasks 
(2 L, 30 °C) using yeast extract (0.3 % (w/v) ), malt extract (0.3 % (w/v) ), peptone (0.5 % (w/v) ), and 
glucose (1.0 % (w/v) ) for preculture, and glycerol (2 % (w/v) ), yeast extract (1 % (w/v) ), KH2PO4 
(0.1 % (w/v) ), Na2HPO4 (0.1 % (w/v) ), and (NH4)2SO4 (0.12 % (w/v) ) for main culture (pH 4.5).
[1a] Cells 
were harvested by centrifugation and disintegrated in a wet bead mill (4 °C, 30-40 % (w/v)  cells in 
aqueous buffer (0.1 mol L-1 TEA, 0.1 mmol L-1 dithiothreitol (DTT), 0.1 mmol L-1 
phenylmethansulfonylfluorid (PMSF, AppliChem, Darmstadt, Germany), pH 7.5), bead diameter 
0.5 mm [ratio bead/cell suspension 2 : 1]. Cell debris was removed by centrifugation (4 °C) and the 
resulting crude extract was purified as described by Peters et al.[1a] This included precipitation (4 °C) 
by adding an aqueous solution of PEG 4,000 (50  % (w/v) , 0.1 mol L-1 TEA, 0.1 mmol L-1 DTT, 
0.1 mmol L-1 PMSF, pH 7.5) to the cell debris to a final concentration of 2.5 % (w/v), centrifugation 
(4 °C), and subsequent increase of the PEG concentration in the supernatant to 17 % (w/v). The 
precipitated protein was collected by centrifugation (4 °C), dissolved in aqueous buffer (0.1 mol L-1 
TEA, pH 7.5) and separated on an anion exchanger (Macro-Prep High Q, Bio-Rad, München, 
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Germany; 4 °C; 0.1 mol L-1 TEA, pH 7.5, 0.1 mmol L-1 DTT, 5 % (v/v) isopropanol, 1 mol L-1 NaCl, 
pH 7.5). CPCR eluted at a NaCl concentration of 260 mol L-1 (pH 7.5), and was concentrated by 
ultrafiltration (size exclusion 30 kDa, 4 °C, 3 bar). Protein for sequencing was additionally subjected 
to affinity chromatography (5’AMP-Sepharose 4B; Sigma-Aldrich, 0.01 mol L-1 TEA, pH 7.0, 1 mmol L-1 
DTT, 3 mmol L-1 NAD+) and gel filtration (Sephadex G 75, Amersham Pharmacia-Biotech, Freiburg, 
Germany). Protein concentration was measured in a spectrophotometer (Beckmann DU, Fullerton, 
CA) by use of Bio-Rad protein assay according to the manufacturers’ advice. 
3.1.3.2 Biochemical Characterization of CPCR1 
Purity of enzyme preparations and protein size were determined by SDS-PAGE according to 
Laemmli[6] (1.5 mol L-1 Tris-HCl, pH 8.8, 10 % ((w/v) ) bisacrylamide, 10 % (w/v) SDS) using Mark12 
wide-range protein standard (Novex, San Diego, CA), bovine serum albumin (BSA, 66 kDa), and white 
egg albumin (WEA, 40 kDa) as size standards. The proteins were stained with an aqueous solution of 
Coomassie brilliant blue (0.05 % (w/v) Coomassie R250, 30 % (v/v) methanol, 10 % (w/v) acetic acid). 
For sequence analysis, the separated, unstained proteins were blotted on a PVDF membrane and 
stained with an aqueous solution of Amidoblack (40 % (v/v) ethanol, 10 % (v/v) acetic acid, 
0.1 % (w/v) amidoblack). In that case, the pre-stained “low range” marker (Bio-Rad) was used as size 
standard for SDS-PAGE. The target proteins were cut out, partly digested with the endoproteases 
Lys-C and Glu-C (Roche Diagnostics), and sequenced by Edman degradation using an Automated 
Sequencer 477A with on-line HPLC 120A (Applied Biosystems, München).[7]The sequences were 
aligned by using MAFFT with default settings.[8] 
The activity of CPCR was determined by measuring cofactor or substrate consumption in a UV/Vi 
spectrophotometer (340 nm; Microplate reader Spectramax Plus 340, Molecular Devices, Ismaning, 
Germany), with HPLC [Beckmann Coulter System Gold (Beckmann, München, Germany), NUCLEOSIL 
100-5 C18 (250 x 4 mm), 40 °C, 60 % H2SO4 (pH 3), 40 % acetonitrile at 0.6 mL min
-1 as mobile phase], 
or GC [HP 5890 Series II (Walbronn, Germany) equipped with FS-FFAP capillary column (25 m, 
250 µm; CS-Chromatographie Service GmbH, Langerwehe, Germany), N2 3.8 mL min
-1, injector 
220 °C, split 1:50, 40 °C (4 min), 100 °C (20K min-1), 180 °C (30K min-1), 180 °C (7 min); internal 
standard decane; typical tR values: acetone = 1.6 min, isopropanol = 2.2 min, decane = 2.9 min, 
acetophenone = 10.1 min, and phenylethanol = 11.0 min], respectively. 1 U is defined as the amount 
of enzyme that catalyzes the reduction of 1 µmol ethyl 5-oxohexanoate per min in aqueous solution 
(0.1 mol L-1 TEA, pH 7.0, 2.5 mmol L-1 NADH+H+, 10 mmol L-1 substrate, 37 °C). To measure substrate 
consumption, NADH+H+ regeneration was performed by addition of isopropanol.  
To determine Topt and pHopt (activity optima for reduction), buffered CPCR solutions (0.1 mol L
-1 TEA, 
pH 7.0) were added to solutions of ethyl 5-oxohexanoate at different temperatures (25-52 °C, pH 7.0) 
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or pHs (6-8, T = 37 °C) and measured for initial NADH+H+ consumption, as described in the previous 
paragraph. 
3.1.3.3 Cloning and Sequencing of CpSADH and CPCR1 
Genomic DNA was extracted from C. parapsilosis DSMZ 70125 cells by dissolving cell walls with 
Zymolase 100T (37 °C, 1 h, 0.9 mol L-1 sorbitol, 0.1 mol L-1 EDTA, 0.05 % (v/v) mercaptoethanol), the 
cell membranes with SDS (1 % (w/v) ) and the proteins with protease K (10 mg mL-1, 60 °C, 30 min, 
reaction stopped by addition of 0.5 mol L-1 potassium acetate). The DNA was precipitated with 
ethanol (100 %, 2 volumes, -20 °C, 1-2 days). RNA was digested in the resuspended DNA (10 mmol L-1 
Tris-HCl, pH 7.5, 1 mmol L-1 EDTA, pH 8.0), with RNAse (30 min, 37 °C), and the DNA was finally 
precipitated with isopropanol (100 %). The gDNA was twice washed with ethanol (70 %), dried, 
resuspended in buffer (10 mmol L-1 Tris-HCl, pH 7.5, 1 mmol L-1 EDTA, pH 8.0), and stored at -20 °C. 
The genomic DNA libraries of C. parapsilosis were prepared as described in the user’s manual of the 
Universal Genome Walker kit (BD Biosciences, Clontech, Heidelberg, Germany). Four libraries were 
constructed with the genomic DNA of C. parapsilosis by digesting with EcoRV, DraI, StuI and PvuII. 
The kit also provides human genomic DNA as positive control library that has to be digested with 
PvuII, and a pre-constructed human genome-walker library. Each of the digested DNA libraries was 
ligated to the genome walker adaptor. The digested and ligated libraries were stored at –20 °C until 
use. For long-term storage, the libraries may also be kept at –80 °C. 
The gene coding for CpSADH was amplified by conventional PCR from the DraI-digested genomic 
DNA library of C. parapsilosis DSMZ 70125 strain according to the instruction manual of (BD 
Biosciences). Primers were deduced from published sequences.[6b] An N-terminal His6-tag was 
introduced into the forward primer in order to facilitate easy purification. The fragment was ligated 
into the multiple cloning site of pET26b+ (Novagen) and the resultant expression vector 
pET26b+CpSADH28his was transformed into E. coli BL21(DE3). 
3.1.3.4 Measurement of Activity on Indicator Substrates 
Comparative activity measurements of CPCR preparations were performed on a Cary 300 UV/Vis-
spectrophotometer (340 nm; Varian). All substrates were used in 5 mmol L-1 in triethanolamine 
buffer (0.1 mol L-1, pH 8.0). Absorption was monitored at room temperature for 2 min. CPCR1 was 
provided from commercial source (X-zyme, Düsseldorf, Germany). CpSADH was recombinantly 
expressed in E. coli and used as crude extract. All measurements were performed in triplicate. 
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3.1.3.5 Computational Analysis 
Homology modeling of the structure of two CpCR isoenzymes was performed using YASARA Structure 
Version 11.6.16 with default settings (PSI-BLAST iterations:[10] 6, E value cutoff: 0.5, templates: 5, 
OligoState: 4).[11] A position-specific scoring matrix (PSSM)[12] was used to score the obtained 
template structures. Four X-ray templates were selected for modeling the CPCR1 structure (349aa): 
Yeast ADH I from S. cerevisiae with bound trifluorethanol (347 residues with quality score 0.522, PDB 
ID 2HCY), ADH from Brucella melitensis (341 residues with quality score 0.590, PDB ID 3MEQ), ADH 
from Bacillus stearothermophilus Strain Lld-R (339 residues with quality score 0.560, PDB ID 1RJW), 
ADH from Pseudomonas aeruginosa with bound ethylene glycol (341 residues with quality score 
0.555, PDB ID 1LLU). The best scoring model (Z score -0.73) was a hybrid model built on X-ray 
structure 2HCY and 1RJW and consisted of a dimer of dimers with two bound Zinc ions, one NAD(H) 
and one trifluoroethanol per monomer. 
Five X-ray templates were selected for the modeling of CpSADH structure (336aa): N249Y Mutant of 
ADH from Sulfolobus tokodaii Strain7 (347 residues with quality score 0.550, PDB ID 2EER), SsADH 
from Sulfolobus solfataricus (347 residues with quality score 0.547, PDB ID 1NTO),  SsADH 
N249Y/W95I (340 residues with quality score 0.541, PDB ID 3I4C), SsADH  (347 residues with quality 
score 0.534, PDB ID 1JVB) and SsADH complexed with NAD(H) and 2-ethoxyethanol (347 residues 
with quality score 0.524, PDB ID 1R37). The best scoring model (Z score -1.96) was built on X-ray 
structure 1R37 consisting of a dimer of dimers with two bound Zinc-ions, NAD(H) and 2-
ethoxyethanol per monomer. 
For the docking studies, one close dimer of the modeled structures was used, all energy calculations 
were performed using AMBER03[13] for the protein and GAFF[14] with AM1/BCC charges[15] for the 
substrates. All residues within 15 Å radius of the bound alcohol were free to move. The active site 
above the bound NAD(H) is located at the interface of the two Rossmann-fold monomers. The Zn-
bound alcohol-ligand in the active site of the homology models was manually replaced by the 
respective substrates in their keto form and relaxed using cycles of steepest-descent minimization 
and simulated annealing MD[5b] from 298K to 5K. Reference calculations for binding energies were 
performed using the substrates in a water box and the apo-enzyme with water coordinated to the 
catalytic Zn2+. The stabilization energies of the substrates in a catalytic orientation were calculated by 
subtracting the solvation energy for the substrate from the energy in the Zn2+ bound state and the 
energy difference of an actives-ite subset consisting of 10 residues lining the binding pocket in the 
substrate-bound state versus the apo-structure with bound water. (CpCR1: Thr 101, Ala 105, Trp 110, 
Trp 148, Tyr 175, Leu 326, Tyr 350, Val 351, Phe B337, Val B341 ; CpCR2:  Ser 46, Val 50, Leu 55, Trp 
116, Leu 119, Leu 262, Phe 285, Trp 286, Gly B272, Leu B276) 
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3.1.4 Results and Discussion 
3.1.4.1 Biochemical and Molecular Characteristics of CPCR Preparations 
For systematic investigation, the native host C. parapsilosis DSMZ 70125 was cultivated under the 
same conditions as in the original work on CPCR.[1a] Accordingly, partially purified lysate from this 
culture revealed a substrate spectrum and relative enzymatic activities similar to the reported data 
(see Table S1, 3.1.6), thus indicating the presence of the desired enzyme. A NADH-dependent protein 
with distinct carbonyl reducing activity could be purified to homogeneity. 
Table 1 Measured and published biochemical features of carbonyl reductase from Candida parapsilosis.  
*Data was measured by M. Bhattacharjee (PhD thesis 2006, RWTH Aachen University) 
Nevertheless, molecular weight, pH optimum and temperature optimum of the isolated protein were 
at odds with the published biochemical data of original CPCR (Table1). The molecular weight of one 
subunit of the homodimeric CPCR was originally reported as 67.5 kDa,[1a] whereas the purified 
protein found in this study was only 40 kDa. Proteins at both sizes, 67.5 kDa and 40 kDa, respectively, 
were found in a SDS-PAGE analysis of partly purified Candida lysate and a comparable commercial 
CPCR preparation (Codexis, USA, Figure S1, 3.1.6), but a direct allocation of any of these proteins to 
carbonyl reduction activity was not possible. The temperature and pH optima for ethyl 5-oxo-
hexanoate reduction of both partially purified CPCR and the dialyzed commercial preparation from 
Codexis were found at 43-47 °C and 5.5, respectively, not at 36-40 °C and 7.8-8.0 as reported by 
Peters et al.[1a, 5a]  This cannot be related to a failure in purification since both preparations revealed 
distinct CPCR activity. 
The obtained biochemical data indicate that, despite the identical expression, purification and very 
similar substrate range, the carbonyl reducing protein investigated in this study was not identical to 
the CPCR preparation described by Peters et al.[1a] However, it was similar to the CPCR preparation 
traded by Codexis. Surprisingly, the biochemical properties also complied with a recombinantly 
expressed NADH-dependent secondary alcohol dehydrogenase (CpSADH) isolated from 
C. parapsilosis type strain IFO 1396 (Table 1).[16] The reported substrate range of this enzyme lies 
within the substrate range of CPCR preparations, but as the authors investigated only a few 
compounds, it could not be deduced whether it covers the complete range. 
Feature      CPCR this work
*
     Codexis-CPCR       CPCR published    CpSADH 
Weight/subunit [kDa] ≈40 ≈40 67.5 36 
pH opt. (reduction) 6.0 5-5.5 7.8-8.0 5.5-6.5 
Temp. opt. (reduction) [°C] 48 43-47 36-40 50 
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In order to elucidate the relation between the here purified carbonyl-reducing protein and CpSADH, 
the genes coding for the isolated enzymes were identified and compared to each other. 
 
Figure 1 Alignment of the complete amino acid sequence from the purified carbonyl reductase protein (CPCR1) with the 
amino acid sequences of ADH 1 and ADH 2 from C. albicans and ADH1 from bakers´ yeast. Partial sequences derived by 
Edman degradation are highlighted in grey and the N-terminal presequence is underlined. Bold letters indicate identical 
amino acids. Edman degradation and retrieval of the CPCR1-DNA sequence was performed and published by M. Bönitz-
Dulat (PhD thesis, 2001, RWTH Aachen University). 
3.1.4.2 Identification and Analysis of the Amino Acid Sequence 
The homogeneously purified carbonyl-reducing protein was digested and separated into six distinct 
pieces. In order to identify the N-terminal amino acid sequences, the resulting fragments and the 
complete protein were submitted to Edman degradation[17] on an Automated Sequencer 477A  with 
online HPLC according to Baumann.[7] All fragments revealed an overall sequential homology of 82 % 
to the known alcohol dehydrogenase 2 and 81 % to alcohol dehydrogenase 1 from Candida albicans. 
According to this homology, the fragments were aligned in their natural order (Figure 1) and used to 
design degenerate primers for gene amplification. 
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Starting from a primer aligning within the internal nucleic acid sequence coding fragment 3, the 
complete open reading frame (orf) for expression of the 40 kDa protein was identified in a two-step 
molecular walking process. The orf consists of 1212 nucleic acid bases and codes for 403 amino acids 
(Figure 1). Surprisingly, the N-terminal sequence determined by Edman degradation revealed that 
the active enzyme is 55 amino acids shorter than deduced from the coding sequence and starts with 
a proline instead of methionine. 
This implies that a processing of the protein takes place in the host organism, although typical 
sequential cleaving signals could not be identified. As expected from the sequencing of protein 
fragments, the protein was highly homologous to ADH 1 from C. albicans (73 %), and also revealed a 
strong homology to ADH 2 from the same organism (71 %). However, these homologies exclusively 
lay in the protein part coding the active enzyme; while no homologies with any known alcohol 
dehydrogenase could be found for the N-terminal extension. In accordance with that observation, 
difficulties experienced with the heterologous expression of carbonyl reductase when only the partial 
sequence coding the active protein was used (data not shown) imply that the function of the N-
terminal extension sequence lies in protein folding rather than in activity. Recently, shotgun 
sequencing followed by expression profiling of Candida parapsilosis CDC317 revealed the presence 
an almost identical nucleotide sequence as retrieved in this work (gene bank accession: HE605207.1 
contig 006139).[18] Automated annotation yielded the CPCR protein sequence (gene bank accession: 
CCE44033.1). The coding sequence for CpSADH was also found in the same strain (gene bank 
accession: HE605205.1 contig 005807).[18] 
The protein coded by the complete nucleic acid sequence has a calculated molecular weight of  
≈43.1 kDa, the calculated weight of the active part of that protein is ≈37.0 kDa. Both do not comply 
with the molecular weight of 67.5 kDa reported for CPCR by Peters et al.[1a], but they are in good 
accordance with the findings on the molecular weight of CpSADH (≈36 kDa) and the carbonyl 
reducing protein purified here. This last protein will hence be designated CPCR1 (≈40 kDa). 
However, despite the compliance between the biochemical data determined for CPCR1 and CpSADH, 
only little homology (31.5 %) was found between the amino acid sequences of these enzymes. 
Instead, the active part of the amino acid sequence of CPCR1 is largely identical with the sequence of 
a commercial recombinant CPCR (personal communication, Shukrallah Na’amnieh, X-zyme). 
Differences can only be found at the N-terminus, since the commercial CPCR is expressed as an N-
terminal fusion protein. 
Nevertheless, running a PCR with primers generated from the amino acid sequence of CpSADH on 
the genomic DNA of C. parapsilosis DSMZ 70125 revealed that CpSADH is present in this host 
organism as well. It is known from Saccharomyces cerevisiae that yeast organisms can be hosts of 
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alcohol dehydrogenase isoenzymes.[19] The expression of these isoenzymes strongly depends on O2 
availability, ethanol content, and cell age.[20] For example, under anaerobic conditions, four NADH-
dependent alcohol dehydrogenases and a NADPH-dependent one are expressed in parallel.[21] Also 
for Candida maltose, different ADH isoenzymes expression levels could be detected depending on 
the carbon source used.[22] Against this background, a contribution of two distinct enzymes to the 
reported CPCR activity would be possible.[1a] 
In order to allocate CPCR activity either to CPCR1 or to CpSADH or rule both of them out, a novel 
strategy involving computational chemistry was applied. Homology modeling and modeling of 
substrate binding patterns were used to identify differences in the substrate range of both enzymes. 
Various CPCR preparations were then subjected to experimental verification. 
Table 2 Results from sequence alignment and modeling parameters. 
 
3.1.4.3 Computational analysis of CPCR Structure and Binding of Substrates 
Based on the sequences of CPCR1 and CpSADH, two homology models were constructed applying 
YASARA Structure Version 11.6.16 software[11] (see Figure S2, 3.1.6). Details on chosen templates, 
sequence identities and similarities are given in Table 2. According to the 3D-quality assessment (Z 
score) of the modeled structures (see Table 2) the models are rated “good” in the case of CPCR1 and 
“satisfactory” for CpSADH. 
A look into the substrate binding pocket of the two models reveals that the volume available for 
substrate binding is much larger in CpSADH than in CPCR1 (525 Å3) and in CPCR1 (300 Å3, see Figure 2 
C & D).[23] Having more space to accommodate bulky substrates hints to a broader substrate range of 
CpSADH. Furthermore, most of the active-site residues in CPCR1 are identical to the X-ray template 
2HCY (ADH1 from bakers´ yeast); this suggests a similar substrate range of both enzymes (see 
Figure S3). 
The clear assignment of a molecular identity to any of the carbonyl reductases found in C. 
parapsilosis, as intended in this work, required the identification of substrates that are able to 
discriminate one from the other. This was facilitated by the observed high similarity of CPCR1 to 
ADH1 from bakers´ yeast, as the known substrate scope of the latter could easily be compared with 
the reported substrate scope of the original CPCR. Earlier studies on ADH1 from bakers´ yeast reveal 
Enzyme CPCR1 CpSADH 
X-ray template 2HCY (2.44 Å) 1R37 (2.3 Å) 
Organism S. cerevisiae ADH1 S. solfataricus ADH 
Cofactor NADH NADH 
Ligand 2,2,2-trifluorethanol 2-ethoxyethanol 
alignment score 1383 (99 %) 441 (97 %) 
sequence identity [%] 74.9 34.3 
sequence similarity [%] 84.1 53.5 
overall Z score -0.729 (good) -1.961 (satisfactory) 
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that cyclohexanone and benzaldehyde are not substrates[24], whereas, in the original paper about 
CPCR, structurally similar substrates such as 4-methyl-cyclohexanone or acetophenone were well 
converted.[1a] Hence, cyclohexanone and acetophenone were used as indicator substrates for the in 
silico substrate screening. Additionally, ethyl 5-oxohexanoate and methyl-3-oxovalerate were 
included as reference substrates because these are known to be converted by both enzymes. 
 
Figure 2 A) Binding site of the CPCR1 model with bound 2,2,2-trifluorethanol (magenta) and B) binding site of the 
CPSADH-model with bound ethoxyethanol (magenta). Catalytic residues around Zn
2+
 and NADH are represented in ball 
and stick, all other residues in stick representation. Residues from the monomer B are colored red. Binding sites of C) 
CPCR1 model and D) CpSADH model in van der Waals representation. 
Molecular docking of these selected indicator substrates in a reactive conformation bound to the 
catalytic zinc was performed, and the relative stabilization energy in the active site was calculated by 
using the general AMBER force field (see Tables S3 & S4, 3.1.6).[13] Only the reference substrate 5-
oxohexanoate shows favorable stabilization energy for CPCR1; the other three indicator substrates 
reveal unfavorable relative energy values (Figure 3B). In contrast, CpSADH showed even better 
relative energy values for cyclohexanone compared to the reference substrate. Methyl-3-oxovalerate 
shows modest and acetophenone shows medium stabilization energies bound to CpSADH in a 
reactive conformation according to the energy calculations.  
When comparing the calculated relative stabilization energy data to the relative activities measured 
with the recombinant enzymes CPCR1 and CpSADH, a clear similarity of the substrate pattern can be 
observed (Figure 3A). Strikingly, cyclohexanone is very well accepted by CpSADH but not by CPCR1 as 
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predicted by the in silico modeling. As methyl-3-oxovalerate and acetophenone are converted by 
CpSADH but are only weakly accepted by CPCR1, the broad substrate spectrum can now evidently be 
assigned to CpSADH. The commercial CPCR preparation traded by Codexis was found to have an 
intermediate relative activity profile, thus indicating that a mixture of at least the two identified CPCR 
isoenzymes is present. 
  
Figure 3 A) The bar diagram represents relative volumetric enzyme activities of three different CPCR preparations for 
ethyl 5-oxohexanoate, methyl-3-oxovalerate cyclohexanone and acetophenone. B) The bar diagram depicts the 
calculated relative activation energies (ΔE) for the same substrates for the two CpCR homology models. 
3.1.5 Conclusion 
The activity of the synthetically potent CPCR described by Peters et al. in 1993[1a] can be allocated to 
at least two distinct carbonyl reductases (E.C.1.1.1.1). These enzymes show low homology in amino 
acid sequence, but high similarity in the overall fold. Monomers of both have a molecular weight 
lower than reported by Peters et al. It might well be, however, that this is an artifact resulting from 
problems with protein denaturation in the reported study because the molecular weight observed by 
Peters et al. is in good accordance with the weight of the homodimeric complexes forming the active 
structures of both CPCR1 and CpSADH. 
Interestingly, the wide substrate range reported for CPCR does not result from a complementary 
combination of both substrate spectra. Rather, the enzymes can rather be classified as a minor and 
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major CPCR, which we suggest calling CPCR1 and CPCR2. CPCR2, which is identical with CpSADH 
described by Kojima et al.[9, 16] converts all compounds so far described for CPCR, whereas CPCR1 fails 
to convert of a couple of bulky substrates. Both isoenzymes are probably present in CPCR 
preparations from the native source (C. parapsilosis), although they have not yet been 
experimentally verified in parallel. It can be assumed that enzyme expression in C. parapsilosis reacts 
extremely sensitively to small changes in cultivation conditions, that is, even if data from 
fermentation indicates comparability of the physiological state of the organism, the composition of 
carbonyl reductases can considerably vary. 
The molecular identity of CPCR was elucidated by the rational combination of classical biochemical 
methods and computational chemistry; in consideration of the extremely broad range of compounds 
converted by CPCR, this turned out to be a fast and most efficient method of identifying differences 
in substrate conversion. In future it might contribute to improving of the investigation of sequence-
function relationships in similar systems. 
3.1.6 Supplementary Information 
 
 
Figure S1 Coomassie stained SDS-PAGE of differently concentrated CPCR preparations and commercial CPCR (Codexis, 
USA). M1/M2: Size markers; L1, L2, L3: lyophilized CPCR purified from a batch fermentation, a shake flask culture, and a 
concentrated shake flask culture; C: Commercial CPCR. The gel was prepared and published by S. Steinsiek (PhD thesis, 
2006, RWTH Aachen University) 
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Figure S 2 CPCR1 (left) and CpSADH (right) quaternary structures are modelled as tetramers (dimer of dimers). The first 
dimer contains Chain A (green) and Chain B (red), second dimer is formed by Chain C (cyan) and D (magenta). Cofactor 
NADH and two bound Zn-ions are coloured blue. 
  
Figure S 1 Sequence Alignment of CPCR1 and CpSADH with the homologous X-ray templates ADH1 from yeast S. 
cerevisiae (2HCY) and ADH from Sulfolobus solfataricus (1R37), respectively. Figure is created using JalView, colours 
are according the Zappo.code for indication of chemical similar amino acids 
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  Table S1. Conversion by partially purified CPCR preparation of selected substrates 
related to the conversion of ethyl 5-oxohexanoate as standard substrate. 
Measurements were done photometrically using equation 1 for analysis. 
Equation 1: Vol.act.= Vtot*dA/dt VCPCR
-1
* *d (Vol.act: volumetric activity [UmL
-1
]; Vtot: 
total volume [µL]; VCPCRvolume of dissolved enzyme [µL]; dA: change in absorption 
[min
-1
]; : extinction coefficient of NADH [6.22 mLµmol
-1
cm
-1
]; d: cuvette width) 
Substrate Conversion [%] 
by CPCR 
Measured* 
 
Conversion [%] 
by CPCR 
Published
[x]
 
            
Ethyl 5-oxohexanoate  
100 100 
Laevulinic acid ethyl ester 
63 76 
Ethylacetoacetate 
81 71 
Methyl-3-oxovalerate 
71 67 
2,5-Hexadione 
54 46 
2,4-Pentadione 
18 15 
2-Pentanone 
17 40 
Acetophenone 
75 34 
4’-Fluoroacetophenone 
75 40 
4’-Bromoacetophenone 
103 40 
3’-Chloroaceto-phenone 
38 35 
O
O O
*The data was generated and published by S. Steinsiek (PhD thesis, 2006, RWTH 
Aachen University) 
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Table S2 Comparison of active site residues of CPCR1 and CpSADH 
with according X-templates. Bold letters indicate differences 
between X-ray template and CPCR-model. Shaded residues indicate 
the larger active site residue when comparing CpCR1 and CpSADH. 
Active site volume was calculated by 
http://www.modelling.leeds.ac.uk/pocketfinder/. 
2HCY CpCR-I 1R37 CpCR-II 
Thr45 Thr101 Ser40 Ser46 
Trp54 Trp110 Phe49 Leu55 
Trp92 Trp148 Trp95 Gly91 
Asn110 Asn166 Leu111 Val108 
Leu116 Leu172 Trp117 Trp116 
Tyr119 Tyr175 Ile120 Leu119 
Thr120 Thr176 Asn121 Gly120 
Met270 Leu326 Leu272 Leu262 
Val295 Val351 Val296 Trp286 
Tyr294 Tyr350 Leu295 Phe285 
Ile156 Val212 Ile157 Leu157 
Phe281B Phe337B Pro282B Gly272B 
Val285B Val341B Leu286B Leu276B 
Active site sequence identity [%] 
84.6 23.1 
Active site volume [Å3] 
300 312 525 544 
Table S3 CPCR1: Calculated energy-values given in kJ/mol using AMBER03/GAFF within Yasara. Active site residues 
are Thr 101, Ala 105, Trp110, Trp 148, Tyr 175, Leu 326, Tyr 350, Val 351, Phe 337B, Val 341B.  
Compound 
Solvation 
energy 
compound 
energy bound 
to Zn 
active site  
apo-energy 
difference 
reactive complex 
energy 
relative 
reactive complex 
energy 
Ethyl 5-
oxohexanoate 
-162,68 -371,37 109,8 -98,89 0 
Methyl-3-
oxovalerate 
-297,62 -501,88 122,23 -82,03 16,86 
Cyclohexanone -57,42 -279,33 150,94 -70,97 27,92 
Acetophenone -54,68 -250,22 124,21 -71,33 27,56 
Table S4 CpSADH: Calculated energy-values given in kJ/mol using AMBER03/GAFF within Yasara. Active site residues 
are Ser 46, Val 50, Leu 55, Trp 116, Leu 119, Leu 162, Phe 285, Trp 286, Gly 272B, Leu 276B .  
Compound 
Solvation 
energy 
compound 
energy bound 
to Zn 
active site  
apo-energy 
difference 
reactive complex 
energy 
relative 
reactive complex 
energy 
Ethyl 5-
oxohexanoate 
-162,68 -375,54 124,25 -88,61 0 
Methyl-3-
oxovalerate 
-297,62 -505,24 123,31 -84,31 4,3 
Cyclohexanone -57,42 -273,43 124,77 -91,24 -2,63 
Acetophenone -54,68 -258,65 117,48 -86,49 2,12 
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3.2 Asymmetric Reduction of Ketones with Recombinant E. coli Whole 
Cells in Neat Substrates 
3.2.1 Abstract 
The asymmetric reduction of ketones is performed by using lyophilized whole cells in neat substrates 
with defined water activity (aw). Ketones and alcohols prone to be unstable in aqueous media can 
now be converted via biocatalysis. 
3.2.2 Introduction 
Biocatalysis is receiving increasing attention as a powerful synthetic tool providing environmentally-
friendly reaction conditions with high regio- and stereoselectivities.[1] However, a broader extension 
of industrial biocatalysis is still hampered due to several reasons, e.g. restricted enzyme availabilities, 
in-sufficient productivities and stabilities, time- and material-intensive work-ups in aqueous media – 
often leading to waste production, as well as costs related to catalysts and cofactors.[2] Low product 
concentrations resulting from a limited water solubility of many organic compounds can be, to some 
extent, enhanced by reaction engineering using, organic co-solvents or water-organic biphasic 
systems.[3] On the other hand, process stability of biocatalysts can be increased and costs for 
catalysts and cofactors can be reduced by use of whole cells rather than isolated enzymes.[4] 
For the industrial performance of the asymmetric reduction of prochiral ketones by alcohol 
dehydrogenases the demand for expensive nicotinamide cofactors plays a particular role in cell-free 
systems.[5] Hence, the use of whole cells exhibits the major advantage that cofactors can be 
intrinsically recycled via the coupling of a second substrate or by a second enzyme.[6] Few reduction 
reactions have been reported which work in water-organic mixtures showing exceedingly high 
substrate loads and no or only little demand for external cofactor.[5, 7] However, in such water-based 
systems emulsions may be formed, decreasing isolated yields and requiring tedious product 
separation. Moreover, the general applicability of the latter method is restricted when substrates 
and products with low stability in aqueous environments are involved. 
Herein we show that E. coli whole cells, overexpressing a NADH-dependent carbonyl reductase, are 
able to perform enantioselective carbonyl reduction in quantitative yields in a solvent-free system 
without external co-factor addition (Figure 1). 
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3.2.3 Results and Discussion 
The reaction setup only requires substrate, co-substrate, and the biocatalyst at a defined water 
activity (see below). Despite its potentiality, there are only few examples using dried yeast cells in 
organic solvents,[8] as well as lyophilized E. coli overexpressing an alcohol dehydrogenase from 
Rhodococcus ruber in 99 % (v/v) isopropanol.[9] In that latter example, however, cells displayed little 
catalytic activity, presumably due to cell rehydration before using them in the micro-aqueous 
system.[9] 
 
Figure 1 Biocatalytic reduction of acetophenone using lyophilized E. coli cells overexpressing carbonyl reductase in a 
solvent-free system with isopropanol-coupled cofactor regeneration. 
As a model reaction, acetophenone as substrate and isopropanol as ancillary co-substrate for 
cofactor regeneration were used (Figure 1). The catalyst was a NADH-dependent carbonyl reductase 
from Candida parapsilosis (CPCR)[10] overexpressed and directly applied in E. coli whole cells. In this 
highly non-natural environment the biocatalyst was able to effectively produce S-phenylethanol (ee 
>99 %; >98 % conversion) with high productivities (300-500 g L-1) (Figure 2).[11]  Compared to existing 
production processes, the developed reaction system has advantage in simplicity, economics (cheap 
starting material, no NADH addition, very limited waste production, high added value), scalability and 
high yields.[5, 7, 9] Moreover, a key feature is the straightforward work-up as the whole cells can easily 
be separated and product downstream requires only evaporating co-substrate and co-product.  
Further studying the whole-cell-catalyzed reduction of acetophenone demonstrated a dependence of 
the initial reaction rate on the volumetric substrate to co-substrate ratio, indicating the underlying 
equilibrium conditions (Figure 2). 
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Figure 2 Conversion of acetophenone by E. coli whole cells overexpressing CPCR in solvent-free conditions. Different 
volumetric ratios of isopropanol to acetophenone were set (50:50 ▲, 70:30 ■ □). Closed symbols: daily removed 
acetone; open symbol: No acetone removal. 
Nevertheless, the conversion of acetophenone was always driven to completion, when acetone was 
intermittently removed from the reaction, and the enantioselectivity was always at maximum 
(ee >99 %).[12] Obviously, with a highly optimized process development these full conversions could 
be achieved in much shorter reaction times. Remarkably, after 14 days of operation in the system 
cells still displayed activity rendering this biocatalyst extremely stable.[13] This is consistent with the 
reported stable operation of E. coli cells harboring an alcohol dehydrogenase at high concentrations 
of isopropanol in aqueous media,[14] and can mainly be attributed to the enzyme preserving 
microenvironment of the host cell.[4a] Inhibition or inactivation of the catalyst at elevated co-
substrate concentrations could not be observed. Consequently, with this system it was possible to 
produce up to 500 g L-1 optically pure (S)-phenylethanol. 
The role of the water on the activity of the biocatalyst was analyzed in depth, since it is widely 
accepted that water plays a crucial role for biocatalysis in non-conventional media,[15] for lyophilized 
whole cells in gas-solid reactor systems,[16] and for whole cell biocatalysis in transesterification and 
trans-glucosylation reactions.[17] Lyophilized cells were exposed to seven different aw values ranging 
from dry (aw = 0) to wet (aw = 1) and used under solvent-free conditions (see Figure 3).
[18] For low aw 
values biocatalytic activity is increasing with water activity, which is in agreement with former 
findings.[16] The optimum water activity is around aw value of 0.84 (see Figure 3). Additionally, non-
equilibrated wet cells were active but rapidly deactivated within few hours, whereas lyophilized cells 
remained stable for several days (data not shown). 
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Figure 3 Initial reaction rate of acetophenone in neat substrates employing E. coli whole cells with overexpressed CPCR. 
Dried cells and reaction mixtures were previously equilibrated to different water activities. 
[18a, 19]
 
As indicated previously, application of the here described solvent-free reaction system may be 
particularly beneficial for the asymmetric reduction of compounds exhibiting low stabilities in 
aqueous environments. For instance, propargylic ketone 3-butyn-2-one is instable in aqueous media, 
shows thermal decomposition and, moreover, has been reported to deactivate enzymes and cells.[20] 
Notably, the corresponding (S)-3-butyn-2-ol is an important building block for anti-asthma drugs like 
5-lipooxygenase inhibitors[20c], the potent β2-adrenergic stimulant broxaterol
[21] or the protease 
inhibiting hydroxyethylene dipeptide isosteres.[22] In virtue of this importance, the enzymatic 
production of (S)-3-butyn-2-ol has already been attempted via the asymmetric reduction of 3-butyn-
2-one with alcohol dehydrogenases or via the enantioselective hydrolysis of the corresponding 
esters. To overcome substrate and product instability in aqueous media, either biphasic systems 
were applied, or derivatized trimethylsilan-based compound was used as substrate, albeit at the cost 
of adding further synthetic steps.[20b, 20c, 21, 23] 
So far, the alcohol dehydrogenases displayed moderate to low enantioselectivities in monophasic 
systems (5-86 %[20-21]), whereas the hydrolase-catalyzed ester hydrolysis led to high ee´s, but with 
limited conversions at 50 %.[24] To date, there is only one multi gram-scale preparation of S-3-butyn-
2-ol using an alcohol dehydrogenase from Pseudomonas aeruginosa in a biphasic system with ee 
>99 %, though at low conversion (45.5 %).[20a] 
In the herein developed solvent-free whole-cell system high enantioselectivities were achieved 
(ee = 99.9 %; Figure 4).[11] Data are at odds with the value reported by Schubert for CPCR for 3-butyn-
2-one (ee = 49 %).[20c] However, in the mentioned work, CPCR was used not in recombinant form but 
as a crude extract from the Candida host. Hence, discrepancies may be explained by the acceptance 
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of butynone by yeast oxidoreductases other than CPCR which in turn may lower the ee, as it has been 
reported for other yeast systems like baker’s yeast.[25] 
 
Figure 4 Biocatalytic reduction of 3-butyn-2-one using lyophilized E. coli cells overexpressing CPCR in the developed 
solvent-free system with isopropanol-coupled co-factor regeneration. 
According to the above-described findings that increasing the co-substrate concentration favors the 
product formation, a volumetric ratio 90:10 (isopropanol to 3-butyn-2-one) at optimum aw was set 
up in this case. As proof-of-concept 67.6 % conversion was achieved in 24 h, corresponding to 
57.4 g L-1 of optically pure S-3-butyn-2-ol. This product concentration is already 2-fold higher than the 
so far reported maximum value (24.7 g L-1).[20a] Without acetone removal (hence, under non-
optimized conditions), full conversion could be obtained within 120 h, yielding a product 
concentration of 87 g L-1. This example notably points out that this solvent-free reduction system, 
while lacking bulk water, is very powerful in accessing optically pure alcohols, even if substrates 
and/or products are instable in aqueous solutions. It can be expected that this will open new 
biocatalytic routes to the production of so far non- or hardly accessible building blocks. 
3.2.4 Summary and Outlook 
In summary, lyophilized E. coli whole-cells overexpressing carbonyl reductase are able to perform 
enantioselective reductions of ketones in neat substrates conditions, leading to the production of 
enantiomerically pure alcohols in large amounts. The approach of lyophilized E. coli whole-cells in 
solvent-free conversions is characterized by a high cost-effectiveness (high added-value, no cofactor 
addition, simple work-up) and by an environmentally-friendly operation mode (largely diminished 
waste production, bio-based catalyst). A further notable point is use of compounds in the reaction 
system that unstable in aqueous environments. Together with the further inherent advantages of 
biocatalysis (high selectivity, high activity), the described solvent-free system may represent a 
competitive alternative to classical chemical production of optically pure alcohols. 
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3.3 Synthetic Toolbox to Chiral Alcohols via Asymmetric Ketone Reduction 
with Recombinant E. coli Cells in Neat Substrates  
3.3.1       Introduction 
Biocatalytic asymmetric reduction of prochiral ketones to manufacture enantiopure alcohols is 
nowadays considered as fully complementary to classical chemical routes.[1] Asymmetric reduction is 
rendered by high atom efficiency and cost-effectiveness since 100 % theoretical yield is possible and 
cheap ketonic starting material is converted to high value-added products.[1-2] The chiral alcohols 
serve as key building blocks in pharmaceutical, food, fragrance and agricultural industries.[3] As 
biocatalysts, alcohol dehydrogenases (ADHs), also called carbonyl or keto reductases (CRs), are used 
herein as isolated enzymes or in whole cells to convert ketones to the corresponding alcohols with 
supreme stereoselectivities unmatched by chemical catalysis. 
These enzymes are dependent on costly nicotinamide cofactors such as NADH and NADPH, which 
deliver the required oxidation (NAD(P)+) or reduction (NAD(P)H) equivalents in stoichiometric 
amounts. The latter drawback was addressed by effective methods to regenerate the cofactor by 
enzyme- or substrate coupled approaches as well as other biocatalytic or chemical routes.[4] The 
cofactor regeneration in an enzyme-coupled approach by the application of formiate dehydrogenase 
or glucose dehydrogenase on industrial scale has recently been reported.[4b] Furthermore, isolated 
enzymes suffer from low process stabilities since they are not suited for conditions usually present in 
industrial processes such as elevated temperatures or high concentrations of organic molecules.[5] 
For this, either the process has to be optimized for the catalyst or the enzymes have to be improved 
to match process requirements. Protein engineering has lately been demonstrated to be a suitable 
strategy to improve an ADH for industrial-scale applications.[6] 
The two problems of cofactor regeneration and enzyme stabilities can also be addressed by the 
application of whole cells as biocatalysts. In this case the enzyme stays inside the production host 
(e.g. E. coli) and the cofactors are provided by the microorganism.[7] Regeneration of the cofactor 
takes place intracellularly by a second enzyme or the same enzyme.[7] Additionally, whole cells are 
more robust towards hazardous conditions and protect the enzymes they contain.[8]  
A general weakness of biocatalysis, regardless if cells or enzymes are used, is the dependency on 
aqueous environment for optimal performance, which results in low productivities due to low 
solubility of organic substrate and product molecules. To alleviate this drawback, various reactor 
concepts for reduction of hydrophobic ketones were developed, which are relying on membrane 
separation of the biocatalyst containing aqueous phase and substrate containing organic phase.[9] 
Additionally, medium engineering is undertaken to find suitable reaction conditions providing high a 
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biocatalyst stability and selectivity accompanied by substrate loadings exceeding 100 g L-1.[10] Species 
isolated from extreme environments can withstand very high temperatures or co-solvent 
concentrations (>80 % (v/v)) and effectively carry out ketone reduction.[11] However, due to host 
enzymes in whole cells also accepting the substrate molecules, stereoselectivity can be reduced, thus 
limiting the general applicability of this approach.[12] 
In the previous chapter 3.2, the concept of ketone reduction in a medium composed of only the 
substrate acetophenone and the cosubstrate isopropanol was demonstrated to work with lyophilized 
E. coli whole cells containing the carbonyl reductase from Candida parapsilosis (CPCR2).[13] This 
reaction mode provides substrate loads up to 500 g L-1 with stereoselectivity at maximum (>99 % ee). 
Furthermore, the water-labile compound 3-butyn-2-one was converted to the (S)-alcohol with ee 
>99 % in this system; whereas, biotransformation in aqueous medium showed ee of only 49 % ee.[13a, 
14] The system showed strong dependency on water activity (aw) as well as limitation of the reaction 
rate by the thermodynamic equilibrium of the reaction. However, conversion could be completed by 
intermittent removal of the coproduct acetone by simple evaporation and replenishing of 
isopropanol.[13] 
3.3.1.1 Selection of Biocatalysts 
To examine whether this system is restricted to CPCR2, ADHs from Rhodococcus erythropolis 
(ReADH) and Lactobacillus brevis (LbADH) were applied in the same system in recombinant form 
overexpressed in E. coli.[15] Both enzymes are reported to exhibit a broad substrate spectrum and 
high stereoselectivity and are used in preparative or industrial scale.[15b, 16] ReADH resembles CPCR2 
with respect to stereoselectivity, cofactor dependency and biochemical properties (see Table 1). In 
contrast, LbADH is complementary to CPCR2 and ReADH since it exhibits anti-Prelog specificity and 
depends on NADPH as cofactor. 
Table 1 Comparison of enzymes selected for application in the neat substrate system 
Source Enzyme name Enantioselectivity Cofactor Source 
Candida parapsilosis  CPCR2 Prelog NADH [13b, 13c, 17] 
Rhodococcus erythropolis ReADH Prelog NADH [15a, 18] 
Lactobacillus brevis LbADH anti-Prelog NADPH [15b, 19] 
 
3.3.1.2 Selection of Benchmark Substrates 
Furthermore, the versatility of the reaction system was investigated by reduction of various 
structurally different benchmark substrates (see Table 2). Herein, the substrate class of aromatic 
ketones is covered by acetophenone and 4-chloroacetophenone. The corresponding alcohols are 
useful building blocks for chiral high value-added products and are often applied as model 
substrates.[20] Alcohols with cyclohexanone moiety are found in many natural products and 
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cyclohexanone is chosen as substrate for this class.[21] A key intermediate for manufacture of statin 
drugs is ethyl (S)-4-chloro-3-hydroxybutanoate, which is produced on industrial scale via reduction of 
the corresponding ketoester; thus 4-chloroacetoacetate represents the substrate class of keto 
esters.[3a, 22] Also the (R)-alcohol is valuable in the synthesis of L-carnitin.[3a, 23] Moreover, aliphatic 
alcohols constitute interesting building blocks.[24] As long chain aliphatic ketone, 2-octanone is 
selected due to the versatile application field of (S)- and (R)-2-octanol as building blocks in organic 
synthesis or production of liquid crystals.[23, 25] Especially, manufacturing enantiomerically pure 
2-butanol from 2-butanone is difficult since many enzymes cannot differentiate between the methyl- 
and the ethyl-substitution at the carbonyl carbon.[1] At last, 3-butyn-2-one as small propargylic 
ketone, is applied, which is prone to degradation in aqueous buffers.[14, 26] The corresponding 
alcohols have several functions as outlined in 3.2.[13a] 
Table 2 Benchmark substrates selected for reduction in the neat substrate system 
Substrate 
structures 
                         
Substrate 
class aromatic 
substituted, 
 aromatic 
cyclic keto ester 
long, 
 aliphatic 
short, 
  aliphatic 
small, 
 propargylic 
 
3.3.1.3 Mass Transfer Limitation, Cofactor Availability & Process Stability 
Whole cell biotransformation is a powerful tool in biocatalysis but limited mass transfer across the 
membrane or cell wall can prevent potential catalysts from application in industrial processes.[27] In 
gram-negative bacteria such as E. coli the outer membrane, composed of an amphiphilic 
lipopolysaccharide layer (LPS), constitutes an effective barrier for small hydrophobic molecules.[28] 
Thus, uptake of hydrophobic substrates like acetophenone may account for a major limitation in the 
overall reaction rate. Therefore, the influence of different permeabilizers on reaction rate was 
tested. Furthermore, the effect of cofactor addition and increased temperatures was analyzed. The 
intracellular level of NADH in E. coli cells was estimated to be around 1 mmol L-1[29]; however, in the 
system applied here substrates are present in molar concentrations. Hence, the availability of 
cofactor in neat substrates might limit the reaction speed. 
Catalyst stability is besides activity and selectivity the most important feature for the development of 
an economic viable biocatalytic process.[5a, 30] Thus, the performance of the whole cells in neat 
substrates was tested in repeated batch mode reusing the catalyst. 
3.3.1.4 Deracemization for Production of Chiral Alcohols 
Asymmetric reduction of prochiral ketones is a direct and efficient way to access chiral alcohols. 
However, in some cases the ketonic starting material can be more expensive or less stable than the 
corresponding racemic alcohol.[3b] In Table 3, three examples are demonstrated wherein the 
O
Cl
O OO
O
O
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O
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prochiral ketone is much more expensive than the racemic alcohol. The most striking case is for the 
pair 4-hydroxybutanone and 1,3-butanediol where the ketone is 67.5x more expensive than the 
racemic alcohol (1215 € kg-1 vs. 18 € kg-1, see Table 3, entry 3). From an economical point of view it 
makes more sense to use the racemate as starting material. In this example, the added-value for 
production of (S)-1,3-propanediol would be only 4.6x for the ketone but 311x for full conversion of 
the racemate as substrate. 
Table 3 Price comparison of ketones with their corresponding alcohols in racemic and enantiopure form. All prices are 
deduced from Sigma-Aldrich online catalogue taking the largest quantity and comparably purities. 
Entry Ketone Racemic alcohol (R)-alcohol (S)-alcohol Source 
1 
COOH
O
 
COOH
OH
 
COOH
OH
 
COOH
OH
 
[31] 
2930 € kg-1 134 € kg
-1 2580 € kg-1 1190 € kg-1 
2 
O
OH
5
 
OH
OH
5
 
OH
OH
5
 
OH
OH
5
 
[32] 
62,200 € kg-1 1830 € kg-1 437,000€ kg-1 - 
3 
OH
O
 OH
OH
 OH
OH
 OH
OH
 
[33] 
1215 € kg-1 18 € kg-1 5040 € kg-1 5590 € kg-1 
 
In such cases, racemate resolution presents an attractive route to obtain the desired enantiomer by 
asymmetric oxidation of the undesired enantiomer to the corresponding ketone. This is indeed 
possible with enzymes, since the asymmetric ketone reduction catalyzed by ADHs is fully reversible. 
The alcohol oxidation is promoted by NAD+, which can be regenerated by providing acetone as 
auxiliary cosubstrate instead of isopropanol. Racemate resolution by asymmetric oxidation holds the 
drawbacks that the yield is limited to 50 % and high ee requires high conversions. 
The maximum yield with a racemate as starting material can be boosted to 100 % when the oxidation 
is followed by reduction of the produced ketone. This can be achieved with an ADH accepting the 
produced ketone exhibiting an opposing stereoselectivity than the ADH used for oxidation. The 
overall process is called deracemization, since the racemate is completely resolved to one 
enantiomer. Deracemization can be achieved by concurrent or consecutive combination of 
asymmetric oxidation of one enantiomer to the prochiral ketone using one ADH and the asymmetric 
reduction using an ADH showing the opposite enantiopreference (see Scheme 1). 
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Scheme 1 Deracemization: Racemic starting material is subjected to asymmetric oxidation where only one 
enantiomer is converted by ADH1 to the ketone. In the second step, the produced ketone is asymmetrically 
reduced by ADH2 to produce the desired enantiomer. ADH1 and ADH2 have opposing stereoselectivities.
Here, an exemplary approach to deracemized 1-phenylethanol to pure (R)-1-phenylethanol by 
consecutive application of the neat substrate system running first the oxidation reaction with (S)-
selective CPCR2 and then the reduction reaction with (R)-selective LbADH is undertaken. 
Generally, the versatility of the neat substrate system with respect to the biocatalysts, substrates and 
reaction direction will be demonstrated. Additionally, the limitations like mass transfer, cofactor 
availability, temperature and operational stability will be investigated. 
3.3.2 Materials and Methods 
3.3.2.1 Supply of Biocatalysts 
Whole cells of E. coli with overexpressed CPCR2 or ReADH were produced in-house by flasks 
cultivation or high-cell density fermentation. LbADH was provided from an external source as ready-
to-use cell pellet. For protein expression of CPCR2, conditions as stated in 2.2.1 and 2.2.2 were 
applied. For production of ReADH cell pellet, the expression conditions were generally the same as 
for CPCR2, but temperature after induction was shifted to 25 °C according to Abokitse et al.[15a] 
Carbonyl reducing activity of the cells was monitored using the NADH-depletion assay described in 
2.2.6. 
After production of cell mass, the pellets were washed in ice cold KPi-buffer (0.1 mol L
-1, pH 6.8). If 
not processed immediately, pellets were flash frozen in liquid nitrogen and stored at -20 °C. For self-
contained experiments, only cells from one production batch were applied to keep the 
comparability. 
3.3.2.2 Pre-treatment of Whole Cells & Liquid Substrates 
For operation in the neat substrate system, cells were dried by lyophilization according to 2.3.3 and 
water was removed from liquid substrates by molecular sieves. Cells and substrates were 
equilibrated to certain water activity (aw) values by exposing the dry material to the vapor phase of 
saturated salt solutions. The composition of the applied salt solutions and the corresponding aw 
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values are shown in Table 2 in chapter 2.3.3. Additionally, the experimental setup for establishment 
of different aw values is depicted in Figure 8 in the same chapter. 
3.3.2.3 General Setup of the Neat Substrate System 
The standard system used for evaluation of the neat substrate system was composed of substrate 
and cosubstrate in a volumetric ratio of 1:9, if not indicated differently. Usually, acetophenone as 
model substrate and isopropanol as model cosubstrate were employed. Whole cells and liquid 
substrates were equilibrated to optimal aw, which were determined for the individual catalysts as 
described in 2.3.3. Catalyst load was established according to the cell-specific activity of the 
individual catalysts (CPCR2: 120-200 g L-1, ReADH: 300 g L-1, LbADH: 200 g L-1). Standard reactions 
were carried out at 30 °C in an over-head shaker at 50 rpm, if not indicated differently. 
Samples volumes of 250 µL were withdrawn and directly analyzed by chiral gas chromatography 
according to 3.3.2.7. 
3.3.2.4 Permeabilization of Whole Cells & Cofactor Addition 
An amount of 500 mg CPCR2 cell pellet of one batch was resuspended in 2 mL KPi buffer (0.1 mol L
-1, 
pH 6.8) containing different permeabilizing agents as listed in Table 4. After incubation (1 h, 30 °C, 
50 rpm overhead shaking), cells were pelleted by centrifugation and washed with KPi buffer. The 
supernatant was removed after another centrifugation step and the pellets were flash frozen in 
liquid nitrogen. Finally, the frozen cells were pre-treated as described in 3.3.2.2 and operated in the 
standard reaction system as outlined in 3.3.2.3. For cofactor addition, cell pellets were treated in the 
same way applying KPi buffer supplemented with varying concentrations of NAD
+ (0, 10, 20 
&  30 mmol L-1). 
Table 4 Concentrations of agents used for permeabilization of E. coli whole cells 
Agent Concentration [%] (w/v)] 
toluene 0.1 1 
Cetyltrimethylammoniumbromid (CTAB) 1 
polymyxin B sulfate 0.08 
 
3.3.2.5 Repeated Batch Operation 
For investigation of operational catalyst stability, the standard reaction batch according to 3.3.2.3 
was carried out applying CPCR2 whole cells in 4 mL scale. After 24 h operation, cells were pelleted 
and washed in 4 mL isopropanol of aw = 83.6 %. Washed cells were pelleted again and replenished 
with fresh substrate solution for the next batch reaction. This procedure was repeated four times 
always using the same cells. 
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3.3.2.6 Deracemization of 1-phenylethanol 
For deracemization of 1-phenylethanol to yield pure (R)-1-phenylethanol first asymmetric oxidation 
with (S)-selective CPCR2 whole cells was performed followed by reduction using the (R)-selective 
LbADH catalyst. Herein, the standard reaction as described in 3.3.2.3 was carried out in 4 mL scale. 
For oxidation, 1-phenylethanol as substrate and acetone as cosubstrate were mixed with CPCR2 
whole cell catalyst. For the reduction, the final mixture from the oxidation reaction was 
supplemented with isopropanol as cosubstrate and LbADH whole cells according to 3.3.2.3. 
At certain time points, additional cosubstrate (acetone in oxidation mode and isopropanol in 
reduction mode) was added or completely removed by evaporation. After evaporation (150 rpm, 
40 °C, 100 mbar in IKA® RV10 evaporator), the reaming mixture was replenished with the 
appropriate cosubstrate to continue the reaction. 
Table 5 Conditions for gas chromatographic separation of ketone/alcohol pairs and typical retention times. AcPh stands 
for acetophenone and PhEt for phenylethanol. AcAc is short for acetoacetate and But is an abbreviation for butyrate. 
substrate/product 
pair 
column 
N2 pressure 
[kPa] 
temperature profile 
retention time 
[min] 
3-butyn-2-one 
/ 
3-butyn-2-ol 
ChiraSil-DEX CB 50 
initial: 80 °C, 11 min 
gradient: 70 °C min-1 
hold: 150 °C, 4 min 
3-butyn-2-one 
(R)-3-butyn-2-ol 
(S)-3-butyn-2-ol 
4.5 
8.3 
8.6 
2-butanone 
/ 
2-butanol 
ChiraSil-DEX CB 40 
Initial: 60 °C, 14 min 
gradient: 70 °C min-1 
hold: 180 °C, 4 min 
2-butanone 
(R)-2-butanol 
(S)-2-butanol 
7.8 
13.6 
13.9 
Cyclohexanone 
/ 
cyclohexanol 
FS-Cyclo DEX 
beta I/P 
50 
Initial: 70 °C, 4 min 
gradient: 70 °C min-1 
hold: 120 °C, 0 min 
cyclohexanone 
cyclohexanol 
7.0 
7.7 
2-octanone 
/ 
2-octanol 
ChiraSil-DEX CB 55 Initial: 90 °C, 25 min 
2-octanone 
(R)-2-octanol 
(S)-2-octanol 
16.6 
21.8 
22.4 
p-Cl-AcPh 
/ 
p-Cl-PhEt 
ChiraSil-DEX CB 70 
Initial: 140 °C, 0 min 
gradient: 1 °C min-1 
hold: 65 °C, 0 min 
p-ClAcPh 
(R)-p-ClPhEt 
(S)-p-ClPhEt   
10.7 
17.5 
18.5 
Et-4-Cl-AcAc 
/ 
Et-4-Cl-3-OH-But 
ChiraSil-DEX CB 70 
Initial: 100 °C, 4 min 
gradient: 70 °C min-1 
hold: 120 °C, 15 min 
Et-4-Cl-AcAc 
(S)-Et-4-Cl-3-OH-but 
(R)-Et-4-Cl-3-OH-but 
- 
19.6 
18.0 
AcPh 
/ 
1-PhEt 
ChiraSil-DEX CB 70 Initial: 120 °C, 10 min 
AcPh 
(R)-1-PhEt 
(S)-1-PhEt 
4.7 
6.4 
6.8 
AcPh 
/ 
1-PhEt 
FS-Cyclo DEX 
beta I/P 
70 Initial: 120 °C, 22 min 
AcPh 
(R)-1-PhEt 
(S)-1-PhEt 
10.5 
19.5 
205 
 
3.3.2.7 Chiral Gas Chromatography 
Determination of conversion and selectivity of all substrates and products after operation the neat 
substrate system were performed by gas chromatography using a Hewlett Packard 5890 series II 
chromatograph equipped with chiral columns (FS-CycloDEX beta-I/P, CP-ChiraSil-DEX CB) and 
nitrogen as carrier gas. Protocols were developed to separate substrates form cosubstrate and 
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products. Special emphasis was laid on separation and assignment of the two enantiomers utilizing 
authentic commercial standards. Temperature profiles, pressures and typical retention times are 
listed in Table 5. The compounds 2-octanol and ethyl-4-chloro-3-hydroxy-butyrate (Et-4-Cl-3-OH-But) 
had to be derivatized to achieve satisfactory separation of the enantiomers. Derivatization was done 
using N-methyl-N-trimethylsilyl-trifluoroacetamide (MSTFA, Merck) in 10x molar excess and heating 
to 80 °C for 20 min. 
Conversion and enantiomeric excess were calculated by comparison of the corresponding peak areas 
obtained from the chromatograms according to the equations in 2.3.1. 
3.3.3 Results and Discussion 
3.3.3.1 Application of Three Different ADHs in Neat Substrates and Effect of Water Activity (aw) 
Together with CPCR2, here, also alcohol dehydrogenases from Lactobacillus brevis (LbADH) as well as 
Rhodococcus erythropolis (ReADH) both overexpressed in E. coli, were applied in pure acetophenone 
and isopropanol in 1:9 volumetric ratio. The different whole cell catalysts were equilibrated via 
vapour phase to different water activities (aw) according to Greenspan.
[34] 
Relative reactions rates were monitored for seven different aw-values ranging from dry cells 
(aw = 0 %) to wet cells (aw = 100 %). Herein, for whole cell catalysts no initial reduction of 
acetophenone was detected when cells were dry, but reaction rates increased rapidly with increasing 
aw. LbADH reached maximal reaction rate at aw = 93.2 %; whereas CPCR2 has highest reaction rate at 
aw = 83.6 % and ReADH at aw = 75.1 % (see Figure 1). With increasing aw, reaction rate drops 
significantly for all three catalysts. The effect was less pronounced for LbADH since the relative 
reaction rate is still at 72 % for wet cells (aw = 100 %); whereas it is only 28 % for ReADH and 12 % for 
CPCR2, respectively. 
It can be deduced that reduction of acetophenone with E. coli containing overexpressed ADHs in neat 
substrates is not limited to CPCR2, but that the concept is rather applicable to at least two additional, 
if not more, ADHs. Herein, LbADH is most different from CPCR2 and ReADH since it is NADPH-
dependent and exhibits anti-Prelogs´ specificity.[15b] 
The increase in catalytic activity with increasing aw is most likely linked to overexpressed enzyme, 
which needs a critical amount of water to become active in organic medium as reported for many 
other enzymes[35] or whole cell catalysts at low water concentrations.[36] 
The decrease in reaction rate at higher aw-values is possibly due to catalyst inactivation, since the 
progression curves indicate that the reaction stopped within the first 7 hours for higher aw-values of 
93 % and 100 % for ReADH and CPCR2 (data not shown). Also for E. coli swelling of cells was reported 
for aw >90 % possibly leading also to influx of isopropanol and acetophenone inactivating the enzyme 
inside the cell.[37] 
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Figure 1 Dependence on water activity of the three different ADH whole cell catalysts in neat substrates. 
Lyophilized E. coli in isooctane showed a similar response for transesterification activity versus aw 
with a recombinant lipase.[38] Herein, the decrease in conversion at high water concentration was 
explained by induction of diffusional limitations of the substrate and also preference for hydrolysis. 
Furthermore, optimal aw-values were also identified in gas-solid reactions with Saccharomyces 
cerevisiae and Rhodococcus erythropolis as reductive whole cell catalysts.[36a, 36c] Viability of E. coli 
cells was not examined in this system; however, in gas-solid reactor lyophilized cells of Rhodococcus 
erythropolis did not survive but retained reducing activity.[36c] 
3.3.3.2 Conversion of Structurally Diverse Ketones & Stereoselectivity of the Alcohols 
To demonstrate the broad applicability of asymmetric reduction in neat substrates, structurally 
diverse ketones were selected and used with the three whole cell catalysts. In Table 6 conversions of 
all substrates and the enantiomeric excess of the corresponding alcohols are listed. 
Biotransformations were carried out in the standard reaction conditions at optimum aw as previously 
identified for the three individual whole cell catalysts (see Figure 1). 
All tested substrates were accepted and converted in most cases to more than 80 % giving product 
concentrations of 50-100 g L-1 (see Table 6). Differences in final conversion may be due to varying 
position of equilibrium or differences in activity of the individual enzymes towards the substrates. In 
principle, it is possible to obtain 100 % conversion by removal of the co-product acetone and 
replenishment of cosubstrate as reported previously (see 3.2.3, Figure 2).[13a] Conversion of 
cyclohexanone was described for the first time for CPCR2 and ReADH (see Table 6). Additionally, for 
ReADH asymmetric reduction 3-butyn-2-one was not reported previously but showed high 
conversion. For 2-butanone reduction, 2-pentanol was successfully applied instead of isopropanol for 
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cofactor regeneration, demonstrating the variability of the system with respect to the ancillary 
cosubstrate. Inhibition phenomena like substrate or product inhibition were never observed. 
Taken together, Table 6 illustrates that the newly developed reaction system is capable of reducing a 
whole array of structurally diverse ketones. Hence, it can be expected that the substrate scope 
determined for the three employed ADHs, can be fully exploited in this system. 
Table 6 Conversion & enantioselectivity (ee meas.) of structurally different substrates by LbADH, ReADH and CPCR2 
whole cell catalysts in neat substrates. Literature values of enantiomeric excess (ee lit.) for asymmetric reduction of the 
substrates in aqueous systems are presented as well. 
 [a]ratio of substrate to isopropanol 1:9, reaction times 48-144h [b]nomenclature reversed due to CIP rules 
 [c]2-pentanol was used instead of isopropanol [d]aw = 92.3 %, 
[e]aw = 75.1 %, 
[f]aw = 83.6 % 
 [g]measured with E. coli whole cells [h]ee determined in microemulsion system [i]measured with Candida lysate 
 
In general, enantiomeric excess of the aromatic alcohols as well as for ethyl 4-chloro-3-
hydroxybutanoate and 2-octanol observed in this system are >98 % and hence, as good as reported 
for isolated enzymes in aqueous systems (see ee lit. in Table 6). This supports the assumption that 
the whole cell catalysts performed in neat substrates at defined low water concentration in the same 
way as the isolated enzymes in dilute buffer. It can be speculated that the host ADHs are inhibited by 
the high concentration initial of isopropanol and are therefore not affecting ee. 
For small substrate such as 2-butanone and 3-butyn-2-one; however, ee-values deviate from values 
reported in literature (see Table 6). For 2-butanone all ee-values found in neat substrates are 
significantly smaller than obtained in buffer systems. Stereoselectivity for (R)-3-butyn-2-ol was 
slightly reduced for LbADH but significantly increased for CPCR2 and reverted for ReADH. These 
findings indicate that for small substrates the presence of high amounts of substrates and 
cosubstrates as well as the low water concentration greatly influence stereoselectivity. 
It has been reported for other ADHs in non-conventional media that stereoselectivity can be affected 
by the reaction medium as well as by the water activity of the system. For example, ADH from 
Thermoanaerobium KET4B1 changed ee in a range of 23-65 % depending on type and concentration 
of co-solvents for 2-butanone reduction.[50] Furthermore, stereoselectivity of ADHs from 
Thermoanaerobacter ethanolicus and Sporobolomyces salmonicolor were reported to be dependent 
Substrates[a] 
   [b]             [c]  
LbADH[d] 
conversion [%] 61 88 99 >80 97 85 80 
ee  meas. [%]  >99 R 97.5 R - >99 S >99 R >1.4 R 46.6 R 
ee lit. [%] >99 R[39] >99 R[40]      -[41] >99 S[40]  >99 R[42] 35 R[43][g] 60 R[14] 
ReADH[e] 
conversion [%] 50 86 99 >80 97  84 79 
ee  meas. [%]  >99 S >99 S - >99 R >99 S >0.4 S 42.8 R 
ee lit. [%] >99 S[44] >99 S[20] - >99 R[45] >99 S[44] - [45b] - 
CPCR2[f] 
conversion [%] 50  64 90 (-) >80 83  79 64 
ee  meas. [%]  >99 S >99 S - >99 R >98 S >62 S >99 S 
ee lit. [%] >99 S[46] - - >99 R[47] >99 S[48] >99 S[49][h] 49 S[14][i] 
O
Cl
O OO
O
O
Cl
O
OO
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on the co-solvents.[51] A strong increase in enantioselectivity was detected with increasing aw-values 
for an ADH from Thermoanaerobium brockii in hexane, converting 2-pentanone with 2-butanol as 
cosubstrate.[35c] However, when approaching aw = 83.6 % at 25 °C enantioselectivity dropped again. 
For LbADH, in particular, racemization was reported for 2-butanol in aqueous buffer depending on 
the enzyme preparation, substrate and cosubstrate concentration as well as on reaction time.[52] 
Nevertheless, ee-values for (R)-2-butanol of 95 % with LbADH could be obtained by application of a 
biphasic system and optimization of reaction conditions.[15b, 52-53] The same enzyme showed varying 
ee-values (33-43 % R) for reduction of 600 mmol L-1 2-butanone depending on the type and amount 
of co-solvent used.[43] LbADH employed in the here developed system produces almost racemic 
2-butanol (see Table 6) indicating that reaction conditions are not appropriate for selective 
reduction. The ee might be influenced by aw or substrate concentration. Hence, performance of the 
whole cell catalyst at different aw-values has to be investigated as well as the impact of the 
cosubstrate and substrate concentrations, for instance by substrate dosing. If the ee is time-
dependent, a tighter sampling has to be carried out to resolve this. Here, only the end conversion 
after 48h was recorded.  
The effect on ee with 2-butanone as substrate was examined more closely for the model enzyme 
CPCR2. Herein, the ee-value of whole cells with overexpressed CPCR2 was determined in aqueous 
buffer (see Table 7, entry 2) and compared to the ee obtained in neat substrates (see Table 7, 
entry 1). Additionally, CPCR2 was purified and used in aqueous buffer and 50 mmol L-1 2-butanone 
according to 2.3.1 (see Table 7, entry 4). 
Table 7 Enantiomeric excess of 2-butanone with CPCR2 in different reaction systems after 48h. 
entry catalyst substrate medium ee-value 
1 
E. coli whole cells with 
overexpressed CPCR2 
1.12 mol L-1 isopropanol, 2-butanone, ratio 9:1 (v/v) 62 % S 
2 
E. coli whole cells with 
overexpressed CPCR2 
0.45 mol L-1 
0.1 mol L-1 KPi (pH 6.8), 5 % (v/v) 
isopropanol 
37 % S 
3 
E. coli whole cells with 
empty vector 
0.45 mol L-1 
0.1 mol L-1 KPi (pH 6.8), 5 % (v/v) 
isopropanol 
no 
reaction 
4 purified enzyme 0.05 mol L-1 
0.1 mol L-1triethanolamine (pH 8.0), 
2.5 % (v/v) isopropanol, 1 mmol L-1 NADH 
>99 % S 
 
Purified CPCR2 was able to convert 2-butanone with high enantioselectivity (ee >99 % S, see Table 7, 
entry 4), which is consistent with values found in literature.[49, 54] When overexpressed in whole cells 
of E. coli; however, ee-values are significantly lower; whereas cells containing only empty vector did 
not show 2-butanone conversion under the tested conditions as displayed in Table 7 in entry 3. 
These results imply that host ADHs do not interfere with the reaction but that the CPCR2 enzyme 
cannot perform optimal in conditions present in the whole cell approaches. As reported for LbADH, 
stereoselectivity may also be dependent on substrate concentration, which was 1.12 mol L-1 in the 
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neat substrate system (see Table 7, entry 1) and 0.45 mol L-1 in aqueous buffer (see Table 7, entry 2), 
respectively. High ee-values; however, were obtained with comparably low substrate concentrations 
like 0.05 mol L-1 as applied with purified CPCR2 (see Table 7, entry 4) or 0.001 mol L-1 as reported 
previously.[49] Hence, for obtaining high ee for 2-butanol, reaction conditions might be optimized 
towards lower substrate loads for instance by setup of a continuous reaction system with constant 
low 2-butanone concentration but high productivities. Otherwise, influences of water activity, 
reaction time and cosubstrate on ee might be investigated as well. 
For reduction of 3-butyn-2-one, CPCR2 exhibits excellent stereoselectivity (>99 % S) in the neat 
substrate system (see Table 6 and [13a]); whereas crude Candida lysate exhibits an ee of only 49 % S 
(see Table 6). This finding was already discussed in chapter 3.2.2. For LbADH, selectivity was 
moderate in aqueous buffer and in neat substrates with 60 % R and 46 % R, respectively. However, 
selectivity is higher in buffer systems. For ReADH, a reversion of stereoselectivity was observed, since 
it was expected that (S)-3-butyn-2-ol would be produced but (R)-3-butyn-2ol was detected with ee of 
42.8 % (see Table 6). Inversion of stereoselectivity was, as yet, not observed for ReADH in any 
reaction medium. However, it is the first time that conversion of this compound was reported for 
ReADH, and hence, a substrate-size induced reversion of stereospecificity is possible as found for 
ADH from Thermoanaerobium brockii.[55] 
Some effects on stereoselectivity in non-conventional media have been reported for yeasts used as 
reductive whole cell catalyst. When operated in pure benzene, bakers´ yeast showed reverse 
selectivity, which was explained by variation of the Km-values by the solvent of two or more 
concurrently active enzymes.[24] Furthermore, lyophilization of the yeasts Zygosaccharomyces rouxii 
and Debaryomyces hansenii affected stereoselectivity after reduction of ketones in comparison to 
non-lyophilized cells wherein inactivation of substrate-competing oxidoreductases were thought to 
account for the detected differences.[56] However, these effects can be ruled out here, since E. coli 
enzymes seem not to convert 2-butanone under the conditions in neat substrates (see Table 7, 
entry 3). 
In sum, the newly developed reaction system comprised of just substrates and lyophilized whole cell 
catalyst, exhibit high conversions for all tested ketones and retained high stereoselectivity for most 
of the tested substrates. These findings make this method for ketone reduction a valuable tool for 
production of chiral alcohols in high concentrations. However, especially for small ketones 
enantioselectivity was not sufficiently high for industrial demands (ee >95 %). From literature, it turns 
out that for CPCR2 and LbADH stereoselectivity for production of 2-butanol might be dependent on 
the substrate load or time.[17, 49, 53-54] Thus, ee can be optimized by reaction engineering for instance 
by establishment of a continuous operation mode or substrate dosing. 
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3.3.3.3 Mass Transfer Limitations of the Reaction System 
Asymmetric ketone reduction is preferably carried out in whole cells since the expensive 
nicotinamide cofactors are supplied and recycled by the cell. This advantage is economically most 
relevant, but the cell as “reaction vessel” can inhibit effective mass transfer of products and 
substrates.[27a, 57] The cell membrane provides a natural barrier for mass transfer and leads to 
decreased space time yields in whole cell biocatalysis. For E. coli used as whole cell biocatalyst for 
oxidation of cyclic ketones, mass transfer of cyclohexanone across the membrane was identified as 
the major rate limiting step and not enzyme performance or NADH availability.[29] However, for the 
neat substrate system used here, E. coli whole cells are lyophilized prior use and lyophilization was 
found to make the cytoplasmic membrane permeable.[58] This would reduce mass transfer 
limitations. Nevertheless, the cell envelope seems to be still intact enough to protect cofactors and 
enzyme from leaching, as the catalyst is active in the system for more than 14 days (see 3.2.3 
Figure 2). 
The problem of mass transfer limitation can be alleviated by permeabilization of the E. coli cells using 
different agents. Herein, organic solvents are used since decades to promote mass transfer.[57b, 59] 
Also detergents[38, 60] and antibiotics[61] have been applied for this purpose as well as mechanical 
methods.[62] Interestingly, isopropanol, applied here as cosubstrate, was shown to have a 
permeabilizing effect on the yeast Trichosporon brassicae increasing biocatalytic activity.[62] 
Herein, two rather low concentrations of toluene (0.1 % & 1 % (w/v)) were chosen since it was 
reported that E. coli whole cells treated with this organic solvents significantly increased reaction 
rate in asymmetric ketone reduction.[63] Furthermore, the cationic detergent cetyl 
trimethylammonium bromide (CTAB) was applied at 0.2 % (w/v)[60b], since treatment with this agent 
dramatically increased initial rate and final conversion in setup with horse liver ADH and NADH-
dependent hydrogenase in gram-negative bacteria.[60a] Rate enhancement was also observed for 
other biotransformations using CTAB-permeabilized E. coli whole cells.[38, 64] At last, the antibiotic 
polymyxin B sulfate targeting the cell wall of gram-negative microorganisms was used. This agent is 
reported to act like a detergent by making the cell wall more permeable.[65] The compound was used 
with E. coli whole cells to facilitate mass transfer of substrates across the membrane in reduction of 
aromatic ketones[61b] and a whole-cell screening assay.[61a] 
Figure 2 displays the influence of cell permeabilization on the initial reaction rate in acetophenone 
reduction in the neat substrate system. Notably, permeabilization in general resulted in an increase 
of reaction rates; hence, no substantial enzyme or cofactor leaching took place as a consequence of 
membrane perforation. Alteration in stereoselectivity was not detected for any additive. 
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Toluene at 1 % (w/v) and polymyxin B sulfate represent effective permeabilizers, since reaction rates 
could be improved by more than twofold. The cationic detergent CTAB was shown to slightly increase 
reaction rate; however, deviation is high. No significant increase was detected for 0.1 % (w/v) 
toluene addition. 
The outer membrane is the most effective mass transfer barrier for small hydrophobic molecules 
such as acetophenone.[28] As toluene, CTAB and polymyxin B sulfate mainly target the LPS layer of the 
outer membrane of gram negative bacteria a positive effect on initial reaction rates is not 
surprising.[59, 60b, 66] However, especially the treatment with toluene may have some negative effects 
such as cofactor leaching.[63a, 63c, 67] 
 
Figure 2 Reaction rate in pure isopropanol and acetophenone (ratio 9:1) with E. coli whole cells overexpressing CPCR2 
after treatment with different permeabilizing agents. 
These findings indicate that the system is limited by mass transfer phenomena and that cell 
permeabilization with 1 % (w/v) toluene or 60 µmol L-1 polymyxin B constitutes an effective method 
to improve initial reaction rates. Twofold improvement of reaction rate is significant; though, further 
increase might be achieved by optimizing the permeabilizing process. 
3.3.3.4 Cofactor Limitations of the Reaction System 
To examine, whether the reaction system is limited by the amount of cofactor available, cells were 
resuspended in NAD+ containing solution prior to lyophilization. The effect of NAD+ addition was 
interpreted on the basis of initial reaction rates in the reaction system with acetophenone and 
isopropanol and results are depicted in Figure 3. 
Resuspension of the whole cell biocatalyst in NAD+-solution displayed a clear positive response as 
reaction rate almost linearly increased upon cofactor addition (see Figure 3). The reaction rate could 
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be improved 2.7-fold for 30 mmol L-1 NAD+ relative to the system with untreated cells. The trend 
observed for further cofactor addition tends to saturation. Stereoselectivity was not affected. 
This observation supports the idea that cofactor concentration limits the performance of the system. 
Intracellular cofactor levels were not determined and it is also not clear how much of the supplied 
NAD+ was imported to the cells. However, one possible explanation for the observed trend is that 
basal cofactor levels are beyond Km of CPCR2 and addition lead to an increase in reaction velocity 
according to Michealis-Menten kinetics (see Figure 3).[68] 
 
Figure 3 Reaction rate in pure isopropanol and acetophenone (ratio 9:1) with E. coli whole cells overexpressing CPCR2 
after resuspension in NAD+-solutions. 
The basal level of NADH in resting E. coli cells was reported to be around 1000 µmol L-1 [29] and Km of 
free CPCR2 being 38 µmol L-1 for NADH and 77 µmol L-1 for NAD+, respectively.[17] Hence, the free 
enzyme would be most likely saturated with cofactor and exhibit maximum velocity. However, for 
ketone reduction with E. coli whole cells, addition of 1 mmol L-1 cofactors resulted in significant rate 
acceleration as reported by Weckbecker et al.[67] Herein, an NADPH-dependent ADH and an NADH-
dependent formiate dehydrogenase (FDH) for cofactor recycling were employed exhibiting Km 
(NADPH) = 140 µmol L-1 for the ADH and Km (NAD
+) = 90 µmol L-1 for FDH, respectively. Hence, local 
concentration of cofactors at the enzymes might be different from the determined values of the 
whole cells and the apparent Km of the whole cell catalyst might also be increased. The latter 
phenomenon has been reported for E. coli cells overexpressing a tryptophanase, wherein the Km of 
the whole cell was about ten times higher than Km of the isolated enzyme.
[69] 
Nevertheless, cofactor in the neat substrate system is recycled by the same enzyme, which is also 
carrying out the reduction of the prochiral ketone employing ancillary cosubstrate. For further 
increasing productivity of the reaction system, enzyme-coupled cofactor regeneration might be 
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established. For this, a “designer cells” can be developed expressing a synthetic-ADH with reduction 
preference and a regeneration-ADH utilized to reduce the NAD(P)+ cofactor.[4b] Such systems have 
already been shown to be superior to other cofactor regenerating approach.[61b, 67, 70] 
3.3.3.5 Influence of Temperature on the Reaction System 
The influence of reaction temperature on the reaction rate of the neat substrate system was 
analyzed by conducting the standard reaction setup with E. coli overexpressing CPCR2. Here, three 
temperatures 30 °C, 40 °C and 50 °C were chosen and relative reaction rates are plotted in Figure 4. 
So far, for a standard setup 30 °C was chosen as reaction temperature and among the selected 
temperatures, it displayed the highest reactions rate (see Figure 4). Running the reaction at 40 °C 
resulted in slightly reduced reaction rate but at 50 °C productivity was decreased by 90 %. 
Stereoselectivity was again not affected. 
Biocatalysis at elevated temperatures is usually a tradeoff between catalyst stability and activity. Like 
most chemical reactions, the rate of an enzyme-catalyzed reaction increases as the temperature is 
raised. The rate rises up to a catalyst-specific temperature optimum, which is 36-40 °C for reduction 
by CPCR2[13c], and declines due to catalyst degradation or enzyme denaturation. Most enzymes from 
mesophilic hosts, like the yeast Candida, denature at temperatures >40 °C as seen for the 
temperature profile for purified CPCR2.[13c] Hence, one reason for the observed trend is the thermal 
denaturation of CPCR2 in the E. coli whole cells; however, after 24h reaction catalyst activity was still 
detectable at 50 °C. 
 
Figure 4 Relative reaction rates in pure isopropanol and acetophenone (ratio 9:1) with E. coli whole cells overexpressing 
CPCR2 operated at different temperatures for 24h. 
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As the CPCR2 is enclosed in the cell and protected against hazardous conditions in the exterior, also 
the cell stability at elevated temperatures has to be taken into account. Furthermore, the response 
to temperature of a whole cell catalyst compared to the isolated enzyme may be different as shown 
for ADH from Rhodococcus ruber in E. coli. In this work, ketone reduction with previously lyophilized 
E. coli cells was carried out at 19 % (v/v) isopropanol and a sharp drop in activity was observed at 
reaction temperatures just above 40 °C.[71] However, optimal temperature of the isolated ADH was 
determined to be 65 °C indicating that the microbial host dictates stability.[71] These results are in 
accordance with the temperature profile observed in neat substrates (see Figure 4). 
The loss of enzymatic activity of E. coli at temperatures higher than 40 °C can be explained by melting 
of the cell membranes, which was investigated previously by differential scanning calorimetry.[72] The 
cell membrane comprises an effective protective barrier against uptake of organic molecules, such as 
isopropanol or acetophenone.[28] Thus, thermal destruction of the membrane integrity may lead to 
influx of these compounds into the cell finally resulting in enzyme deactivation. In contrast, optimum 
temperature for an E. coli whole cell catalyst harboring a mesophilic hydantoinase was found to be 
55 °C; however, they did not state reaction times.[73] 
3.3.3.6 Operational Stability of the Catalyst in the Reaction System 
Catalyst stability under process conditions is one of most important parameters for implementation 
of a biocatalytic synthesis route in industrial scale.[5a, 30] Therefore, catalyst stability was assayed in 
the standard reaction system by performing five consecutive reactions and recycling the cells, which 
is also known as repeated batch operation mode. 
 
Figure 5 Operational stability of the whole catalyst in the standard reaction system in repeated batch mode. Reactions 
were terminated after 24h and cells were washed with isopropanol prior to addition of fresh reaction solution. 
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As Figure 5 depicts, final conversion is decreasing only after the first batch and remains constant for 
the following batches. From this result an excellent operational stability can be inferred, since final 
conversion dropped only from 55.4 % to 40.5 % in five days. The initial loss in catalytic activity after 
the first day of operation may be explained by inactivation of cells, which were not optimally 
conditioned by lyophilization and aw-equilibration. These cells were then inactivated within the first 
24 h and did not contribute to conversion in the following batches. High stability was already implied 
previously when cells were operated in the system for 14 days still showing activity (see 3.2.3 
Figure 2). 
Gratifyingly, catalyst stability is high; however, for catalyst loads in the neat substrate system were 
rather high (50-200 g cell dry weight L-1), depending on activity and expression level of the ADHs 
applied. For industrial processes, a ratio of substrate to catalyst of >20 (better >50[1]) is demanded to 
reduce costs and promote downstream processing.[74] For the neat substrate system, substrate 
loading up to 500 g L-1 was demonstrated (see 3.2.3) leading to substrate to catalyst ratios ranging 
from 2.5 to 10, is close to the benchmark. By demonstration of high operational stability, it is 
possible to reuse the cells, thereby drastically reducing catalyst costs. Furthermore, expression levels 
can be increased as well as pre-treatment of the cells to preserve as much biocatalytic activity as 
possible. 
3.3.3.7 Sequential Deracemization in Neat Substrates 
The complete resolution of racemic alcohol or deracemization was carried out in the neat substrate 
system by applying (S)-selective CPCR2 and (R)-selective LbADH for production of (R)-1-
phenylethanol from the racemate in sequential fashion. The first part of the reaction was the 
asymmetric oxidation of (S)-1-phenylethanol to acetophenone by driving the NAD+-regeneration by 
acetone. In this case, the (R)-enantiomer remains untouched since CPCR2 is strictly (S)-selective. This 
reaction can only result in a maximum yield of 50 % of the desired enantiomer, as it is typical for 
racemic resolution reactions. At high conversions the reaction mixture contains 50 % (R)-1-
phenylethanol at high ee and nearly 50 % prochiral acetophenone. Hence, the reaction mixture can 
be subjected to an asymmetric reduction with (R)-selective LbADH and isopropanol for NADH 
regeneration. The biocatalyst converts acetophenone to (R)-1-phenylethanol leading to an overall 
maximum yield of 100 % with high ee. The concept is outlined in Figure 6. 
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Figure 6 Sequential deracemization of 1-phenylethanol by consecutive use of two whole cell catalysts with opposing 
stereoselectivity. Here, oxidation was performed first with (S)-selective CPCR2 and afterwards reduction was carried out 
with (R)-selective LbADH 
As displayed in Figure 7, oxidation of (S)-1-phenylethanol by the CPCR2 whole cell biocatalyst 
progressed well within the first five days but approached equilibrium conditions after accumulation 
of ~40 % acetophenone. Fresh pre-equilibrated acetone was replenished after 5 and 9 days (see 
Fig. 7, evaporation steps #1 and #2). Thereby, a new driving force was established to achieve high 
conversions. After 13 and 18 days the substrate to cosubstrate ratio was increased from 1:9 to 1:18 
for the same reason (see Fig. 7, evaporation steps #3 and #4). After 21 days, only 1.54 % of the 
unwanted (S) enantiomer was left and ee of 94.1 % for (R)-1-phenylethanol was achieved. The 
thermodynamic driving force at the end of the reaction is very weak and in ten days of operation 
only 1.44 % of the unwanted (S) enantiomer was converted. It is important to note that all remaining 
(S)-1-phenylethanol, which is not oxidized to acetophenone, will lower the final ee after reduction in 
sequential deracemization. Hence, highest conversion in the first oxidation step is demanded.
 
Figure 7 Conversion and enantioselectivity of sequential deracemization of 1-phenylethanol. The arrows indicate 
removal of coproduct and replenishment with fresh cosubstrate. 
Oxidation with CPCR Reduction with LbADH 
Results & Discussion 
 
97 
 
For the reduction step, remaining acetone and isopropanol were removed by evaporation and the 
resulting mixture of acetophenone and (R)-1-phenylethanol was replenished with fresh pre-
equilibrated isopropanol as cosubstrate. As whole cell catalyst, E. coli with overexpressed 
(R)-selective LbADH was applied. Figure 7 depicts fast initial reduction of acetophenone and further 
increase of ee within the first days. As for the oxidation, the reaction speed slowed down due to 
attainment of equilibrium conditions. Therefore, acetone as co-product was removed alongside with 
isopropanol by evaporation on day 24, 33 and 36 and fresh isopropanol was added (see Fig. 7, 
evaporation steps #5. #6 and #7). After 39 days of operation, 96.1 % of (R)-1-phenylethanol (96 g L-1) 
was yielded with ee = 96.5 %. Successful operation of each catalyst for about 20 days in neat 
substrates again illustrates the high process stability as previously shown in the repeated batch 
experiment (see Figure 5). 
The results demonstrate that complete deracemization is possible by application of the neat 
substrate system with different catalysts of opposing stereoselectivity. Final conversion and ee are 
>95 % and hence, satisfying since they exceed the benchmarks regarded as relevant for industrial 
application. Furthermore, deracemization illustrates the versatility of the developed reaction system 
since the complete set of products can be obtained by smart combination of the biocatalysts, 
substrates and cosubstrates. As long as the catalysts exhibit reasonable activity and high, but 
opposing, stereoselectivity on a common substrate; a desired enantiomer can be manufactured from 
the ketone or the racemate. 
As a concept, deracemization of 1-phenylethanol is a valid approach but the operation last 39 days, 
which is far too long to be attractive for industrial application. Hence, optimization is required and 
reaction engineering such in-situ product removal to retain a thermodynamic driving force might be 
applied. Furthermore, initial reaction rates may be increased by minimizing limitations like mass 
transfer or cofactor availability as identified previously in this work. 
Deracemization of alcohols by was carried out before in versatile setups like in vivo deracemization 
employing two or only one microorganisms as native and recombinant host or in vitro 
deracemization using combinations of different isolated enzymes also together with chemical 
catalysts.[2b, 75] 
Recently, combination of two microorganisms to deracemize alcohols was performed in one pot with 
Microbacterium oxydans ECU2010 and Rhodotorula sp. AS2.2241 or Aspergillus niger CCT 1435 and 
Candida albicans CCT 0776.[32, 76] Herein, one species carries out the oxidation whereas the other 
takes care of the stereoselective reduction. However, the enzymes responsible for the reactions are 
unknown and not overexpressed unlike the ADHs used in the here presented system. The knowledge 
about the identity of the active enzyme is very beneficial, since substrate scope as well as 
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stereoselectivity and possible limitations in application are already reported for the enzymes utilized 
here. Furthermore, since the enzymes are present in E. coli in recombinant form they can be 
produced easily on a large scale and high cell-specific activity with leads to high volumetric 
productivity. 
So far, the reaction is performed in two steps, since if the two whole cell biocatalysts would be 
operated at the same time the net driving force of the reaction would be zero. However, a reaction 
setup with four enzymes able to perform one-pot one-step deracemization of alcohols was 
reported.[77] Herein, the different cofactor preference of the ADHs is exploited and regeneration of 
NADH and NADPH was driven by two separate enzymatic processes. In principle, this could also be 
achieved with the neat substrate system if the two ADHs exhibit strict preference for only one 
cosubstrate but accept the racemic alcohols to be deracemized. By driving the oxidation with only 
one ketonic cosubstrate and the reduction at the same time by the alcoholic cosubstrate the two 
reactions are decoupled. Such one-step one-pot approach would shorten reaction time; however, for 
high conversions fresh coproducts have to be removed to retain reasonable reaction rates. 
3.3.4 Conclusion 
The closer investigation of the neat substrate system first described in chapter 3.2 demonstrates that 
the principle of asymmetric ketone reduction with CPCR2 in E. coli whole cells can be transferred to 
other ADHs. The enzymes ReADH and LbADH performed in a similar way as CPCR2 and did not show 
inactivation or inhibition under the conditions tested. This opens the road to apply additional ADHs in 
this system like ADH from Lactobacillus kefir, horse liver ADH or ADH1 from bakers´ yeast to broaden 
the scope to manufacture various enantiopure alcohols. Also different enzymes classes may be 
tested in this system since E. coli as lyophilized whole cell seems to be compatible with pure 
isopropanol, which can aid as effective solvent for organic molecules. 
As the conversion of various benchmark substrates in the neat substrate system suggests, the full 
scope of the applied ADHs can be exploited. However, a severe limitation seems to be reduced 
stereoselectivity at elevated substrate concentrations as implied for the small ketones 2-butanone 
and 3-butyn-2-one. This problem might be addressed by to convey the neat substrate system to 
continuously operated reaction mode wherein the substrate concentration is kept low. 
As several reaction parameters for the neat substrate were investigated, an optimized process can be 
envisaged wherein the reaction rate is increased by cell permeabilization and cofactor addition the 
optimal reaction temperature. For this, a substrate with high value-added corresponding product can 
be selected from the benchmark substrates exhibiting high conversion and selectivity such as 2-
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octanone or 4-chloroacetoacetate. The ultimate goal would be to run a process at preparative kg-
scale with substrate loads >100 g L-1, conversion and ee >99 % in less than a day. 
At last, the versatility of the neat substrate system by means of deracemization was demonstrated. 
The direction of reaction could be steered by the selection of cosubstrate to either promote 
oxidation with acetone or reduction with isopropanol. By smart combination of the catalyst and the 
reaction medium both enantiomers from ketone or racemate are accessible. However, reaction 
times are still too long and have to be optimized. 
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3.4 Reengineered Carbonyl Reductase for Reducing Methyl-substituted 
Cyclohexanones 
3.4.1 Abstract 
The carbonyl reductase 2 from Candida parapsilosis (CPCR2) is a versatile biocatalyst for production 
of optically pure alcohols from ketones. Prochiral ketones like 2-methyl cyclohexanone are; however, 
only poorly accepted, despite CPCR2’s large substrate spectrum. The substrate spectrum of CPCR2 
was investigated by selecting five amino positions (55, 92, 118, 119 and 262) and exploring them by 
single site-saturation mutagenesis. Screening of CPCR2 libraries with poor (14 compounds) and well-
accepted (2 compounds) substrates showed that only position 55 and position 119 showed an 
influence on activity. Saturation of positions 92, 118 and 262 yielded only wild-type sequences for 
the two well-accepted substrates and no variant converted one of the 14 other compounds. Only the 
variant (L119M) showed a significantly improved activity (7-fold on 2-methyl cyclohexanone; 
vmax = 33.6 U mg
-1, Km = 9.7 mmol L
-1). The L119M substitution exhibited also significantly increased 
activity towards reduction of 3-methyl (>2-fold), 4-methyl (>5-fold) and non-substituted 
cyclohexanone (>4-fold). After docking 2-methyl cyclohexanone into the substrate binding pocket of 
a CPCR2 homology model, we hypothesized that the flexible side chain of M119 provides more space 
for 2-methyl cyclohexanone than branched L119. This report represents the first study on CPCR2 
engineering and provides first insights how to redesign CPCR2 towards a broadened substrate 
spectrum. 
3.4.2 Introduction 
Biocatalysis enables novel and innovative production of chemicals with high regio- and 
stereoselectivity under often environmentally-friendly conditions.[1] Especially, the asymmetric 
reduction of prochiral ketones to the corresponding enantiomerically pure alcohols by carbonyl 
reductases (CR) or alcohol dehydrogenases (ADH; EC 1.1.1.1) display a very attractive synthesis route 
to these important building blocks used in chemical and pharmaceutical industries.[2] 
The particularly versatile NADH dependent carbonyl reductase CPCR2[3] from Candida parapsilosis 
was first isolated from the strain DSM 70125 and characterized by Peters et al.[4] The identical 
enzyme was later isolated from a related strain IFO 0369 and expressed in E. coli by Yamamoto et 
al.[5] The homodimeric CPCR2 consists of two subunits (each 36 kDa) and belongs to the medium-
chain and zinc-containing alcohol dehydrogenase family. The wild type enzyme was recombinantly 
expressed in E. coli and employed in several synthetic setups to produce high value-added chiral 
alcohols like (R)-1,3-butanediol by racemic resolution.[6] and ethyl (R)-4-chloro-3-hydroxybutanoate 
by asymmetric reduction of the corresponding ketone.[7] Furthermore, CPCR2 preparations were 
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utilized to obtain (S)-ethyl-hydroxyesters[4] and propargylic alcohols.[8] Additionally, wtCPCR2 was 
used to validate an enzyme-membrane reactor[9], an enzyme emulsion reactor[10] and a biphasic mini-
reactor.[11] Recently, we have employed CPCR2 in E. coli whole cells in neat organic substrates and in 
absence of any additional solvent with yields up to 500 g L-1 enantiopure alcohol.[12] 
CPCR2 has a broad substrate spectrum and exhibits generally high enantiomeric excess (ee >95 %).[4-5, 
8, 13] It was only recently distinguished from the isoenzyme CPCR1, which has a narrow substrate 
spectrum.[3] 
Key for substrate acceptance is the general shape of the binding pocket. CPCR2’s binding pocket was 
proposed to be composed of a small pocket with high affinity to small alkyl groups and a larger 
pocket accommodating small methyl and ethyl groups but preferably aromatic groups.[13b] The latter 
architecture is in agreement with the common fold of the substrate binding pocket of zinc-
dependent medium-chain ADHs.[14] 
Figure 1 Substrates reported for CPCR2 and normalized to ethyl 5-oxo-hexanoate reduction.
[4]
 Substrates, which are well 
accepted (> 50 % relative activity), are grouped in the left box, substrates, which are poorly accepted (< 20 % relative 
activity), are displayed in the right box. The relative activities were determined using ethyl-5-oxohexanoate as reference 
substrate. X: hydroxyl group, or halide (-Cl, -Br, -F) and n indicates the number of carbons in the chain (n: 1 to 4). 
Despite the broad substrate spectrum of CPCR2, there are classes of prochiral ketones which are only 
poorly converted, like ortho-substituted acetophenones, 2-methyl cyclohexanone (2-MCHone) or 
ketones carrying bulky side chains neighboring the carbonyl function (see Figure 1; dashed line).[13b] 
These substrates are generally difficult to be accepted by ADHs.[15] The corresponding (S)-alcohols of 
the poorly accepted substrates represent; however, industrially valuable synthons like (S)-2-
chlorophenylethanol derivates, which serve as key intermediates for anticancer drugs.[2c] 
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Consequently, there is a demand to enlarge the substrate scope of CPCR2 towards substrates as 
depicted in Figure 1 (right box). 
Tailoring of substrate scope can be achieved by rational design of the substrate binding pocket, 
random mutagenesis or combinations thereof. Structurally guided exchanges of amino acids that 
affect substrate- and stereospecificity require a crystal structure or a reliable homology model. For 
example Green and co-workers could increase activity of ADH1 from bakers´ yeast up to 10-fold for 
hexanol oxidation by enlarging the substrate binding pocket.[16] Unlike rational design, random 
mutagenesis allows to discover mutations, which are located more distantly from the active site as 
shown for AdhA from Pyrococcus furiosus.[17] Recently, the activity of a carbonyl reductase for an 
unnatural substrate was increased by 3000-fold after including 19 substitutions in a directed 
evolution campaign.[18] 
In this study, we used a semi-rational approach targeting five amino acid residues to improve CPCR2 
activity towards 14 poorly accepted substrates. Widening the substrate spectrum will make CPCR2 an 
attractive catalyst in organic synthesis and will possibly provide a deeper understanding about the 
underlying structure-function relationships that govern acceptance of cyclic ketones. 
3.4.3 Materials & Methods 
3.4.3.1 Preparation of Chiral Standards 
Preparation of the four stereoisomers of 2-methylcyclohexanol (2-MCHol) was done by 
stereoselective reduction of 2-MCHone with carrot root as described previously.[19] The conversion 
was monitored by gas chromatography (GC) and compared with commercial standards cis- and trans-
2-MCHol. The major peaks were assigned to the (S)-alcohol. 
3.4.3.2 Molecular Modeling 
Homology modeling of the structure of CPCR2 (wtCPCR2) was performed previously.[3] Docking 
studies were performed on a close dimer of the modeled CPCR2 structure and relaxed models of 
wtCPCR2, CPCR2-L119M with zinc-bound 2-MCHone in a reactive conformation were constructed. All 
energy calculations were performed using the modeling suite YASARA[20] employing AMBER03 force 
field[21] for the protein and GAFF[22] with AM1/BCC charges[23] for the substrates. 
All residues within 15 Å radius of the bound alcohol were free to move. The active site above the 
bound NAD(H) is located at the interface between the two monomers possessing Rossmann-fold. The 
Zn-bound alcohol-ligand in the active site of the homology models was manually replaced by the 
respective substrates in their keto form and relaxed using cycles of steepest descent energy 
minimization and simulated annealing molecular dynamics (MD) simulations from 298 °K to 5 °K. 
Reference calculations for binding energies were performed using the respective substrates in a 
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water box and the apo-enzyme with water coordinated to the catalytic Zn2+. The stabilization 
energies of the substrates in a catalytic orientation were calculated by subtracting the solvation 
energy for the substrate from the energy in the Zn2+ bound state and the energy difference of an 
active site subset consisting of ten residues lining the binding pocket in the substrate bound state 
versus the apo-structure with bound water (Ser46, Val50, Leu55, Trp116, Leu119, Leu262, Phe285, 
Trp286, GlyB272, LeuB276, B denote amino acid of the other monomer). 
3.4.3.3 Cloning of CPCR2 into pET22 
The CPCR2 gene construct was newly designed with an N-terminal extension consisting of a protease 
recognition site for tobacco etch virus (TEV) protease, an alanine decamer as spacer helix and a 
streptavidin affinity tag for convenient purification. The gene sequence was retrieved from Genbank 
accession number AB010636. The CPCR2 DNA construct was synthetically produced applying codon 
optimization for E. coli (GeneArt, Invitrogen, Darmstadt, Germany). The gene construct was cloned 
into pET22b+ vector (Invitrogen, Darmstadt, Germany) with NdeI and NotI restriction enzymes and 
T4 ligase. The attachment of the N-terminal extension had no influence on activity with 
acetophenone when compared to the originally cloned CPCR2 (data not shown). 
3.4.3.4 Site Saturation Mutagenesis 
Degeneracy at five selected sites (Leu55, Pro92, Gly118, Leu119 &Leu262) was introduced by site-
saturation mutagenesis using degenerated primer sets and a two-step protocol for polymerase chain 
reaction (PCR) adapted from Wang & Malcom.[24] Herein, Phusion High Fidelity DNA polymerase 
(New England Biolabs) was applied with 20 ng of template DNA. First, PCR with single primers was 
run followed by a second PCR were primer pairs were mixed again. NNN codon degeneracy was 
employed to cover all 64 possible codons. Primer pairs used for PCR are listed in Table 1. 
Table 1 Primer sequences for site-saturation. 
Primer name 5´-3´sequence 
L55-for catgtgatttatgaaggtNNNgattgcggtgataattatg 
L55-rev cataattatcaccgcaatcNNNaccttcataaatcacatg 
P92-for gttgcatgtgttggtNNNaatggttgtggtgg 
P92-rev ccaccacaaccattNNNaccaacacatgcaac 
G118-for gcctttggcgactggtttNNNctgggttatgatggtgg 
G118-rev ccaccatcataacccagaNNNaaccagtcgccaaaggc 
L119-for ggcgactggtttggtNNNggttatgatggtgg 
L119-rev ccaccatcataaccNNNaccaaaccagtcgcc 
L262-for gttattatgccggttggcNNNggtgcaccgaatctgtc 
L262-rev gacagattcggtgcaccNNNgccaaccggcataataac 
Sites of saturation mutagenesis are highlighted in italics 
Digestion of template DNA (pET22b-CPCR2) was done by addition of 20 U DpnI (New England Biolabs) 
to 50 µL PCR product and incubation at 37 °C overnight. Purified PCR products were transformed to 
E. coli BL21 (DE3) by electroporation and plated on agar plates containing 100 µg mL-1 ampicillin. 
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3.4.3.5 Mutant Library Generation 
Quality of the library was analyzed by sequencing seven random clones from each saturated position. 
Per amino acid position, about 240 clones represent all possible codons with a probability of 95 %.[25] 
High quality libraries (<30 % wild-type occurrence) were constructed by transferring single colonies 
from agar plate to 96-well microtiter plates (flat bottom, polystyrene) filled with 100 µL LB medium 
supplemented with 100 µg/mL ampicillin. Plates were tightly sealed and incubated (16 h, 37 °C, 
900 rpm and 70 % humidity). For long-term storage, 100 µL of 50 % (v/v) glycerol was added to each 
well and the libraries were stored at -80 °C. 
3.4.3.6 CPCR2 Protein Expression in Microtiter Plate 
Expression in microtiter plates was performed by preparing a pre-culture using 10 µL of glycerol 
stock to inoculate 140 µL of LB medium supplied with ampicillin (100 µg mL-1) in 96-well plates (flat 
bottom, polystyrene). Plates were closed with lids, tightly sealed and incubated for 16 hours (37 °C, 
900 rpm and 70 % relative humidity). Then, 10 µL of the pre-culture were transferred to 140 µL TB 
medium (per litre: 12 g Tryptone, 24 g yeast extract, 4 mL glycerol, 0.017 mol L-1 KH2PO4, 
0.072 mol L-1 K2HPO4) supplied with ampicillin 100 µg/mL (V-bottom, polystyrene) and incubated (1 h, 
37 °C, 900 rpm and 70 % relative humidity). 
Expression was initiated by supplementing 10 µL isopropylthiogalactoside (IPTG at) 0.1 mmol L-1 final 
concentration. Subsequently, protein expression took place for 6-8 hours at 15 °C at 900 rpm. For 
storage at -20 °C, cells were pelleted (18350x g, 10 min, 4 °C) and medium was removed. For lysis, 
150 µL of lysis buffer (50 mmol L-1 K2HPO4, 300 mmol L
-1 NaCl, 5 mg mL-1 lysozyme, pH 8.0) was added 
in each well. Cell pellets were mechanically lysed by pipetting up and down 100 times applying a 96-
well liquidator96 pipetting tool (Steinbrenner Laborsysteme GmbH). Afterwards, the suspension was 
incubated (1 h, 37 °C, 900 rpm and 70 % relative humidity) to intensify enzymatic cell wall 
destruction by lysozyme. 
3.4.3.7 CPCR2 Protein Expression in Flasks 
Batch expression of CPCR2 was carried out in 250 mL TB medium with ampicillin (100 µg mL-1) 
inoculated with 4 mL of an overnight culture grown in LB medium with ampicillin (100 µg mL-1; 37 °C, 
250 rpm). When cell density reached 0.6-0.8 OD600, expression was induced by supplementing 
0.1 mmol L-1 IPTG. Final expression was carried out overnight (15 °C, 250 rpm). Cells were harvested 
by centrifugation (2820x g, 10 min, 4 °C) and resuspended in 4 volumes of lysis buffer 
(50 m mol L-1 K2HPO4, 300 mmol L
-1 NaCl, pH 8.0). Mechanical lysis was performed by sonification 
3 times (1 min, 40 % amplitude with 40 cycles, Bandelin M73 sonotrode). Supernatant containing the 
soluble CPCR2 was clarified by centrifugation (2820x g, 10 min, 4 °C) and use for subsequent 
experiments. 
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3.4.3.8 CPCR2 Protein Purification 
Crude cell extract was applied to affinity chromatography employing a streptavidin gravity column 
(Strep-Tactin® Sepharose, IBA TAGnology). Purification was performed according to the 
manufacturer’s instructions. Elution fractions were analyzed by SDS-PAGE and CPCR2 concentrations 
were determined with the Bradford assay employing bovine serum albumin as standard. Fractions 
showing high enzyme activity were pooled and used for further measurements. 
3.4.3.9 CPCR2 Activity Assay in Microtiter Plate 
The NADH depletion assay in microtiter plate format was performed spectrophotometrically (Tecan 
Infinite M1000).). Here, 50 µL of crude extract was mixed with 150 µL of a substrate cocktail (see 
3.4.6) in 100 mmol L-1   TEA at pH 8.0. The reaction was initiated by addition of 50 µL of 5 mmol L-1 
NADH and absorption was monitored at 340 nm for 5 min (ε = 16,900 M-1 cm-1). Instrument and 
solutions were pre-warmed to 30 °C. 
3.4.3.10 CPCR2 Activity Assay in Cuvette 
CPCR2 activity assay in cuvette format was carried out in a Cary 300 UV/Vis spectrophotometer 
(Varian). Varying concentrations of substrate were mixed with 0.3 mmol L-1 NADH in 
100 mmol L-1 TEA, pH 8.0. The reaction was initiated by transferring 10 µL of CPCR2 solution of 
appropriate dilution to the cuvette and flushing with 1 mL of the substrate solution. The absorption 
at 340 nm was monitored for 2 min at 30°C (ε = 16,900 M-1 cm-1). 
3.4.3.11 Determination of Kinetic Parameters KM and vmax 
Kinetic characterizations of wtCPCR2 and CPCR2-L119M were carried out using the standard activity 
assay in cuvette-scale. 2-methyl cyclohexanone was used as substrate in concentrations ranging from 
0 to 30 mmol L-1 (0.1 mol L-1 TEA, pH 8.0). Purified CPCR2 concentration were varied to determine 
initial activities and to calculate Km and vmax. The data was fitted using SIMFIT, Version 6.3.2 and all 
measurements were conducted in triplicate. [26] [26] 
3.4.3.12 Determination of Temperature and pH-optimum 
To determine the effect of temperature on the activity, CPCR2 assays were performed in cuvette 
format at temperatures from 18.5 to 47.8 °C with acetophenone as substrate. Twelve temperatures 
were taken into account and measurements were carried out in triplicates. To determine the kinetic 
parameters, enzyme assays were done in cuvette format with 2-methylcyclohexanone with 
concentrations ranging from 0 to 40 mmol L-1. At least ten different concentrations were applied for 
each data set and each set was performed in triplicates. To determine the effect of pH on activity, 
enzyme assays were performed in microtiter plate at pH 6.5 to 9.5 with acetophenone as substrate in 
triplicates. 
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3.4.3.13 Asymmetric Reduction of 2-methylcyclohexanone 
For reduction of 2-MCHone, 40 mL buffer (100 mmol L-1 TEA, pH 8.0) were mixed with 10 % (v/v) 
isopropanol, 10 mmol L-1 NADH and 500 µL 2-MCHone (0.94 mmol L-1). Finally, purified wtCPCR2 (2 U) 
or CPCR2-L119M (30 U) were supplemented in purified form. The reaction was stirred (500 rpm, 
30 °C) until maximum conversion was reached. Conversion was monitored by non-chiral GC. Educts 
and products were extracted 3 times with 50 mL CH2Cl2. Excess CH2Cl2 and isopropanol were 
removed by evaporation under reduced pressure. 
3.4.3.14 Determination of Conversion, Enantiomeric & Diasteromeric Excess 
Non-chiral GC analysis 
Conversion of 2-MCHone was monitored using Agilent GC device (HP5890 Series II) equipped with a 
flame ionization detector and a chiral column (FS-Cyclodex beta-I/P column 25 m, 0.25 mm, CS 
Chromatographie) at 10 psi nitrogen gas. The temperature program was: 120°C, 4 min, isothermal. 
Substrates were separated from products and typical retention times were determined for 2-
MCHone (3.2 min), trans-2-MCHol (3.5 min) and cis-2-MCHol (3.7 min). The molecular identity of the 
individual peaks was validated by comparison with commercially available standards (racemic cis-2-
MCHol, racemic trans-2-MCHol, purchased from Sigma-Aldrich). 
Derivatization of 2-methyl cyclohexanols for chiral GC 
Conversion mixtures were extracted with CH2Cl2 (3 times; 50 mL), dried (MgSO4; 30 min), filtrated, 
concentrated to a final volume of ~500 µl and supplemented with 3 mL CH2Cl2 (dried with MgSO4). 
Derivatisation was initiated by supplementing 2.8 mL of trifluoroacetic anhydride (excess in molarity: 
~5-fold) and incubated (60 °C, 30 min; slowly stirred) under argon gas. Residual trifluoroacetic acid 
and CH2Cl2 were removed subsequently by evaporation under reduced pressure. As control the 
identical procedure was performed for the commercial racemic mixture of cis and trans 2-MCHol 
(Sigma-Aldrich). 
Chiral GC Analysis 
Enantio- and diastereomeric excess of the biotransformation was determined by applying derivatized 
2-MCHol. The instrument (Focus GC, Thermo Scientific) equipped with a Chirasil-Dex-CB column (25 
m x 0.25 mm, CS Chromatographie) at 0.7 bar helium. The temperature program was: 50°C/1° min - 
80°C/15 min – 160°C, 10 min. 
The identity of the single peaks was validated by comparison of the peaks with GC-standards, which 
were synthesized earlier. 
Typical retention times were determined for 1-(S), 2-(R) 2-MCHol (21.4 min), 1-(R), 2-(S) 2-MCHol 
(22.5 min), 1-(S), 2-(S) 2-MCHol (22.2 min), and 1-(R), 2-(R) 2-MCHol (22.9 min). Chiral standards for 
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all stereoisomers of 2-MCHol were produced according to Baldassarre et al. applying 
biotransformation of 500 µL 2-MCHone with 200 g chopped carrot root (Daucus carota) resuspended 
in 200 mL tap water.[19] 
3.4.4 Results & Discussion 
3.4.4.1 Rational Site Selection 
The reported crystal structure of a homologous ADH (35 % sequence identity) from Sulfolobus 
solfataricus (SsADH, PDB: 1R37 [27]) was used as “closest relative” for selecting amino acid positions 
for site saturation mutagenesis. Furthermore, the comprehensive medium-chain 
dehydrogenase/reductase engineering database was consulted[14] and an alignment of 37 crystal 
structures of zinc-containing medium-chain ADHs was analyzed for variable regions within the 
Substrate-Recognition Site (SRS). Two such regions were recognized and termed SRSI (“ceiling”) & 
SRSII (“right wall”). Finally, five amino acid residues (L55, P92, G118, L119 and L262) within or near 
these regions were selected for semi-rational design of the substrate binding pocket and targeted in 
five single site saturation experiments (see Figure 2 
 
Figure 2 Representation of the substrate binding pocket of wtCPCR2. The five amino acid residues selected for saturation 
mutagenesis are displayed as sticks surrounded by a mesh showing van-der-Vaals radii. The catalytic zinc (Zn
2+
) is 
depicted as black sphere and the substrate ethoxyethanol (ETX) and the cofactor NADH are represented as sticks. 
According to Knoll & Pleiss L55, G118 and L119 are located in SRSI and P92 in SRSII.
[14]
 The amino acid L262 is at the 
entrance channel. 
Amino acids L55, G118 and L119 are located in the SRSI region, amino acid P92 is found in the SRSII 
region and amino acid L262 is situated at the substrate entrance channel. Probing positions in four 
different regions (substrate entrance (L262), “ceiling” (Leu55, L119), “right wall” (P92), second 
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coordination sphere (G118) will reveal which regions are important for substrate acceptance in 
CPCR2. 
Unique for wtCPCR2 is the occurrence of the amino acid proline at position 92 within SRSII; all related 
ADH-enzymes contain a tryptophan or a phenylalanine at the corresponding position. Mutations of 
this position had an impact on substrate acceptance in ADHs from horse liver (F93)[28], yeast 
(W93)[29], Sulfolobus solfataricus (W95)[30] and human liver (F93).[31] 
Residues located in SRSI (“ceiling”) were reported to be variable among ADHs and held responsible 
for differences in substrate acceptance in individual ADHs.[14] The positions L55, G118, and L119 
selected for saturation mutagenesis in wtCPCR2 correspond to L58, G119, and I120 in the closely 
related SsADH and are reported to exhibit substrate contact or to be in close proximity to the co-
crystallized substrate.[32] 
Amino acid L262 at the substrate entrance channel corresponds to amino acid L272 in SsADH, which 
is in direct contact with the substrate.[32] Mutation at this position exhibits impact on substrate 
acceptance like reduced activity on 2-butanol in ADH of Thermoanaerobacter ethanolicus (Y267G).[33] 
and a 7- to 10-fold increased activity for the substrates butanol, pentanol and hexanol in ADH1 from 
S. cerevisiae (Met294L)[34], respectively. 
3.4.4.2 Screening with Acetophenone & 2-butanone 
A first screening of the five libraries obtained from saturation mutagenesis was done with 
acetophenone as large and 2-butanone as small substrate. As wild type CPCR2 (wtCPCR2) accepts 
both substrates very well.[4] This was done to investigate the importance of the selected amino acids 
for the catalytic machinery. Sequencing of the seven most active clones from each library revealed 
that no exchanges occurred at positions 92, 118, 119 and 262 indicating that, with regard to the 
conversion of the two selected substrates, the amino acids placed in these positions in wtCPCR2 
provide optimal performance. However, two variants with ~30 % higher activity towards 2-butanone 
than wtCPCR2 were identified after saturation mutagenesis on amino acid 55. Here, leucine was 
exchanged for phenylalanine and tryptophan. The activity of both variants on acetophenone was 
comparable to wild type. 
The exchange from an aliphatic leucine to an aromatic phenylalanine or tryptophan narrows the 
available space in the substrate binding pocket and by this promotes conversion of the small 
substrate 2-butanone. This can be deduced from the finding of Green et al. that tight binding of small 
substrates by ADH1 from baker’s yeast is “disturbed” upon enlargement of the substrate binding 
pocket[16], and the report of Ziegelmann-Fjeld et al., where a more than ten times increased Km for 2-
butanol was found for a W267A variant of ADH from Thermoanaerobacter ethanolicus.[33] The finding 
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that reduction of acetophenone was not affected by reduction of the substrate site was somewhat 
surprising, but might be explained by probable beneficial interactions of the π-systems of the 
substrates and the amino side chains of phenylalanine and tryptophan. 
3.4.4.3 Screening with Poorly Accepted Substrates & Identification Improved Variants 
For fast and efficient screening of the five libraries from site saturation mutagenesis for improved 
conversion of poor substrates, conversion of 14 different substrates by purified wtCPCR2 was 
determined (NADH depletion assay; see Table S1), and the substrates exhibiting less than 20 % 
activity relative to acetophenone were combined to four sets of substrate mixtures with a 
combination of three or four substrates each. Towards each set wtCPCR2 showed less than 15 % 
relative activity (see Table S2). The libraries from site-saturation mutagenesis were screened with 
these substrate mixtures for activity and variants with the highest activity were re-screened with 
single substrates of the respective mixture. Two variants from library L119 showed a significantly 
improved activity (~twofold) with 2-methyl cyclohexanone (2-MCHone) when compared to wild type. 
Analysis of the DNA sequence of both variants revealed a nucleotide exchange from cytosine to 
adenine resulting in an amino acid replacement from leucine to methionine. Exchanges to 
methionine are generally rare events since this amino acid is encoded by only one nucleotide triplet. 
The substitution leucine to methionine is evolutionary the most conservative one, since it has the 
highest score of +2 in BLOSUM substitution matrix.[35] 
 
Figure 3 Specific activities of wtCPCR2 & CPCR2-L119M on acetophenone and various cyclohexanones. Activities were 
determined at 5 mmol L
-1
 substrate concentration employing the standard NADH depletion assay; measurements were 
conducted in triplicate. 
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3.4.4.4 Substrate Specificity and Selectivity of CPCR2-L119M 
The variant CPCR2-L119M and wtCPCR2 were purified to homogeneity and analyzed in more detail 
concerning the substrate profile and catalytic parameters (SDS-PAGE; see Figure S1). 
The catalytic activities towards acetophenone as reference substrate, cyclohexanone and substituted 
cyclohexanones are illustrated in Figure 3. Notably, highest activity is observed for non-substituted 
cyclohexanone and activity drops in the course of 4-methyl, 3-methyl and 2-methly cyclohexanone. 
This trend is comparable between wtCPCR2 and variant L119M (e.g. wtCPCR2 from 3.0 (2-MCHone) 
to 18.3 U mg-1 (4-MCHone) // L119M from 8.5 (2-MCHone) to 95.6 U mg-1 (4-MCHone). The most 
significant improvement of specific activity was achieved towards 4-methyl cyclohexanone (5.2-fold 
higher than of wtCPCR2). 
Table 2 Kinetic parameters of reduction of 2-MCHone with wtCPCR2 and CPCR2-L119M. 
Enzyme 
Km vmax kcat kcat Km
-1 
[mmol
-1
] [U mg
-1
] [sec
-1
] [M
-1
 sec
-1
] 
wtCPCR2 7.9 ± 1.3 4.6 ± 0.3 276 3.5 *10
4
 
CPCR2-L119M 9.7  ± 0.8 33.6  ± 1 2077 2.1 *10
5
 
The catalytic parameters for reduction of 2-MCHone were estimated by measuring initial rate 
activities. The Km of CPCR2-L119M is similar to the one of wtCPCR2 (see Table 2), however, kcat is 
more than 7-fold higher under substrate saturation conditions (see Table 2). Optima in temperature 
and pH remain unchanged when comparing wtCPCR2 and CPCR2-L119M (see Figure S2 & S3). 
Furthermore, the specific activity improvement of purified CPCR2-L119M towards 2-MCHone (see 
Figure 3), correlates well with the activity improvement found in the library at position 119 by 
screening crude cell extracts with the substrate set containing the screening substrate 2-MCHone. 
Table 3 compares the kinetic parameters of wtCPCR2 and CPCR2-L119M for reduction of 2-MCHone 
with literature data for purified alcohol dehydrogenases demonstrating a notably superior specific 
activity of variant CPCR2-L119M (>3-fold; Table 3). 
Table 3 Kinetic parameters for reduction of 2-MCHone to 2-MCHol of purified alcohol dehydrogenases. 
Species Enzyme 
vmax Km km/vmax Substrate conc. Source 
[U mg
-1
] [mmol
-1
] [mmol (L mg U)
-1
] [m mol
-1
] 
Candida 
 parapsilosis 
wtCPCR2 4.6 ± 0.3 7.9 ± 1.3 0.58 40 
this 
work 
Candida  
parapsilosis 
CPCR2-L119M 33.6  ± 1 9.7  ± 0.8 3.46 40 
this 
work 
Thermus species 
ATN1 
TADH 6.97 - - 20 
[37]
 
Commononas  
testosteroni 
QH-EDH 9.24 81 0.11 - 
[38]
 
Thermoanaerobium 
brockii 
- 6.0 - - 150 
[39]
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Selectivity of wtCPCR2 and CPCR2-L119M was investigated in the reduction of 2-MCH on analytical 
scale. The detected relative amounts of the four possible products and enantiomeric and 
diasteromeric excess are depicted in Table 4. 
It was found that for both wtCPCR2 and CPCR2-L119M about half the generated product was the 
trans 1-R,2-R isomer. This is surprising since wtCPCR2 produces in general (S)- rather than (R)-
alcohols. A significant difference in selectivity of wtCPCR2 and CPCR2-L119M was found with regards 
to the cis-products (1-R,2-S & 1-S,2-R). In particular, variant CPCR2-L119M produced an about 3-fold 
higher amount of 1-R,2-S than wtCPCR2 resulting in a slightly higher enantiomeric excess. 
For synthetic application of wtCPCR2 or CPCR2-L119M selectivity for 2-MCHone reduction is too low 
and needs to be improved. However, product mixtures of 2-MCHol were reported previously for 
horse liver ADH [36] and various whole cell biotransformations.[37] 
Table 4 Relative amounts of 2-MCHols produced with wtCPCR2 & CPCR2-L119M and ee (R) & de trans. 
enantiomer [%] 
trans trans cis cis 
ee 1-R de trans 
1-S,2-S 1-R,2-R 1-S,2-R 1-R,2-S 
structure 
OH
1
2
 
OH
1
2
 
OH
1
2
 
OH
1
2
 
  
wtCPCR2 27.2 50.6 18.4 3.9 9.0 55.5 
CPCR2-L119M 28.0 46.4 13.4 11.8 16.4 48.8 
 
3.4.4.5 Structure-function Relationships & Substrate Docking 
A role of position 119 in substrate recognition of CPCR2 can be deduced from the corresponding 
position 141 in distantly related ADH isoenzymes from human liver were reported (29 % sequence 
identity). The ADH isoenzymes (β1β1//σσ) show different responses to pyrazole-like inhibitors, 
wherein the σσ isoenzyme has low affinity to 4-methylpyrazole and the β1β1 isoenzyme exhibits high 
affinity. This is modulated by position 141 as was shown by the exchange of M141 in σσ-ADH to L141 
as in native β1β1-ADH, which resulted in 35-fold increase in affinity to 4-methylpyrazole.
[38] 
Additionally, the substrate spectrum of the σσ-M141L variant towards primary alcohols (C2- C6) was 
affected. Maximal activity was decreased for all employed alcohols and Km values showed an increase 
from C2 to C4 and a decrease for C5 and C6.  
Inhibitory effects and changes in substrate specificity were attributed to changes of the available 
space within the substrate binding pocket by a M141L substitution and not to an altered transition 
state as suggested earlier.[38] Whether this is also the case for the CPCR2 variant can be investigated 
by docking 2-MCHone into the substrate binding pocket of wtCPCR2 and CPCR2-L119M. 
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The “best” active site mutation for increased activity towards 2-MCHone was the replacement of 
leucine to methionine at position 119. To elucidate structure-function relationships, substrate 
docking was performed for the screening substrate 2-MCHone in pro-cis orientation within the 
substrate binding pocket of wtCPCR2 and CPCR2-L119M based on PDB-1R37.[27]  
 
Figure 4 Model 2-MCHone in the substrate binding pocket of wtCPCR2 and CPCR2-L119M. 
Figure 4 shows 2-MCHone, the catalytic zinc ion as well as the NADH cofactor and the amino acid 
residue 119. Computational studies revealed differences in the orientation of 2-MCHone and side 
chain conformation of amino acids at positions 119 in the variant enzymes. The positioning of 2-
MCHone in CPCR2-L119M compared to wtCPCR2 is almost unaltered, but the terminal methyl group 
of the methionine in CPCR2-L119M points away from the 2-methyl group of 2-MCHone, whereas the 
isobutyl-side chain of leucine in wtCPCR2 sterically constrains the 2-methyl group of 2-MCHone. The 
replacement of leucine for methionine may therefore provide more flexibility to the binding and 
release of 2-, 3-, 4-MCHones and cyclohexanone resulting in higher catalytic activity of CPCR2-L119M 
(see Figure 3) as observed in the experimental studies. The volumes of the amino acids are; however, 
very similar: leucine = 166.7 Å3, methionine = 162.9 Å3. 
Stabilization energies of MCHones and CHone related to the standard substrate acetophenone (see 
Table 5) indicate for both wtCPCR2 and CPCR2-L119M that cyclohexanone is preferred over the 
methyl-substituted cyclohexanones; the screening substrate 2-MCHone has the most unfavorable 
stabilization energy. This is in good agreement with the experimental data (see Figure 3). 
Stabilization energies are between 6 and 26 kJ/mol lower in CPCR2-L119M than in wtCPCR2 and 
therefore considerably improved. Again this fits well to the catalytic performance of wtCPCR2 and 
CPCR2-L119M towards the examined substrates (Figure 3 and Table 5). Thus, there is a good 
correlation between calculated stabilizing energies and experimentally determined specific activities.  
The computational study can also partially explain the enantiomeric preference of wtCPCR2 and 
CPCR2-L119M in the conversion of 2-MCHone (Table 4 and Figure 4). CPCR2-L119M yields 3-fold 
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more cis-1-R,2-S 2-MCHol (see Table 4) which can likely be attributed to the pro-cis orientation of the 
2-MCHone in the binding pocket. The L119M substitution generates “free space” for the 2-methyl 
group of 2-MCHone since the branched iso-butyl side chain is replaced by a non-branched 
methionine side chain. However, for a detailed study, all binding modes of 2-MCHone (cis, trans 
isomers, chair and boat conformation) would have to be considered and a crystal structure in which 
cyclohexanol or similar substrates are bound to an ADH and that could serve as promising starting 
structure to elucidate enantiopreferences would be required; to our knowledge, there is no such 
structure to date. 
Table 5 Stabilization energies of different substrates in wtCPCR2 & CPCR2-L119M models relative to acetophenone. 
Substrate 
wtCPCR2 CPCR2-L119M 
kJ mol
-1 
U mg
-1
 kJ mol
-1
 U mg
-1
 
Acetophenone 0 26.5 0 16.2 
2-MCHone 1.5 3.0 -5.75 8.5 
3-MCHone -1.5 16.8 -13.4 37.7 
4-MCHone -0.25 18.3 -14.0 95.6 
Cyclohexanone -2.63 35.8 -29.2 144.6 
3.4.5 Conclusion 
This work represents the first study wherein amino acid positions of a carbonyl reductase from 
Candida parapsilosis (wtCPCR2) responsible for substrate recognition were rationally identified and 
subjected to saturation mutagenesis and screening. The screening system developed for this purpose 
is based on NADH-depletion and was optimized for homogeneous expression of wtCPCR2 in 96-well 
microtiter plates with a standard deviation of 15 %. It can most likely be employed for other ADHs 
with only minor modifications.  
It was demonstrated that for broadening the substrate scope towards reduction of branched 
2-MCHone the amino acid in position 119 plays a crucial role. Substitution of leucine for methionine 
in that position boosted the specific activity towards 2-MCHone by up to 7-fold. The variant CPCR2-
L119M is ~3-fold more active in the conversion of 2-MCHone than any ADH investigated with this 
substrate so far. If selectivities can be further improved, CPCR2-L119M could become a synthetically 
attractive catalyst for the production of chiral cyclohexanol moieties occurring in complex 
compounds like menthol.  
The effect of the single mutation L119M on activity and selectivity could partially be interpreted on 
the molecular level by comparing stabilization energies and taking the pro-cis orientation of 2-
MCHone into account. Saturation mutagenesis at position 119 and the identified L119M substitution 
represent a first hint that a conservative substitution in close proximity to the active site could be 
important to broaden the substrate profile and/or preserve catalytic activity. 
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3.4.6 Supplementary Information 
Selection of screening substrates 
Fourteen single substrates were investigated with purified wtCPCR2 applying the standard cuvette 
scale activity test. Activity relative to acetophenone for every substrate was less than 20 % (see 
Table S1). Additionally, single substrates and combinations thereof were tested with wild type 
enzyme expressed in microtiter plate format as described in the materials and methods section. 
Herein, activities compared to acetophenone where always less than 20 % (see Table S1). 
Table S1 Activity of poorly accepted substrates relative to acetophenone. Measurements were performed with purified 
CPCR2 and in crude lysate.  
no. substrate 
rel. act. 
with pure 
enzyme 
[%] 
rel. act. 
with crude 
lysate 
[%] 
 no. substrate 
rel. act. 
with pure 
enzyme 
[%] 
rel. act. 
with crude 
lysate 
[%] 
1 
 
17.9 2.8 
 
8 
 
8.3 2.7 
2 
 
8.4 27.6 
 
9 
 
0 - 
3 
 
7.9 6.5 
 
10 
 
17.5 - 
4 
 
3.4 0 
 
11 
 
4.7 - 
5 
 
10.4 2.5 
 
12 
 
6.7 - 
6 
 
11.1 10.7 
 
13 
 
10.0 - 
7 
 
8.1 5.5 
 
14 
 
8.0 - 
 
Four sets of substrates were generated and cumulative activity of substrate combinations was 
determined under screening conditions (substrate concentration 5 mmol L-1 each, crude lysate). 
Relative activities are summarized in Table S2. 
 
Set 1, 3 & 4 showed no inactivation of CPCR2 when the assay was performed together with 
acetophenone, however, set 2 displayed a slight inactivation (70 % activity compared to pure 
acetophenone), which is most likely attributed to β-chloro propiophenone. 
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Table S2 Activity of substrate sets under screening conditions relative to acetophenone. 
set no. compounds rel. act [%] 
1 
 
9.1 
2 
 
10.6 
3 
 
13.6 
4 
 
6.1 
 
Comparison of wtCPCR2 & CPCR2-L119M 
 
Figure S1 SDS-PAGE of wtCPCR2 and CPCR-L119M of pooled elution fractions after strep-tag purification. M is protein 
weight standard (Fermentas PAGE Ruler #SM0671). Molecular weight of a CPCR2 monomer is 38.95 kDa. 
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Figure S2 Comparison of the temperature optima of wtCPCR2 and CPCR2-L119M 
 
 
Figure S3 Comparison of the pH-optima for ketone reduction of wtCPCR2 and CPCR2-L119M 
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3.5 Design of a Carbonyl Reductase from Candida parapsilosis Towards 
Enhanced Activity & Stability 
3.5.1 Abstract 
The carbonyl reductase from Candida parapsilosis (CPCR2) is an industrially attractive biocatalyst for 
producing chiral alcohols from ketones. The homodimeric enzyme has a broad substrate spectrum 
and an excellent stereoselectivity, but is rapidly inactivated at aqueous-organic interfaces. The latter 
limits CPCR2’s application in biphasic reaction media. 
Reengineering the protein surface of CPCR2 yielded a variant CPCR2-(A275N, L276Q) with 1.5-fold 
increased activity, 1.5-fold higher interfacial stability (cyclohexane/buffer system), and increased 
thermal resistance (ΔT50 = +2.7  °C). Site-directed and site-saturation mutagenesis studies discovered 
that position 275 mainly influences stability and position 276 governs activity. After single site-
saturation of position 275, amino acid exchanges to asparagine and threonine were discovered to be 
stabilizing. Interestingly, both positions are located at the dimer interface and close to the active site 
and computational analysis identified an inter-subunit hydrogen bond formation at position 275 to 
be responsible for stabilization. 
Finally, the variant CPCR2-(A275S, L276Q) was found by simultaneous site-saturation of position 275 
and 276. CPCR2-(A275S, L276Q) has compared to wtCPCR2 a 1.4-fold increased activity, a 1.5-fold 
higher interfacial stability, and improved thermal resistance (ΔT50= +5.2 °C). 
3.5.2 Introduction 
Alcohol dehydrogenases (ADHs) are synthetically important enzymes for the production of optically 
pure alcohols, which are key intermediates for the synthesis of pharmaceuticals, agrochemicals, 
biomaterials and food ingredients.[1] The operation of ADHs in aqueous organic biphasic systems is 
often beneficial for process performance and downstream processing since, for instance, 
concentration of hydrophobic substrate molecules is increased and in situ product extraction from 
the organic phase is possible.[2] The application of ADHs for fine chemical synthesis in biphasic 
systems [1c, 3] is often limited by a low stability under process conditions, which determines process 
economics.[4] Process stability of isolated enzymes in aqueous organic reaction systems can be 
increased by protein engineering.[5] Protein engineering strategies comprise rational design, directed 
evolution or combined approaches, in which enzyme properties are tailored by amino acid 
exchanges.[6] 
Rational protein engineering was mainly applied to alter substrate acceptance and selectivity of 
ADHs by changing amino acids in the substrate binding pocket. For instance, the substitution W110A 
in an ADH from Thermoanaerobacter ethanolicus enabled the conversion of benzylacetone which 
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was not converted by the wild type enzyme.[7] Stereoselectivity was inverted by single point 
mutations in ADHs from Thermoanaerobacter ethanolicus (I86A) and Sporobolomyces salmonicolor 
(Q245H, P, L).[8] Additionally, the preference for either NADH or NADPH as a cofactor was rationally 
reengineered for ADHs from Lactobacillus brevis as well as for the reductase S1 from Candida 
magnoliae.[9] Thermal resistance was increased for ADH from Clostridium beijerinckii by introduction 
of a proline.[10] 
Also random protein engineering strategies consisting of iterative cycles of mutagenesis and 
subsequent screening of generated variants were employed for ADHs to improve activity, 
enantioselectivity, and stability. In detail, four rounds of directed evolution yielded a glyceraldehyde 
dehydrogenase variant with 26-fold improved activity on 2-hydroxybutanone.[11] Enantioselectivity 
for tetra-hydrothiophene-3-one was enhanced from 63 % to 99 % by eight rounds of evolution for 
ADH from Lactobacillus kefir.[12] Five mutagenesis and screening cycles yielded a ketoreductase with 
an overall process performance boost of 3000-fold.[5d] Higher resistance against elevated isopropanol 
concentrations (20 % (v/v)) was achieved for a phenylacetaldehyde reductase from Rhodococcus sp. 
ST-10.[13] 
The carbonyl reductase from Candida parapsilosis DSM 70125 (CPCR2) was selected as protein 
engineering target due to its ability to produce a broad spectrum of enantiomerically pure 
alcohols.[14] The chiral products serve as important building blocks in chemical and pharmaceutical 
industries.[15] The purified CPCR2 enzyme has been applied previously in several non-conventional 
reaction systems such as microemulsions (composed of buffer and cyclohexane [16]) and biphasic 
systems (mixtures of buffer and organic solvent [17]). The latter reports demonstrated that CPCR2 is 
rapidly inactivated at aqueous organic interfaces limiting its application in such industrially relevant, 
biphasic systems.[16-17] 
In this work, we reengineered CPCR2 towards enhanced activity and thermal resistance as well as 
increased stability in the presence of water-immiscible organic solvents. Eleven amino acid positions 
were rationally selected on basis of sequence alignments in order to replace surface-exposed amino 
acids from non-polar to polar. Two of the eleven positions (A275 and L276) proved to be beneficial 
and single as well simultaneous site-saturation mutagenesis of these two positions yielded CPCR2 
variants with improved activity and increased thermal resistance. The CPCR2 variants were analyzed 
computationally and hypotheses on structure-function relationships were concluded. 
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3.5.3 Materials and Methods 
3.5.3.1 Chemicals, Oligo Nucleotides and Enzymes 
All chemicals were purchased from Sigma (Steinheim, Germany), Aldrich (Steinheim, Germany), Fluka 
(Steinheim, Germany), Merck (Darmstadt, Germany) and Roth (Karlsruhe, Germany) if not stated 
otherwise. NADH was purchased from Jülich Chiral Solutions (Jülich, Germany). Primers were ordered 
from Sigma (Steinheim, Germany) or Eurofins MWG (Ebersberg, Germany).Restriction enzymes were 
purchased from Fermentas (St. Leon-Roth, Germany) if not stated differently. 
3.5.3.2 Cloning of CPCR2 and Generation of CPCR2 Variants 
His-tagged CPCR2 constructs were used for purification, activity and stability determination of wild 
type CPCR2 (wtCPCR2) and its variants (see Supplementary Information Table S1). The His-tagged 
CPCR2 was replaced by a Strep-tagged CPCR2 with optimized codon usage for E. coli in order to 
increase expression levels and simplify protein purification to an one-step procedure. The Strep-
tagged CPCR2 was used for all subsequent site-directed mutagenesis and site-saturation mutagenesis 
studies. The His-tagged and the Strep-tagged constructs of wtCPCR2 show very similar catalytic 
parameters (see Supplementary Information  Table S3). Cloning, expression and purification of the 
His-tagged CPCR2 variants was performed as described previously.[14b, 18] The Strep-tagged CPCR2 was 
cloned and expressed as reported earlier.[14d] Strep-tag purification was carried out using 1 mL gravity 
flow columns purchased from IBA TAGnology (Göttingen, Germany). As elution buffer, 0.1 mol L-1 
triethanolamine (TEA), pH 8.0 and 2.5 mmol L-1 desthiobiotin was used. 
3.5.3.3 Construction of CPCR2 Variants and Site-saturation Libraries 
Site-directed mutagenesis of the His-tagged CPCR2 was performed according to the QuikChange® 
protocol (Stratagene, La Jolla, USA). Primer pairs used are listed in Supplementary Information Table 
S2. The general polymerase chain reaction (PCR) program was as follows: initial denaturation for 
2 min at 95 °C, 25 cycles with 50 sec denaturation at 95 °C, 1 min annealing at 55 °C and 6.5 min 
elongation at 68 °C, final elongation for 7 min at 68 °C. PCR products were transformed into E. coli 
JM109 (DE3) using heat shock.[19] 
All Strep-tagged CPCR2 site-directed mutagenesis variants and site-saturation libraries were 
constructed by using a two-step protocol for PCR adapted from Wang & Malcom.[20] Herein, Phusion 
High Fidelity DNA polymerase (New England Biolabs, Beverly, USA) was applied with 20-40 ng of 
wtCPCR2 DNA. In the first step, a PCR with forward and reverse primer in separate tubes was 
performed. The general PCR program for the first step was 95 °C initial denaturation for 5 min and 
three cycles: denaturation at 95 °C for 30 sec, primer annealing at 55 °C for 30-60 sec followed by 
elongation at 72 °C for 3-10 min. In the second step, primer pairs from the first step were mixed and 
a second PCR was carried out. PCR started with 95 °C initial denaturation for 5 min and 18-25 cycles: 
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denaturation at 95 °C for 30 sec, primer annealing at 55 °C for 30-60 sec followed by elongation at 
72 °C for 3-10 min. Primer pairs used for PCR are listed in Supplementary Information Table S4. 
Digestion of template DNA was performed by addition of 1 µL DpnI (New England Biolabs) to 50 µL 
PCR product and incubation at 37 °C overnight. Purified PCR products were transformed to 
commercial E. cloni® BL21(DE3) (Lucigen, Middelton, USA) by electro-poration or heat shock 
according to the manufacturers manual. Transformation mixtures were spread on agar plates 
containing 100 µg mL-1 ampicillin and grown overnight at 37 °C. 
3.5.3.4 NADH-depletion Assays for CPCR2 Activity 
Cuvette-scale activity assays were carried out in a spectrophotometer with heatable cuvette 
chamber (Cary 300 UV/vis, Varian) using 1 mL plastic cuvettes. An assay solution was prepared (3 or 
5 mmol L-1 acetophenone, 0.3 mmol L-1 NADH, 0.1 mol L-1 TEA, pH 8.0). The reaction was started by 
transferring 10 µL of CPCR2 solution to the cuvette and rinsing with 990 µL of the assay solution. 
Protein concentrations of purified CPCR2 protein were typically 25-100 µg mL-1. Absorption at 
340 nm was monitored for 2 min at 30 °C. Enzyme solutions were diluted accordingly to obtain a 
linear decrease in absorption. 
The activity assay in 96-well plate format was performed in a Saphire M1000 spectrophotometer 
(Tecan). Here, 10-50 µL of CPCR2 solution were mixed with 150 µL substrate solution (8.33 mmol L-1 
acetophenone, 0.1 mol L-1 TEA, pH 8.0). The reaction was started by addition of 50 µL of 5 mmol L-1 
NADH and absorption was monitored at 340 nm for 5 min. The micro titer plate chamber and the 
solutions were all heated up to 30 °C. 
3.5.3.5 Kinetic Parameters, Stereoselectivity, T50-value and Interfacial Stability 
Determination of KM & kcat 
Kinetic characterizations of wtCPCR2 and its variants were carried out using the standard activity 
assay in cuvette-scale. Acetophenone was used as substrate in concentrations ranging from 
0-30 mmol L-1 (0.1 mol L-1 TEA, pH 8.0). Purified CPCR2 enzyme was diluted accordingly to obtain a 
linear decrease. All measurements were conducted in triplicate. The data was fitted using SIMFIT, 
Version 6.3.2.[21] The first order rate constant kcat was calculated by dividing vmax, deduced from the 
data fitting, by the CPCR2 concentration used in the assay. 
Determination of Stereoselectivity 
For determination of stereoselectivity 20 mL buffer (0.1 mol L-1 TEA, pH 8.0) were mixed with 2.5 % 
(v/v) isopropanol, 1 mmol L-1 NADH, 1 mmol L-1dithiothreitol and 50 mmol L-1 acetophenone. Finally, 
purified CPCR2 (5 U) was supplemented. The reaction was stirred with 500 rpm at 30 °C for 24 h. 
Educts and products were extracted with 1 mL dichloromethane and subjected to chiral gas 
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chromatographic analysis. Enantiomeric excess was determined using an Agilent GC device (HP5890 
Series II) equipped with a flame ionization detector (250 °C) and a chiral column (CP-ChiraSil-DEX CB 
25 m, 0.25 mm, 2.5 µm, CS Chromatographie). Separation was performed at 10 psi N2 with 120 °C 
isothermal for 30 min. Typical retention times were 10.5 min for acetophenone, 19.5 min for (R)-1-
phenylethanol and 20.5 min for (S)-1-phenylethanol. Identification of the single peaks was done by 
comparison with authentic commercial standards. Enantiomeric excess was calculated by comparing 
the ratios of the peaks areas obtained from automated integration. 
Determination T50 
Residual activity of wtCPCR2 and its variants upon heat treatment was determined by transferring 
50 µL purified CPCR2 into a 96-well plate (Thermowell-96® Corning). The plate was sealed and 
incubated at temperatures ranging from 37-60 °C for 20 min in a PCR cycler (Mastercycler pro S, 
Eppendorf). After incubation, 10-20 µL CPCR2 solution was subjected to the 96-well plate-scale 
activity assay. All measurements were conducted in triplicate. Data was fitted using the software 
ORIGIN version 7.0 applying a Boltzmann model. The temperature at, which 50 % of the initial 
activity was detected, was denoted T50-value. 
Determination of Interfacial Stability 
Interfacial stability of CPCR2 in the presence of a water-organic interface was monitored by 
overlaying 3 mL cyclohexane, n-heptane or methyl tert-butyl ether (MTBE) with 3 mL of CPCR2 
solution (0.1 mol L-1 TEA, pH 8.0). Protein concentrations were 50 µg mL-1 for His-tagged CPCR2 and 
100 µg mL-1 for Strep-tagged CPCR2. The individual organic solvents and the aqueous buffer were 
saturated with each other beforehand. Incubation was performed at room temperature and 100 rpm 
stirring (5 mm Teflon coated stirrer bar). Aliquots were taken from the aqueous phase at regular time 
intervals until at least 75 % of activity was lost (2x half-life). Samples were subjected to the cuvette-
scale activity assay. All measurements were at least performed in triplicate. Data was fitted with a 
model of first order decay using SIMFIT, Version 6.3.2.[21] Half-lives (t1/2) were calculated by dividing 
ln(2) by the apparent deactivation parameter (kapp). 
Determination of Water Solubility of Solvents 
Solvent concentrations within the aqueous phase were determined from solvent-saturated buffer 
samples via GC-analysis using a HP5890 Series II (Agilent, Germany) equipped with a FS-FFAP-CB-0.5 
column (CS-Chromatography, Germany). 1-butanol was used as internal standard and was added 
after sampling. Details of analysis: N2 0.25 bar; injector/flame ionization detector 200 °C; 45 °C for 
3.5 min, 200 °C (20 °K min-1); typical retention times: MTBE 2.1 min, n-heptane 2.2 min, toluene 
3.7 min, and 1-butanol 6.6 min. 
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3.5.3.6 Screening for Improved Stability 
Screening for detergents 
To identify a detergent, which effectively inactivates CPCR2 in crude E. coli lysate, TritonX100 as non-
ionic, sodium dodecyl sulfate (SDS) as negatively charged, cetyltrimethyl ammonium bromide (CTAB) 
as positively charged and 3-[(3-cholramidopropyl)dimethyl-ammonio]-1-propanesulfonate (CHAPS) 
as zwitter ionic detergent were investigated with wtCPCR2 below the critical micelle concentration 
(cmc) and above. TritonX100 (cmc = 0.2-0.9) was used at 0.5 and 1 mmol L-1, SDS (cmc = 
7-10 mmol L-1) at 0.5, 2 and 20 mmol L-1, CTAB (cmc = 1 mmol L-1) at 0.5 and 5 mmol L-1, CHAPS (cmc 
= 6-10 mmol L-1) at 2 and 20 mmol L-1. 
For the stability assay, 10 units of CPCR2 from a crude E. coli extract were mixed in a final volume of 
2 mL in glass vials with detergent solution at 30 °C and 100 rpm stirring (5 mm Teflon coated stirrer 
bar). Enzymatic activity was determined at regular time intervals using the cuvette-scale activity 
assay. Measurements were carried out in duplicate. 
Screening for Detergent Stability 
To find a SDS concentration for library screening, 20 µL crude wtCPCR2 lysate were incubated at 
37 °C for 20 min with 20 µL SDS solution (0.1-2 mmol L-1 SDS in 0.1mol L-1 TEA, pH 8.0) in a 96-well 
plate and shaking (900 rpm, 70 % relative humidity). The residual CPCR2 activity was afterwards 
analyzed using the 96-well plate-scale activity assay. 
For library screening, 20 µL of crude lysates were incubated with 20 µL of 1 mmol L-1 SDS in 
0.1 mol L-1 TEA, pH 8.0 for 20 min in a multi titer plate shaker (900 rpm, 37 °C, 70 % relative 
humidity). Residual activity was quantified using the 96-well plate-scale activity assay. 
Screening of Thermostability 
The T50-value for wtCPCR2 in crude lysates was determined in the same way as described for purified 
CPCR2. For screening libraries, 50 µL of crude lysate was incubated for 20 min at 50 °C and cooled 
down to 4 °C before determination of residual activity applying the 96-well plate NADH-depletion 
assay. 
Molecular Modeling 
Structural basis for the modeling is the recently published homology model of wtCPCR2 based on the 
X-ray structure of Sulfolobus solfataricus ADH (PDB-code 1R37) with bound ethoxyethanol.[14b] We 
constructed relaxed models of CPCR2 with zinc-bound acetophenone in a reactive conformation 
according to the previously published procedure [14b] using Yasara Structure version 11.6.16 software 
[22] and employing the force field AMBER03 [23] for the protein and GAFF [24] with AM1/BCC charges [25] 
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for the substrate. Stability calculation and dimer interaction energies were computed with FoldX 
Version 3.0 Beta 5.1 (c) [26] using the Yasara-FoldX plugin with standard settings.[27] 
3.5.4 Results & Discussion 
In the first paragraph the interfacial stability of wtCPCR2 is described. The second paragraph 
describes the generation of twelve rationally designed variants targeting the surface amino acids at 
positions 24, 26, 78, 79, 83, 222, 226, 275, 276, 307 and 308, which were subsequently screened for 
improved activity and/or interfacial stability. Positions 275 and 276 were selected for in-depth 
characterization since activities and interfacial stabilities were improved simultaneously. The 
concluding paragraph on computational analysis of the CPCR2 variants provides a first hypothesis on 
the role of the investigated amino acids on thermal resistance (position 275) and activity (position 
276). 
3.5.4.1 Interfacial Stability of CPCR2 
Purified wtCPCR2 was incubated in aqueous-organic biphasic systems with methyl tert-butyl ether 
(MTBE), cyclohexane and n-heptane as second phase as well as in monophasic systems composed of 
aqueous buffer saturated with the same solvents. Figure 1 shows stabilities of wtCPCR2 as half-life in 
mono- and biphasic systems. Inactivation in a monophasic system is termed “molecular toxicity” and 
inactivation at aqueous-organic interface is named “phase toxicity”.[28] The experimentally observed 
inactivation in biphasic systems comprises a combination of molecular toxicity and phase toxicity.  
Half-lives of wtCPCR2 show that the presence of cyclohexane and n-heptane in monophasic systems 
does not significantly affect the stability. However, MTBE reduces half-life significantly. This can likely 
be attributed to the considerably higher solubility of MTBE in aqueous buffer (668 mmol L-1) 
compared to cyclohexane and n-heptane (4 and 16 mmol L-1, respectively). Hence, for wtCPCR2 
molecular toxicity correlates well with the solvent concentration in aqueous buffer. Such correlations 
of solvent concentration and enzyme stability have been reported for other enzyme classes.[29] 
If a solvent-saturated buffer is overlaid with the same organic solvent a biphasic system with a 
distinct interface is generated. Upon comparison of enzyme stability in the solvent-saturated buffer 
with the corresponding biphasic system, the singular influence of the water/solvent interface (phase 
toxicity) can be estimated. Figure 1 displays that wtCPCR2 gets rapidly inactivated at the 
water/solvent interface. Its half-life drops up to 30-fold in presence of cyclohexane and n-heptane 
when compared to the half-life in buffer. Phase toxicity is less prominent with MTBE (twofold 
reduction). 
The surface tensions of the organic solvents, which is 50.2 mN m-1 for cyclohexane and n-heptane [30] 
but only 10.2 mN m-1 for MTBE [30], are in good correlation with the reduction in half-life and may 
account for the enzyme inactivation. The finding agrees with previous reports, in which a clear 
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correlation between the decrease in interfacial stability and increasing surface tension of solvents 
was observed for the protease papain.[31] As well, the ADHs from horse liver, Lactobacillus brevis and 
Thermoanaerobium brockii were shown to be, like wtCPCR2, relatively stable in presence of MTBE 
and unstable in emulsions with cyclohexane.[32] However, Gröger et al. reported n-heptane to be a 
better choice than MTBE as organic solvent for a biphasic system when an ADH from Rhodococcus 
erythropolis was employed jointly with a formate dehydrogenase from Candida boidinii.[2a] 
Mutants of CPCR2 were rationally designed, generated and analyzed in order to improve stability and 
obtain a deeper understanding of interfacial inactivation on the molecular level. 
 
Figure 1 Half-lives of CPCR2 in the presence of MTBE, cyclohexane and n-heptane in monophasic (solvent-saturated 
buffer) and biphasic systems. The numbers within the columns specify the average half-life in hours. Figure and results 
taken from PhD thesis A. van den Wittenboer, RWTH Aachen University 2009.
[33] 
3.5.4.2 Rational Site Selection for CPCR2 Variants 
Amino acid positions in wtCPCR2 for site-directed mutagenesis studies were selected following the 
hypothesis to decrease the extent of hydrophobic interactions with the organic solvent molecules by 
exchanging hydrophobic surface residues against hydrophilic residues. Preference was given to 
amino acid positions localized in flexible loop regions, which should ideally enable additional non-
covalent interactions and thus reduce the susceptibility for structural rearrangements upon solvent 
exposure. Based on a protein sequence alignment of related ADHs originating from thermophile 
hostsand visual inspection of crystal structures (see Figure S 1), sites for site-directed mutagenesis 
were identified. Selected hydrophobic residues were exchanged against polar or charged residues 
with similar steric demand (see Table S1). 
3.5.4.3 Activity & Stability of Rationally Designed CPCR2 Variants 
Twelve CPCR2 variants were generated, purified to homogeneity and investigated for specific activity 
using a NADH-depletion assay.[33] An improvement in specific activity compared to wtCPCR2 was 
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found for CPCR2-(A275N, L276Q); whereas most other variants exhibited lower activities (see Figure 
2). In detail, the amino acid exchanges at positions 24, 26, 222, 226, 307 and 308 resulted in a loss of 
>80 % in specific activity. Mutation of positions 78, 79 and 83 was tolerated better, but relative 
specific activity values were still only 29 % for CPCR2-(V78S, I79K, V83E), 33 % for CPCR2-(V78S, I79T, 
V83S) and 86 % for CPCR2-(I79T, V83S), respectively. 
 The five most active CPCR2 variants for further studies were: CPCR2-(V78S, I79T, V83S), CPCR2-(I79T, 
V83S), CPCR2-(V78S, I79K, V83E), CPCR2-(A275N, L276Q) and CPCR2-(L307K, L308K). All five CPCR2 
variants were subjected to stability experiments in mono- and biphasic systems in presence of MTBE, 
cyclohexane and n-heptane. Enantioselectivity of these variants remained unaltered for 
acetophenone as substrate when compared to wtCPCR2 (ee > 99 % with acetophenone, data not 
shown), whereas relative stability was decreased in monophasic systems especially in the presence 
n-heptane and cyclohexane (Figure 3, black bars). 
On the contrary, considerable stabilization was observed in biphasic systems for the three variants 
CPCR2-(V78S, I79T, V83S), CPCR2-(I79T, V83S), and CPCR2-(A275N, L276Q) (see Figure 3, grey bars). 
Best improvement in interfacial stability was observed for the variant CPCR2-(I79T, V83S), which is 
significantly more stable in all investigated biphasic systems when compared to wtCPCR2. 
Variant CPCR2-(A275N, L276Q) exhibits increased activity as well as increased interfacial stability in 
MTBE and cyclohexane (see Figure 2 and Figure 3). The respective amino acid substitutions at 
positions 275 and 276 were further analyzed by individually introducing both substitutions (A275N; 
L276Q) in wtCPCR2. 
 
Figure 2 Specific relative activities of purified CPCR2 variants in relation to wtCPCR2 in buffer (0.1 mol L
-1
 TEA, pH 8; 
5 mmol L
-1
 acetophenone). Specific activity of wtCPCR2 in crude extract was 0.97 U mg
-1
. Figure and results taken from 
PhD thesis A. van den Wittenboer, RWTH Aachen University 2009.
[33]
 
100 
1 
7 
33 
86 
29 
7 11 5 6 
137 
18 
9 
0
20
40
60
80
100
120
140
re
la
ti
ve
 s
p
e
ci
fi
c 
ac
ti
vi
ty
 [
%
] 
Results & Discussion 
 
131 
 
Figure 3 Relative stability of selected CPCR2 variants in the presence of organic solvents. Relative stabilities are 
normalized to the half-lives of wtCPCR2 in the corresponding mono- and biphasic systems (see Figure 1). Figure and 
results taken from PhD thesis A. van den Wittenboer, RWTH Aachen University 2009.
[33]
 
3.5.4.4 Cooperativity of Position 275 and 276 in CPCR2 
Figure 4Fehler! Verweisquelle konnte nicht gefunden werden. shows the individual contributions of 
CPCR2-(A275N) and CPCR2-(L276Q) to the increase of relative activity and interfacial stability in the 
presence of cyclohexane. Cyclohexane was selected as organic solvent due to the strong 
improvements in relative stabilities in the corresponding biphasic system (see Figure 3). 
 
Figure 4 Relative activity in buffer and relative interfacial stability of CPCR2-(A275N, L276Q), CPCR2-(A275N), and CPCR2-
(L276Q) in a biphasic system with cyclohexane. Normalization was done to the activity of wtCPCR2 in buffer (0.1 mol L
-1
 
TEA, pH 8; 5 mmol L
-1
 acetophenone) and to interfacial stability of wtCPCR2 determined in a biphasic system with 
cyclohexane. Specific activity of wtCPCR2 was 25 U mg
-1
. 
The analysis of the single amino acid exchanges on activity and interfacial stability demonstrated that 
CPCR2-(A275N) is slightly more stable but significantly less active compared to wtCPCR2. CPCR2-
(L276Q) is 1.8-fold more active but less stable in the biphasic cyclohexane/buffer system. CPCR2-
(A275N, L276Q) is ~1.5-fold more active and ~1.5-fold more stable than wtCPCR2. Hence, position 
275 influences preferentially interfacial stability while position 276 improves mainly activity. Site-
saturation mutagenesis (SSM) of the positions A275 and L276 was performed with the individual 
single sites (sSSM) as well as with both site simultaneously (dSSM) in order to find out whether the 
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rationally designed variants (CPCR2-(A275N), CPCR2-(L276Q) and CPCR2-(A275N, L276Q)) represent 
the most beneficial amino acid substitutions for increased activity and interfacial stability. 
3.5.4.5 Screening Procedure of Increased Activity and Stability 
Libraries of CPCR2 variants were screened for activity in crude E. coli lysates in 96-well plates 
employing a NADH-depletion assay previously adapted for this purpose.[34] The screening strategy 
comprised three steps: Firstly, initial activity was determined; secondly, residual activities were 
determined after incubation at elevated temperatures (50°C; 20 min) and thirdly, residual activities 
were determined after incubation in the presence of detergent (1 mmol L-1 SDS; 20 min). To eliminate 
variations in protein expression levels, activity ratios were calculated.  
Thermal resistance and SDS stability were selected as criteria for interfacial stability since crude cell 
lysates did not show inactivation of wtCPCR2 after overlaying and extensive incubation with organic 
solvents in 96-well micro titer plates. The latter can likely be attributed to interactions between the 
aqueous/organic interphase and proteins or membrane debris originating from E. coli. To validate 
the screening procedure, the variant CPCR2-(A275N, L276Q) served as a positive control since it was 
already proven to be more active and stable (see Figure 2 and Figure 3). 
Screening assay for Improved Thermostability 
For selection of an appropriate temperature for screen of wtCPCR2 for thermal resistance, the T50-
values of wtCPCR2 and CPCR2-(A275N, L276Q) in crude E. coli lysate were determined by incubation 
at different temperatures for 20 min. Figure 5 shows the typical sigmoidal decrease in relative 
activity with increasing temperature and the T50-value defined as the temperature at which 50 % of 
residual enzymatic activity is left.[4b] CPCR2 wild type has a T50-value of 47.5 ± 0.74 °C and CPCR2-
(A275N, L276Q) of T50= 50.2 ± 0.63 °C. The latter result gives the first indication that thermal 
resistance correlates with interfacial stability, since the T50-value of the positive control CPCR2-
(A275N, L276Q) is increased (ΔT50 = +2.7 °C) along with the interfacial stability (1.5-fold; Figure 3) 
when compared to wtCPCR2. A correlation between thermal resistance and interfacial stability was 
reported in other protein stabilization studies.[35] 
In essence, incubation at 50 °C for 20 min was finally selected to screen for wtCPCR2 variants with 
improved interfacial stability. Residual activities were determined using the 96-well plate NADH-
depletion assay.[14d] The standard deviation of the screening system was calculated to be 8.6 %. 
Screening systems with standard deviations below 14 % were routinely used to identify improved 
variants in 96-well microtiter plate format.[36] 
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Figure 5 Determination of T50-value for wtCPCR2 and CPCR2-A275N-L276Q in crude lysates. The inactivation curves 
indicate that CPCR2-A275N-L275Q could be identified in crude cell extracts in screening campaigns to improve thermal 
resistance. The dotted line indicates 50 % of residual activity. 
Screening Assay for Improved Detergent Stability 
To establish screening conditions for detergent stability, four chemically different detergents were 
probed for their ability to inactivate wtCPCR2 above and below the critical micelle concentration 
(cmc). The NADH depletion assay in cuvettes revealed that all detergents inactivate wtCPCR2 in 
crude E. coli lysates at concentrations above their cmc (see Supplementary Information Figure S2). 
Sodium dodecyl sulfate (SDS) was identified as strong denaturant (50 % residual activity in 
0.5 mmol L-1 SDS; 30 min incubation). The non-ionic TritonX100 showed in contrast to SDS initial 
activation of CPCR2 at submicellar concentrations and the positively charged CTAB exhibits activity 
preserving properties below cmc since CPCR2 activity was unaltered for more than 30 h (see 
Supplementary Information Fehler! Verweisquelle konnte nicht gefunden werden.). 
SDS was chosen for screening of CPCR2 crude lysates in 96-well plate-scale because it was reported 
to inactivate enzymes mainly by interactions with the hydrophobic part of the molecule thereby 
mimicking the interaction with water-immiscible organic solvents.[37] Different SDS concentrations 
(0.1, 0.25, 1 and 2 mmol L-1) were chosen to find conditions for CPCR2 inactivation. Incubation of 
crude wtCPCR2 lysate in micro titer plate for 20 min. demonstrated that 1 mmol L-1 SDS reduced 
activity by half and was therefore chosen for further screening (data not shown). Standard deviation 
of the screening system was determined to be 6.5 %. 
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3.5.4.6 CPCR2 Variants Found by Screening 
CPCR2 SSM libraries were constructed and completeness calculated according to Patrick and Firth 
was high for all three libraries (see Supplementary Information Table S5).[38] Most promising clones 
identified from initial screening of the two sSSM as well as for the dSSM libraries of position 275 and 
276 were rescreened in triplicate. Variants showing significant improvements in activity and/or 
stability were subjected to DNA sequencing. 
Table 4 summarizes relative improvements in activity, thermal resistance and SDS stability of CPCR2 
variants identified in screening of 275-sSSM-, 276-sSSM- and 275, 276-dSSM-libraries. From 275-
sSSM, threonine and asparagine at position 275 exhibit significant improvements in thermal 
resistance and SDS stability. Notably, the previously generated variant CPCR2-(A275N), which 
exhibits higher interfacial stability than wtCPCR2 (see Figure 3), was identified in the library as more 
resistant to thermal and detergent inactivation. The positive correlation proves again that the 
screening strategy with incubation at an elevated temperature allows identifying interfacial stabilized 
CPCR2 variants in crude cell lysates. Screening of 275-sSSM proves that position 275 contributes, as 
previously suggested, to stability, whereas increases in activity were not significant. 
Position 276 improves activity substantially especially for the exchanges to glutamine (2.1-fold), 
arginine (1.5-fold) and lysine (1.4-fold), whereas a significant stabilizing effect was not detected (see 
Table 4). The substitution pattern indicates that polar and positively charged amino acids at position 
276 exhibit a positive effect on CPCR2 activity. Notably, stabilization towards SDS was not observed 
in 276-sSSM. Saturation mutagenesis of position 276 demonstrates its activity improving role as 
proposed earlier for CPCR2-(L276N) (see Figure 4). Like for position 275, the L276Q exchange was 
identified by the screening procedure as highly beneficial. The latter shows again the accuracy of the 
developed screening strategy and chosen conditions. 
Simultaneous saturation at positions 275 and 276 resulted inCPCR2 variants with improved activity, 
thermal resistance, and detergent stability. The best combination found was CPCR2-(A275S, L276Q), 
which yielded improved activity (twofold), thermal resistance (twofold) and significantly higher 
stability in the presence of SDS (1.8-fold). Interestingly, at position 275 serine or threonine were 
found in 5 out of 7 sequenced variants indicating the importance of a hydroxyl group at this position. 
Methionine at position 276 was found to exhibit a substantial stabilizing effect when combined with 
serine, threonine or asparagine at position 275, whereas activity was improved only in combination 
with serine(see Table4).Notably, the double mutant CPCR2-(A275N, L276Q), which was designed 
rationally before, was again identified by screening the dSSM library. 
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Table 4 Relative improvements of CPCR2 variants compared to wtCPCR2 identified after rescreening in96-well micro titer 
plate format. Measurements were performed in triplicates using the NADH depletion assay with crude cell lysates. For 
calculation of activity improvements, the activity ratios of the variants compared to wtCPCR2 were calculated 
(actvariant/actwt). Improvements in thermal resistance (actTemp) and SDS stability (actSDS) were determined by dividing the 
activities after treatment of the variants by the residual activity of wtCPCR2. Before forming the ratios, the residual 
activities were normalized with the activities before treatment to account for variation in expression levels. The best 
performing variant is in bold.The previously designed double mutant A275N, L276Q as well as wtCPCR2 are shaded in 
grey. 
Variant 
Relative activity 
actvariant/actwt 
Residual activity 
relative actTemp 
Residual activity 
relative actSDS 
wtCPCR2 (A275,L276) 1.00 ± 0.17 1.00 ± 0.10 1.00 ± 0.15 
Ala275Thr 1.23 ± 0.44 1.61 ± 0.32 1.53 ± 0.27 
Ala275Asn 0.97 ± 0.24 1.54 ± 0.04 1.58 ± 0.18 
                   Leu276Gln 2.10 ± 0.30 1.17 ± 0.29 1.00 ± 0.35 
                   Leu276Arg 1.54 ± 0.09 1.20 ± 0.21 0.96 ± 0.33 
                   Leu276Lys 1.37 ± 0.15 0.83 ± 0.14 0.60 ± 0.01 
Ala275Ser,Leu276Gln 1.92 ± 0.05 1.96 ± 0.06 1.75 ± 0.44 
Ala275Asn,Leu276Gln 2.12 ± 0.29 1.38 ± 0.09 1.52 ± 0.12 
Ala275Ser,Leu276Met 2.05 ± 0.17 1.40 ± 0.19 1.61 ± 0.32 
Ala275Thr,Leu276Asn 2.33 ± 0.21 1.11 ±0.42 1.49 ± 0.07 
Ala275Ser,Leu276Arg 1.43 ± 0.11 1.26 ± 0.36 1.30 ± 0.10 
Ala275Thr,Leu276Met 0.78 ± 0.21 1.85 ± 0.07 1.73 ± 0.29 
Ala275Asn,Leu276Met 0.71 ± 0.01 1.60 ± 0.07 1.02 ± 0.25 
Overall, the substitution patterns suggest that positions 275 and 276 in CPCR2 tolerate mutations to 
polar amino acids like serine, threonine, asparagine or glutamine. Basic as well as amide amino acids 
at position 276 appear to have positive effects on activity. The three rationally designed variants 
(CPCR2-(A275N), CPCR2-(L276Q) and CPCR2-(A275N, L276Q)) were identified by screening the 
corresponding SSM libraries. The trends in activity and stability deduced from screening in crude 
lysates resemble the results obtained for the purified variants generated beforehand validating the 
rationality within the screening and selection strategy. 
For a detailed analysis, the most beneficial variants CPCR2-(A275T) and CPCR2-(L276Q) as well as the 
best double mutant CPCR2-(A275S, L276Q) were selected for in-depth characterization. The variant 
CPCR2-A275S was not identified by site-saturation in the screening system, despite that the dSSM of 
position 275 and 276 demonstrated the A275S substitution being a very beneficial one (see Table 4). 
Thus, the CPCR2-(A275S) variant was generated by site-directed mutagenesis applying the same 
conditions as for sSSM-275 library construction. 
Results & Discussion 
 
136 
 
3.5.4.7 Characterization of Purified CPCR2 Variants  
The variants CPCR2-(A275T), CPCR2-(A275S), CPCR2-(L276Q) and CPCR2-(A275S, L276Q) were 
selected for characterization in comparison to wtCPCR2. All variants were purified and analyzed in 
terms of kinetic performance (KM, kcat), stereoselectivity (ee), interfacial stability (t1/2), and thermal 
resistance (T50). 
Table 5 Comparison of catalytic and stability parameters of wtCPCR2, CPCR2-A275Sand most beneficial variants 
identified by screening SSM libraries of positions 275, 276. 
CPCR2 variant KM [mol L
-1
] vmax [U mg
-1
] kcat [s
-1
] ee S [%] t1/2 [h] T50 [°C] 
wtCPCR2 0.20 ±0.03 53.2 ±0.9 3213 >99 5.87 ±0.28 48.8 ±0.1 
CPCR2-A275S 0.53 ±0.05 56.0 ±0.8 3186 >99 2.05 ±0.07 48.4 ±0.4 
CPCR2-A275T 0.21 ±0.03 46.3 ±0.8 2678 >99 4.49 ±0.11 51.4 ±0.1 
CPCR2-L276Q 0.72 ±0.06 72.6 ±1.4 4305 >99 3.17 ±0.06 49.3 ±0.2 
CPCR2-A275S-L276Q 0.71 ±0.07 74.8 ±1.7 4773 >99 8.96 ±0.38 54.0 ±0.3 
 
Table 5 lists the catalytic and stability parameters for the purified wtCPCR2 and selected CPCR2 
variants determined with acetophenone as substrate. The performance values demonstrate that KM-
values are higher for all variants except CPCR2-(A275T). Particularly, KM-values increased almost 
threefold for variants with glutamine at position 276 (CPCR2-(L276Q), CPCR2-(S275S, L276Q)). 
Furthermore, specific activity is raised for the same variants by a factor of 1.4 as deduced from the 
turnover frequency kcat. Stereoselectivity (ee) was not changed for any of the variants listed in Table 
5. 
Increased KM-values accompanied by increased kcat were observed before for mutants of ADHs of 
Sulfolobus solfataricus (SsADH). The effect was explained by a faster cofactor release as a direct 
consequence of the major weakening of a binary enzyme complex.[39] 
In summary, the performance characterization of purified wtCPCR2 and variants in Table 5 matches 
well with the results of crude cell lysates from screening of the SSM libraries. For instance CPCR2-
(L276Q) and CPCR2-(S275S, L276Q) exhibited highest activity in crude extracts as well as after 
purification. 
Stability of CPCR2 variants was evaluated by analysis of thermal inactivation (T50-value) and stability 
in the presence of a cyclohexane-buffer interface (half-life in h). Figure 6 depicts the stabilities 
determined for wtCPCR2 and variants. Thermal resistance is significantly improved for CPCR2-
(A275T) (ΔT50 = +2.6°C) and CPCR2-(A275S, L276Q) (ΔT50 = +5.2°C), whereas T50-values for all other 
variants are similar to the ones of wtCPCR2 (see also Table 5; error bars). Surprisingly the single 
substitution A275S does not provide an increased thermal resistance when compared to wtCPCR2. 
The substitution A275S is, however, found in the most stable variant (CPCR2-(A275S, L276Q)). 
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Figure 6 Thermal inactivation curves of purified wtCPCR2 and selected variants. The black horizontal dashed line 
indicates 50 % residual relative activity. 
Comparative analysis of the half-life indicates that thermal resistance and interfacial stability do not 
necessarily correlate as shown in Table 5. The double mutant CPCR2-(A275S, L276Q) showed as 
expected the highest thermal resistance and highest increased half-life (1.5-fold). CPCR2-(A275T) 
shows the second highest thermal resistance (ΔT50 = +2.6°C); however, the half-life is 20 % reduced 
when compared to wtCPCR2. 
Characterization of the CPCR2-(A275S) variant proves that a serine at position 275 is not improving 
thermal resistance or activity and would consequently not be identified as beneficial variant in the 
screening systems. Serine at position 275 is therefore only beneficial in combination with the 
substitutions to glutamine, methionine or arginine at position 276 (see Table 4).The double mutant 
CPCR2-(A275S, L276Q) was identified by dSSM showing a similar activity increase than the rationally 
designed variant CPCR2-N/Q but a significantly higher thermal resistance (CPCR2-(A275N, L276Q): 
ΔT50= +2.6°C, CPCR2-(A275S, L276Q): ΔT50 = +5.2°C). Thus, simultaneous site-saturation yielded a 
better performing CPCR2 variant. 
3.5.4.8 Computational Analysis of the Mutations 
Amino acid substitutions at positions 275 and 276 were analyzed in silico with FoldX to evaluate 
results obtained from screening experiments. For computational analysis, a previously generated 
dimeric homology model was used.[14b] Furthermore, the computational output was discussed in the 
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context of experimental results. Relations to protein structures from related ADHs were used to 
explain the observed increase in interfacial stability and activity. 
Fold-X analysis of beneficial positions 275 & 276 
FoldX analysis provides insights on stabilization energies (ΔΔG) of CPCR2 upon site-saturation 
mutagenesis at position 275 and/or 276 (see Supplementary Information Table S6). 
and Table S7, respectively). The highest stabilization energy was calculated for threonine at position 
275 (ΔΔG = -1.37 kJ mol-1), which could mainly be attributed to dimer stabilization (see 
Supplementary Information Table S6). CPCR2-(A275T) was as calculated by FoldX found to be the 
most stable variant also in screening 275-sSSM. The other stabilizing substitutions A275M 
(ΔG = -0.66 kJ mol-1) and A275C (ΔΔG = -0.56 kJ mol-1) did not show up within the micro titer plate 
screening experiments, probably due to reduced activity. The stable variant CPCR2-(A275N) (see 
Table 4), was calculated to have a slight destabilizing effect (ΔΔG = +0.07 kJ mol-1). Thus, both FoldX 
and experimental data demonstrates that position 275 is a hot spot for stabilization of CPCR2. 
FoldX analysis of position 276 showed that considerable stabilization could only be detected for 
CPCR2-(L276F) (ΔΔG = -0.54 kJ mol-1) and CPCR2-(L276M) (ΔΔG = -0.19 kJ mol-1) (see Supplementary 
Information Table S7). Most other amino acids at this position were considered to destabilize. FoldX 
calculation and experimental results are hence in good agreement (see Table 4). The stabilized 
variants CPCR2-(L276F) or CPCR2-(L276M) were; however, not identified in the screening. 
FoldX analysis calculated that the combination CPCR2-(A275T, L276M) would be the most stabilized 
one (see Table 6). Experimentally, the variant CPCR2-(A275T, L276M) scored second with respect to 
stability (see Table 4). The other double mutants were calculated to be or destabilized or slightly 
stabilized. 
Table 6 FoldX calculations of improved CPCR2 double mutants found by screening- 
Rank 
Mutation Mutation Average Complex stability 
Pos Ala 275 Pos Leu 276 ΔΔG (kcal mol
-1
) ΔΔG (kcal mol
-1
) 
1 Ser Gln 0.84 0.48 
2 Asn Gln -0.09 0.65 
3 Ser Met 0.58 -0.42 
4 Thr Asn 0.39 -0.22 
5 Ser Arg 2.52 1.35 
6 Thr Met -0.58 -1.51 
7 Asn Met 0.74 0.56 
 
Single substitutions calculated by FoldX analysis reflect well the results obtained for SSM and stability 
screening. Double substitutions were not reliably identified by computational analysis. The latter can 
Results & Discussion 
 
139 
 
partially be attributed to the fact that in FoldX calculations the backbone is not flexible and since 
both positions are neighboring each other it is likely that the backbone geometry was altered. 
In FoldX, also interaction energies of the dynamic monomer-dimer equilibrium were calculated 
(complex stability). This analysis showed that mutations at position 275 contribute to a stabilization 
of the dimeric state (see Table S6 and Table S7). 
3.5.4.9 Hypotheses of activating or stabilizing role of position 275 and 276 in CPCR2 
Impact of position 275 on dimer stabilization 
Amino acid 275 is located at the dimer interface of wtCPCR2 according to the homology model [14b], 
and FoldX analysis as well as experimental results from SSM identified CPCR2-(A275T) as most 
stabilizing substitution. Distinct energy contributions to overall stabilization derived from FoldX 
analysis indicated the formation of an inter-subunit hydrogen bond between the side chain of T275 
and the backbone of the second monomer A. 
 
 
Figure 7 Dimer interaction of CPCR2homology model (left) and the SsADH crystal structure (right). The A-chain of CPCR2 
is colored in green and the B-chain is shown in blue. Threonine (black ball and stick) at position 275 forms a hydrogen 
bond to the backbone oxygen of A-P259. The wtCPCR2 amino acid A275 is represented in blue ball and stick mode. Other 
interacting residues are depicted in lines. In SsADH, the chain of monomer A is colored in cyan and the monomer B is 
shown in purple. T285 forms a hydrogen bond with the backbone oxygen of A-M269 analogous to CPCR2-(A275T). 
Figure 7 shows the inter-subunit interactions of monomer B (blue) with monomer A (green) in the 
homodimericwtCPCR2 superimposed with CPCR2-(A275T). It is evident that the replacement to 
threonine at position 275 (black) leads to a hydrogen bond formation with the backbone oxygen of 
P259 in monomer A as acceptor (A-P275, distance 2.74 Å, see Figure 7, left). Alanine in wtCPCR2 (B-
A275) could not establish such a hydrogen bond. A corresponding hydrogen bond between B-T285 
and A-M269 is present in the crystal structure of the related SsADH (see Figure 7, right), which origins 
from a hyperthermophilic host.[40] SsADH is considerably more stable than wtCPCR2 (T50 = 95°C; 30 
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min).[39b] Notably, all stabilizing substitutions inCPCR2 double mutants at position 275 can serve as 
hydrogen bond donor namely serine, threonine and glutamine (see Table 4). The latter finding 
suggests that the formation of this inter-subunit hydrogen bond is a key to stabilize CPCR2 (see 
Figure 7) and can be found in thermostable zinc-containing dimeric ADHs like SsADH. 
Fostering of inter-subunit interactions can be responsible for the difference in stability of 
dehydrogenases. A comparison of an ADH from thermophilic Thermoanaerobacter brockii (TbADH) 
and an ADH from mesophilic Clostridium beijerinckii with 75 % sequence identity revealed that the 
structural determinants strengthening the interface of the subunits are mainly responsible for the 
higher thermostability of TbADH.[41] Assessment of crystal structures of four related malate 
dehydrogenases (MDH) with largely different thermal stabilities showed the importance of the 
subunit interfaces of the oligomers for stability.[42] Mutational analyses of the thermostable MDH 
from Chloroflexus aurantiacus again demonstrated how subunit interactions contribute to stability by 
introduction of an inter-dimer disulfide bond (ΔTm = +15°C) or removal of inter-dimer salt bridges 
(ΔTm = -26.8°C).
[43] Importance of the oligomeric state for stability of dehydrogenases was reported 
additionally for ADH from Clostridium beijerinckii [10], glucose-6-phosphate dehydrogenase from 
Aquifexaeolicus [44] and glucose dehydrogenase from Bacillus megaterium.[45] 
Role of Position 276 on CPCR2 Activity & Stability 
The amino acid position L276 in wtCPCR2 aligns with L286 in the structurally related SsADH. Together 
with T285, the amino acid L286 is positioned at the dimer interface and is located in a short helix (αF; 
280-288).[40, 46] The crystal structure of SsADH reveals that L286 has several inter-subunit interactions 
and constitutes a part of the substrate binding pocket of the monomer A.[40] The inter-subunit 
interactions within SsADH and CPCR2 differ significantly as residue B-L286 forms inter-subunit 
interactions with F49, L52 and L295 of monomer A in dimeric SsADH. The corresponding amino acid 
B-L276 in CPCR2 has only A-F285 (L295 in SsADH) as interaction partner as deduced from the dimeric 
homology model.[14b] Furthermore, L286 in SsADH was shown to have direct contact with C3 and C4 of 
the co-crystallized substrate ethoxyethanol so that similar interactions can be expected for CPCR2.[47] 
Results from 276-sSSM showed an increase in activity (up to twofold) without substantial 
stabilization or destabilization of CPCR2 (see Table 4). Increased activity was found by replacing the 
hydrophobic leucine with glutamine, arginine or lysine (L276Q, L276R and L276K) proving that a polar 
and charged nature is a prerequisite for improved activity. Consistently, FoldX analysis did not predict 
a stabilizing effect for three beneficial substitutions (see Supplementary Information Table S7). A role 
of position 276 in boosting activity has not been reported for ADHs until now. 
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Position 276 preserves this role in the most active double mutant CPCR2-(A275T, L276N) despite 
neighboring position T275, which governs thermal resistance of CPCR2. Notably for hydrolases 
activity and thermal resistance have been improved simultaneously in contrast to 
dehydrogenases.[48] Improving both properties simultaneously is on the molecular level challenging 
since high activity requires in general high flexibility and high thermal resistance requires strong 
interactions (rigidity).[49] A comparison of the sSSM of position 275, position 276 and dSSM yielded 
that best combination of the sSSM (A275T; L276Q) is quite similar to the best result of dSSM (CPCR2-
(A275S, L276Q)). In contrast to sSSM experiments, the simultaneous exchanges (A275N, L276Q), 
(A275S, L276M), (A275T, L276N) and (A275S, L276R) proved to be beneficial for activity and also 
stability (see Table 4). A more detailed analysis on intra- and intermolecular interactions affecting 
stability and activity require crystals of CPCR2 and the generated variants.  
To our best knowledge, there is only one report on improving activity by reengineering the subunit 
interface of ADHs. Plapp and co-workers constructed a variant of ADH from horse liver with three 
substitutions at the dimer interface, which activated the enzyme by allowing more rapid 
conformational changes that accompany coenzyme binding, probably due to movement of the loop 
containing the mutations.[50] 
3.5.5 Conclusion 
In essence, CPCR2was stabilized and activated by rational and semi-rational introduction of surface 
amino acid mutations. To our knowledge, the current report is the first one on activation of an ADH 
by mutagenesis of an inter-subunit residue which in contact or in close proximity to the substrate. 
The developed 96-well multi titer plate screening strategy can likely be used for other 
dehydrogenases to improve thermal resistance, catalytic activity and other properties. 
The amino acid positions A275 and L276 were identified as key residues for improving thermal 
resistance (A275) and activity (L276). Interestingly, the simultaneous saturation of the neighboring 
amino acid positions resulted in variants improved in thermal resistance as well as in activity. The 
best double mutant CPCR2-A275S/L276Q showed 1.4-fold higher activity, 1.5-fold increased half-life 
in aqueous-organic biphasic system and ΔT50 of +5.2°C. 
The inter-subunit interactions of position 275 proved to govern thermal resistance, which is likely a 
general option for increasing thermal resistance of ADHs with similar fold. In addition, the αF-helix 
(280-288 in SsADH) located at the dimer interface plays an important role for ADH activity in general 
and might represent a preferred reengineering target for improving kcat values of ADH. The semi-
rational engineering strategy and the developed screening strategy demonstrate that key 
performance parameter of CPCR2 can rapidly be improved to match application demands. 
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3.5.6 Supplementary Information 
Table S1 CPCR2 variants generated from selected surface amino acids 
No. Variant No. Variant 
1 CPCR2-(L24T, V26S) 7 CPCR2-(L222Q, I226K) 
2 CPCR2-(V26S) 8 CPCR2-(A275K, L276K) 
3 CPCR2-(V78S, I79T, V83S) 9 CPCR2-(A275K) 
4 CPCR2-(I79T, V83S) 10 CPCR2-(A275N, L276Q) 
5 CPCR2-(V78S, I79K, V83E) 11 CPCR2-(V307K, V308K) 
6 CPCR2-(L222R, I226K) 12 CPCR2-(V307N, V308N) 
 
Table S2 Primer sequences for site-directed mutagenesis of NhisCPCR2. 
Primer name 5´-3´sequence 
L24T,V26S_fwd AATTTGAGAAATGATACCCCTTCTCACAAGCCC 
L24T,V26S_rev GGGCTTGTGAGAAGGGGTATCATTTCTCAAATT 
V26S_fwd AATTTGAGAAATGATTTGCCTTCTCACAAGCCC 
V26S_rev GGGCTTGTGAGAAGGCAAATCATTTCTCAAATT 
V78S,I79T,V83S_fwd GGTGATGATTCTACCAACTACAAGTCTGGTGATCG 
V78S,I79T,V83S_rev CGATCACCAGACTTGTAGTTGGTAGAATCATCACC 
I79T,V83S_for GGTGATGATGTCACCAACTACAAGTCTGGTGATCG 
I79T,V83S_rev CGATCACCAGACTTGTAGTTGGTGACATCATCACC 
V78S,I79K,V83E_fwd GGTGATGATTCTAAAAACTACAAGGAAGGTGATCG 
V78S,I79K,V83E_rev CGATCACCTTCCTTGTAGTTTTTAGAATCATCACC 
L222Q,I226N_fwd GTTTATGAAACACAGCCAGAATCCAACTCTCCTGGC 
L222Q,I226N_rev GCCAGGAGAGTTGGATTCTGGCTGTGTTTCATAAAC 
A275K,L276K_fwd GGAGATTTGAAAAAAAGAGAAATTCGAATC 
A275K,L276K_rev GATTCGAATTTCTCTTTTTTTCAAATCTCC 
A275K_fwd_fwd GGAGATTTGAAATTGAGAGAAATTCGAATC 
A275K_fwd_rev GATTCGAATTTCTCTCAATTTCAAATCTCC 
A275N,L276Q_fwd GGAGATTTGAACCAGAGAGAAATTCGAATC 
A275N,L276Q_rev GATTCGAATTTCTCTCTGGTTCAAATCTCC 
V307K,V308K_fwd GAAGGTAAAGTTAAACCCAAAAAAAGAAGTGCC 
V307K,V308K_rev GGCACTTCTTTTTTTGGGTTTAACTTTACCTTC 
V307N,V308N_fwd AGTGAAGGTAAAAACAAACCCAACAACAGAAGTGCC 
V307N,V308N_rev GGCACTTCTGTTGTTGGGTTTGTTTTTACCTTCACT 
Nucleotides different from wild-type sequence are highlighted in bold. 
Table S3 Comparison of His-tagged CPCR2 and Strep-tagged CPCR2 
parameter His-tagged wtCPCR2 Strep-tagged wtCPCR2 
vmax [U/mg] 56.5 53.2 
KM 0.128 0.201 
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Table S4 Primers applied for site-saturation of CstrepCPCR2. 
Primer name 5´-3´sequence 
A275N_fwd CTGGGTGATCTGAATCTGCGTGAAATTCG 
A275N_rev CGAATTTCACGCAGATTCAGATCACCCAG 
A275S_fwd CTGGGTGATCTGTCGCTGCGTGAAATTCG 
A275S_rev CGAATTTCACGCAGCGACAGATCACCCAG 
L276Q_fwd GGTGATCTGGCACAGCGTGAAATTCG 
L276Q_rev CGAATTTCACGCTGTGCCAGATCACC 
A275-SSM_fwd GGTGATCTGGCANNScgtgaaattcg 
A275-SSM_rev CGAATTTCACGSNNTGCCAGATCACC 
L276-SSM_fwd CTGGGTGATCTGNNSCTGCGTGAAATTCG 
L276-SSM_rev CGAATTTCACGCAGSNNCAGATCACCCAG 
A275-L276 dSSM-for CTTTTAATCTGGGTGATCTGNNSNNSCGTGAAATTCGTATTC 
A275-L276 dSSM-rev GAATACGAATTTCACGSNNSNNCAGATCACCCAGATTAAAAG 
Nucleotides different from wild-type sequence are highlighted in bold. N stands for all four nucleotides and S 
stands for G and C. 
Figure S 1 Protein sequence alignment of pdb entries most related to CPCR2. Upper digits refers to CPCR2 numbering, 
lower digits refer to automatic numbering created by alignment. 
 
               10        20        30        40        50        60 
CPCR2 MSIPSSQYGFVFNKQSGLNLRNDLPVHKPKAGQLLLKVDAVGLCHSDLHVIYEG------ 
1R37  ------MRAVRLVEIGKPLSLQEIGVPKPKGPQVLIKVEAAGVCHSDVHMRQGRFGNLRI 
2EER  ------MRAMRLVEIGKPLKLEDIPIPKPKGSQVLIKIEAAGVCHSDVHMRQGR-GNLRI 
1RJW  ------MKAAVVEQFKEPLKIKEVEKPTISYGEVLVRIKACGVCHTDLHAAHGDPVK--- 
2XAA  ------MKAVQYTEIGSEPVVVDIPTPTPGPGEILLKVTAAGLCHSDIFVMDMPAAQ--- 
         24 26 
               70        80        90       100       110       120 
CPCR2 ---LDCGDNYVMGHEIAGTVAAVGDDVINYKVGDRVACVGPN-GCGGCKYCRGAIDNVCK 
1R37  VEDLGVKLPVTLGHEIAGKIEEVGDEVVGYSKGDLVAVNPWQ-GEGNCYYCRIGEEHLCD 
2EER  VEDLGVKLPVTLGHEIAGRIEEVGDEV--YSKGDLVAVNPWE-GEGNCYYCRIGEEHLCD 
1RJW  -----PKLPLIPGHEGVGIVEEVGPGVTHLKVGDRVGIPWLYSACGHCDYCLSGQETLCE 
2XAA  ---YAYGLPLTLGHEGVGTVAELGEGVTGFGVGDAVAVYGPW-GCGACHACARGRENYCT 
     78,79  83 
              130       140       150       160       170       180 
CPCR2 NAFGDWFG---LGYDGGYQQYLLVTR---PRNLSRIPDNVSADVAAASTDAVLTPYHAIK 
1R37  SPR--WLGI-N--FDGAYAEYVIVPH---YKYMYKLRR-LNAVEAAPLTCSGITTYRAVR 
2EER  SPR--WLGI-N--YDGAYAEYVLVPH---YKYLYKLRR-LSAVEAAPLTCSGVTTYRAVR 
1RJW  HQKN--AG---YSVDGGYAEYCRAAADYVVKIPDNLS----FEEAAPIFCAGVTTYKALK 
2XAA  RAADLGITPPGLGSPGSMAEYMIVDS---ARHLVPIGD-LDPVAAAPLTDAGLTPYHAIS 
 
              190       200       210       220       230       240 
CPCR2 --MAQVS-PTSNILLIG-AGGLGGNAIQVAKAFG-AKVTVLDKKKEARDQAKKLGADAVY 
1R37  KAS--LDPTKT-LLVVGAGGGLGTMAVQIAKAVSGATIIGVDVREEAVEAAKRAGADYVI 
2EER  KAS--LDPSKT-LVVIGAGGGLGTMAIQIAKAVSGATIIGVDVREEALEAAKRAGADYVI 
1RJW  VTG--AK-PGEWVAIYG-IGGLGHVAVQYAKAMGL-NVVAVDIGDEKLELAKELGADLVV 
2XAA  RVLPLLG-PGSTAVVIG-VGGLGHVGIQILRAVSAARVIAVDLDDDRLALAREVGADAAV 
 
              250       260       270       280       290       300 
CPCR2 ET----------LPESISPGSFSACFDFVSVQATFDVCQKYVEPKGVIMPVGLGAPNLSF 
1R37  NASM-QD-PLAEIRRITESKGVDAVIDLNNSEKTLSVYPKALAKQGKYVMVGLFGADLHY 
2EER  NASS-QD-PVSEIRRITQGKGADAVIDLNNSEKTLSIYPYVLAKQGKYVMVGLFGADLKY 
1RJW  NPLKED---AAKFMKEKVGG-VHAAVVTAVSKPAFQSAYNSIRRGGACVLVGLPP-EEMP 
2XAA  KSGAGAA---DAIRELTGGQGATAVFDFVGAQSTIDTAQQVVAVDGHISVVGIHAGAHAK 
    222 226 
              310       320       330       340       350       360 
CPCR2 N-LGDLALREIRILGSFWGTTNDLDDVLKLVSEGKVKPVVRSAKL-KELPEYIEKLRNNA 
1R37  H-APLITLSEIQFVGSLVGNQSDFLGIMRLAEAGKVKPMITKTMKLEEANEAIDNLENFK 
2EER  H-APLITLNEVQFIGSLVGNQSDFLGIMSLAEAGKVKPMVTKTMKLEEANEAIDNLENFK 
1RJW  IPIFDTVLNGIKIIGSIVGTRKDLQEALQFAAEGKVKTIIEVQPL-EKINEVFDRMLKGQ 
2XAA  V-GFFMIPFGASVVTPYWGTRSELMEVVALARAGRLDIHTETFTL-DEGPAAYRRLREGS 
          275,276       307,308 
                370  
CPCR2 YE-GRVVFNP--- CR Candida parapsilosis         336aa 
1R37  AI-GRQVLIP--- ADH Sulfolobus solfataricus     345aa (34% seqID) 
2EER  AV-GRQVLVP--- ADH Sulfolobus tokodaii         347aa (35% seqID) 
1RJW  IN-GRVVLTLEDK ADH Bacillus stearothermophilus 339aa (33% seqID) 
2XAA  IR-GRGVVVP--- ADH-A Rhodococcus ruber         345aa (35% seqID) 
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Table S5 Number of clones and completeness of each library (NNS-codon degeneracy and Pc= 95% 
[41]
). 
Library Number of clones Completeness [%] 
275 SSM 172 99.7 
276 SSM 172 99.7 
275/276 dSSM 747 73.2 
 
 
 
Figure S2 Relative activity of wtCPCR2 cell-free lysate after incubation with different detergents below and above the 
critical micelle concentration (cmc). 
Table S6 Energies calculated by FoldX for in silico saturation of position 275 in CPCR2. 
 
 
Suppl e  
Entry 
Mutation 
Average 
complex 
stability 
Corrected 
 average 
Pos 275 
ddG 
(kcal/mol) 
ddG 
(kcal/mol) 
ddG  
(kcal/mol) 
1 275THR -0.61 -1.37 -1.37 
2 275MET -0.52 -1.06 -0.66 
3 275CYS -0.2 -0.56 -0.56 
4 275SER 0.7 -0.05 -0.05 
wt 5 275ALA 0 0 0 
6 275ASN -0.07 0.07 0.07 
7 275VAL 0.23 0.13 0.13 
8 275LYS 0.88 -0.01 0.48 
9 275GLY 0.79 0.5 0.5 
10 275ARG 0.98 0.74 0.74 
11 275GLN 2.02 0.69 0.95 
12 275LEU 1.09 0.03 1.73 
13 275ASP 2.54 2.02 2.02 
14 275GLU 4.22 2.78 2.78 
15 275PHE 2.95 2.12 3.1 
16 275HIS 3.86 2.75 3.28 
17 275ILE 3.26 1.6 3.96 
18 275TYR 4.56 3.68 5.08 
19 275PRO 5.9 1.58 6.01 
20 275TRP 9.82 5.18 9.87 
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Table S7 Energies calculated by FoldX for in silico saturation of position 276 in CPCR2. 
Entry 
Mutation Average 
complex  
stability 
Corrected  
average 
Pos 276 
ddG 
(kcal/mol) 
ddG 
(kcal/mol) 
ddG  
(kcal/mol) 
1 276PHE -0.31 -0.54 -0.54 
2 276MET -0.02 -0.19 -0.19 
3 276ILE 0.11 -0.06 -0.06 
wt 4 276LEU -0.01 -0.03 -0.03 
5 276TYR 0.73 0.09 0.34 
6 276ASN 0.72 0.51 0.51 
7 276GLN 0.47 0.62 0.62 
8 276VAL 1 0.66 0.66 
9 276THR 1.06 0.91 0.91 
10 276HIS 1.79 1.21 1.21 
11 276ARG 1.53 1.3 1.3 
12 276LYS 2 1.43 1.43 
13 276TRP 1.72 0.28 1.44 
14 276ALA 1.39 1.44 1.44 
15 276CYS 1.85 1.45 1.45 
16 276SER 1.89 1.54 1.54 
17 276GLU 2.02 2.08 2.08 
18 276ASP 2.36 2.36 2.36 
19 276GLY 2.84 2.67 2.67 
20 276PRO 1.53 1.32 3.07 
 
This chapter was reproduced from the publication “Design of an Activity and Stability Improved 
Carbonyl Reductase from Candida parapsilosis” Jakoblinnert, A.; van den Wittenboer, A.; Shivange, A. 
V.; Bocola, M.; Heffele, L.; Ansorge-Schumacher, M. B.*; Schwaneberg, U.* Journal of Biotechnology, 
165: 52-62, 2013 with permission from Elsevier 
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4. Conclusion 
The European Union commission has identified Industrial Biotechnology as one of the five key 
enabling technologies for the EU according to the recent report “Preparing for our future: Developing 
a common strategy for key enabling technologies in the EU”, Brussels, 30.09.2009. Based on this 
evaluation, the importance of research in the field of Industrial or White Biotechnology for the 
society becomes evident. In the development towards a greener industry, biocatalysis plays a vital 
role in order to replace old-fashioned chemical processes by more sustainable and cost-efficient ones 
exploiting the synthetic potential of Nature. 
Recent progress in genome sequencing, gene synthesis, bioinformatics as well as metabolic and 
protein engineering are truly revolutionary and will fuel the translation of science and technology 
into standard industrial practice. However, further efforts have to be made to switch to a bio-based 
economy. One way to foster this constitutes the smart integration of biocatalytic steps in complex 
synthesis routes by reaction designs, which are compatible with the existing processes. Herein, the 
aqueous environment, often vital for biocatalytic transformations, comprises several drawbacks and 
biocatalysis in non-aqueous system sis demanded. Another approach is to tailor the biocatalyst to 
match the performance parameters rendering a process economically feasible. Protein engineering is 
the most appropriate tool to achieve this goal and this technology will constantly augment our basic 
understanding how biocatalysts function on the molecular level.  
In this thesis, the carbonyl reductases from the yeast Candida parapsilosis (CPCRs) present the 
central theme. To make this biocatalyst more attractive for industrial application, the paths of 
reaction engineering as well as protein engineering were followed resulting in the development of a 
novel concept for the manufacture of chiral alcohols and a substantial improvement of CPCR catalytic 
properties. 
In the age of rapid DNA sequencing, where massive accumulation of sequence information 
overwhelms the processing and storing of this data, the link between the actual biological function 
and the DNA sequence becomes even more indispensable. One contribution to achieve this is 
presented in this work, where the ketone reducing activity of Candida parapsilosis could be allocated 
to two distinct isoenzymes, now termed CPCR1 and CPCR2. The two enzymes were made 
recombinant by classical biochemical methods; additionally homology models were generated and 
tested for an array of indicator substrates using advanced methods of computational chemistry. By 
testing the elaborate hypothesis in the lab, the allocation of a small substrate scope to CPCR1 and a 
larger substrate scope to CPCR2 was possible. CPCR1 was characterized biochemically for the first 
time and the sequence, connected to its function, is now freely accessible in the GeneBank data base 
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(accession number: JQ659192.1). This interdisciplinary approach constitutes a fast and efficient 
methodology to differentiate between two isoenzymes. In future, this might contribute improving 
the investigation sequence-function relationships in similar systems. 
Biocatalysis is generally carried out in dilute aqueous media as Nature evolved microorganisms and 
enzymes to optimally function in hydrous environments. However, chemists perform reactions 
almost exclusively in organic solvents instead of water due to practical reasons like high substrate 
solubility, easy evaporation and reduction of side-reactions. The pioneering work of Klibanov in the 
1980s; however, demonstrated that biocatalysts can also work in pure organic solvents. Whereas 
much attention was drawn to investigate the phenomena like activity, selectivity and stability of 
isolated enzymes in this non-natural environment, whole cells as biocatalysts were almost neglected. 
Nevertheless, whole cells comprise significant advantages as cofactors are intrinsically provided and 
recycled, enzymes are protected and cells are cheap to produce; but the perception that whole cells 
categorically need water to perform biocatalysis prevented extensive research on their catalytic 
potential in pure organic media. 
In this thesis, recombinant CPCR2 was employed in E. coli whole cells for asymmetric reduction of 
ketones to produce chiral alcohols. This is particularly beneficial since the enzyme must not be 
purified and the cofactor NADH, needed in stoichiometric amounts, is provided by the cell and 
efficiently recycled. The new aspect, presented here, is the operation of this whole cell biocatalyst in 
a system composed of neat organic substrates (isopropanol and acetophenone) and lacking any bulk 
water or other organic solvent. It was rather unexpected that virtually dry cells perform efficiently 
the stereoselective reduction of acetophenone in isopropanol, which acts as cosubstrate for cofactor 
recycling. As a main trigger for biocatalytic activity, water activity of the organic medium and the 
catalyst was identified and full conversion could be obtained by removal of the co-product acetone. 
To this end, up to 500 g L-1 enantiopure alcohol (ee >99 %) could be produced applying this system 
rendering the concept competitive to other processes for chiral alcohol production. However, 
reaction times of two weeks are much too long for an industrial application. Since the 
thermodynamic equilibrium impedes the reaction rather than the biocatalyst activity or stability, the 
reaction times might by shortened by smart reaction engineering promoting in situ (co-) product 
removal for fast and complete conversion.  
The system was expanded to two more ketone reducing enzymes, namely alcohol dehydrogenases 
from Rhodococcus erythropolis (ReADH) and Lactobacillus brevis (LbADH), wherein ReADH exhibts 
Prelog´s specificity and depends on NADH like CPCR2 but is more thermostable. LbADH has opposite 
stereoselectivity and depends on NADPH unlike CPCR2 and ReADH. Gratifyingly, both enzymes 
performed well as whole cell catalysts in the neat substrate system with analogous dependence on 
water activity like CPCR2. This finding implies that the concept may be transferred to even more 
Conclusion 
150 
 
alcohol dehydrogenases, which are recombinantly available. Furthermore, an array of structurally 
diverse ketones was reduced to the corresponding alcohols by all three catalysts mostly at ee >98 %. 
This suggests that the substrate scope of the enzymes reported for aqueous systems can be fully 
exploited also in neat substrates. Nevertheless, selectivity for small ketones was only moderate 
leaving room for optimization for instance by adaption of reaction parameters. 
As factors hampering initial reaction rates, mass transfer across the cell membrane as well as 
cofactor availability were identified. Herein, twofold rate acceleration was achieved by cell 
permeabilization and addition of NADH resulted in 2.7-fold increased reaction rate. From these 
findings, it may be inferred that the performance of the whole cell catalysts can be substantially 
elevated by proper pre-treatment. However, since whole cells comprise a complex system the 
underlying molecular reasons for the observed effects are only accessible indirectly making it difficult 
to rationalize the optimization approaches. Former experiments performed in neat substrates, 
showed that the catalyst was extremely stable under process conditions. This was verified by 
repeated batch operation and cell recycling, wherein biocatalytic performance was nearly unchanged 
within five batches. The striking process stability renders the neat substrate system suitable for 
continuous operation mode and thus broadens its applicability. 
As presented in this thesis, it was possible to produce (S)-alcohols by application of CPCR2 or ReADH 
and the (R)-alcohols with LbADH by reduction of ketones. To complete the synthetic toolbox, 
asymmetric oxidation (racemate resolution) is missing, where one of the enantiomers is oxidized to 
the ketone leaving the other enantiomer behind. This was achieved by simply exchanging 
isopropanol by acetone and driving the reaction towards oxidation. However, the yield of a racemate 
resolution is limited to 50 % as only one enantiomer takes part in the reaction. To overcome this 
limitation, CPCR2 was operated in oxidation mode to produce the ketone from the unwanted (S)-
alcohol; and after this, LbADH was utilized in reduction mode to yield up to 100 % (R)-alcohol. As a 
consequence of the sequential use of oxidation and reduction exploiting the stereocomplementary 
of the enzymes, quantitative conversion (96.1 %) at high enantioselectivity (ee = 96.5 % R) was 
achieved. This demonstrates the compatibility and especially the flexibility of the neat substrate 
system with respect to the reaction direction, tunable by the cosubstrate, and stereoselectivity, 
adjustable by the choice of catalyst. 
The neat substrate system, developed in this thesis, is very much competitive with existing processes 
with regard to substrate load (500 g L-1), selectivity (ee >99 %), sustainability and cost-effectiveness. 
Product work-up is very straightforward since cells can be filtered off and co-products are easily 
removed by evaporation. A key feature constitutes also the tool-box character of the reaction 
system, wherein the starting material and the stereospecific outcome are freely selectable. Certainly, 
the prolonged reaction time is in the focus of optimization and full conversion within one day is 
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envisaged. Strikingly, inhibition phenomena, due to the exceedingly high substrate and product 
concentrations, could not be observed so far. For industrial application of this system in production 
plants, regulations for genetically modified microorganisms (GMO), as used here, may inhibit the fast 
translation into practice. Hence, also non-GMOs might be tested in the neat substrates to circumvent 
this obstacle. 
Protein engineering is a powerful tool to make enzymes fit for applications in industrial processes. 
The carbonyl reductase CPCR2 is already an attractive enzyme for organic synthesis due to its broad 
substrate scope and high stereoselectivity; however, some ketones are only poorly accepted and 
stability in biphasic systems is particularly low. Therefore, two semi-rational approaches were 
undertaken, one to broaden the substrate scope of CPCR2 and the second to make the enzyme more 
stable and resistant in the presence of water-organic interfaces. 
In this thesis, the recombinant CPCR2 was subjected to saturation mutagenesis and screening for the 
first time. To achieve this, a protein expression procedure and activity-based screening strategy were 
successfully developed for microtiter plates. Saturation of five single amino acid positions, located in 
the substrate binding pocket (55, 92, 118, 119 & 262), and screening with 14 poorly converted 
substrates led to one CPCR2 variant with altered substrate acceptance. A CPCR2 variant (CPCR2-
L119M) with the rare substitution from leucine to methionine at position 119 exhibited more than 7-
fold improved turn over with 2-methyl cyclohexanone in comparison to wild type CPCR2, whereas 
selectivity was not altered significantly. Relative to other alcohol dehydrogenases from literature, 
CPCR2-L119M showed superior activity for this substrate. Sequencing of active clones of the other 
four positions revealed only little flexibility with respect to alternative amino acids. In a screening 
with well-accepted substrates the only improved variants were found at position 55 (L55F, L55W); 
whereas the other positions (92, 118, 119 & 262) seem to be strongly conserved. 
CPCR2-L119M was tested for acceptance of substrates with similar structure like cyclohexanone as 
wells as 3- methyl and 4-methyl cyclohexanone. The relative activity profile was similar to that of the 
wild type, but absolute activity was substantially improved for CPCR2-L119M but decreased for 
acetophenone. This indicates that the adaption of the enzyme towards the flexible cyclohexanone 
ring plays the most important role for the alteration of the substrate scope. Molecular modeling of 
2-methyl cyclohexanone into the substrate binding pocket of the wild type and the variant showed a 
steric constraint of the substrate molecule and the branched leucine in the wild type enzyme. This 
constraint was not observed in CPCR2-L119M as the side chain is more flexible allowing a proper 
positioning of the substrate for catalysis. The flexibility of the side chain is mostly likely responsible 
for the difference in acceptance of cyclohexanone moieties. 
To explain the differences in acceptance of all the cyclohexanone isomers and, in particular, the 
selectivity of CPCR2 for these substrates, a more sophisticated computational approach including 
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extensive molecular dynamics calculations has to be carried out. Crystallization of CPCR2 is currently 
attempted and may provide a high resolution crystal structure making more accurate modeling 
possible. On the basis of this, further campaigns to enlarge the substrate spectrum of CPCR2 
targeting new amino acid positions may be undertaken. The selectivity of the wild type CPCR2 as well 
as of the variant with 2-methyl cyclohexanone as substrate are very low (ee <16 % 1-R & de <55 % 
trans) and needs to be improved. 
CPCR2 was also mutated on the surface to achieve stabilization at water-organic interfaces. Rational 
selection and mutagenesis of several surface exposed amino acids led to the variant CPCR2-(A275N, 
L276Q), which was improved in stability and also unexpectedly in activity. Usually, activity and 
stability display antagonists in protein engineering since mutations with higher activity are thought to 
enhance protein flexibility, whereas stabilizing mutations are believed to make the protein more 
rigid. However, the two adjacent amino acid positions were found to act cooperatively, wherein 
position 275 promotes stability and position 276 has an activating effect on CPCR2. 
Single and double site saturation of these positions confirmed this initial finding and lead to the 
identification of a superior double variant CPCR2-(A275S, L276Q), which appeared from screening at 
elevated temperatures and in the presence of SDS. A more stable single variant was identified 
(CPCR2-A275T) as well as a variant with twofold improved activity (CPCR2-L276Q). Moreover, the 
general assumption that thermo- and solvent stability are positively correlated was confirmed for 
CPCR2 by testing the thermostable variants in a cyclohexane-buffer system.  
Investigations on the structural level exhibit that the two mutations are located at the dimer 
interface and close to the active site, wherein position 275 is in hydrogen bonding distance to the 
other monomer and the amino acid at position 276 has direct contact with the substrate. Thus the 
structural model intuitively explains the effect of the substitutions. In silico site saturation and 
stability assessment using FoldX supported the experimental results as CPCR-A275T was identified as 
the most stable variant forming a hydrogen bond with the other monomer. All other amino acids 
found in stabilized variants are hydrogen bond donors as well; thus the inter-subunit hydrogen bond 
can be regarded as the general stabilizing interaction in CPCR2 variants. 
The two positions 275 and 276 located at the dimer interface were never targeted by protein 
engineering in other alcohol dehydrogenases of this class but clearly constitute interesting spots for 
deeper investigation. For instance, further stabilization might be achieved by introduction of a salt 
bridge or targeting adjacent amino acids. Similar to other reports, this study shows that enhancing 
the interactions of the monomers promotes enzyme stability. In particular, stabilization of CPCR2 was 
achieved together with simultaneous activation. 
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For this reason, the impact of position 276 on CPCR2 activation might be examined more closely by 
QM/MM simulations of the protein-ligand complex. Here, arginine, lysine and methionine were 
found to promote activity but the underlying mechanism for activation is still unclear. To get a 
glimpse on the importance of this position 276 in catalysis, the effect on substrate scope and 
selectivity of CPCR2 variants might be tested in future.  
 
The successful development of the “neat substrate system” for the manufacture of molar amounts of 
chiral alcohols, which is flexible with respect to the catalyst, the substrates, the stereoselectivity and 
the starting material, is one main outcome of this thesis. Surprisingly, the biocatalyst exhibits very 
high stereoselectivity and stability in pure substrate, which is most important for translation of this 
concept into industrial application. On the first glance, the high stability of the CPCR2 catalyst in the 
“neat substrate system” seems to make the development of a more stable CPCR2 for operation in 
organic media obsolete. But, so far, high stereoselectivity for 2-butanol could only be achieved with 
pure enzyme. Thus, a CPCR2 enzyme variant stable in biphasic reactor systems is still valuable. 
Protein engineering, as a second main result, was demonstrated to be applicable to CPCR2 and 
substantial improvements with respect to enlargement of the substrate scope and enzyme stability 
were achieved. Ultimately, in this thesis several successful approaches to enlarge the tool box of 
chiral alcohols accessible by asymmetric ketone reduction with CPCR2 were demonstrated and may 
lead to the development of sustainable industrial biocatalytic processes in the future. 
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5 Appendix 
5.1 List of Abbreviations 
Abbreviation Meaning 
A alanine 
A adenine nucleotide base 
Å Ångström 
ADH alcohol dehydrogenase 
ADPR adenosine diphosphoribose 
Ala alanine 
AMP adenosine mono phosphate 
Amp/amp Ampicillin 
APS ammonium persulfate 
Arg arginine 
Asn asparagine 
aw water activity 
BLAST basic local alignment search tool 
C cysteine 
C cytosine nucleotide base 
C. Candida 
CAST combinatorial active site design 
CCTCC China Center for Type Culture Collection 
CHAPS 3-[(3-Cholramidopropyl)dimethyl-ammonio]-1-propanesulfonate  
Cl chlor 
cmc critical micelle concnetration 
CO2 carbon dioxide 
CPCR Candida parapsilosis carbonyl reductase 
CpSADH carbonyl reductase secondary alcohol dehydrogenase 
CR carbonyl reductase 
CTAB cetyl trimethyl ammonium bromide 
Cys cysteine 
D aspartic acid 
d day 
DCM dichloro methane 
DMSO dimethylsulfoxide 
DNA desoxyribonucleic acid 
dNTP deoxyribonucleotide 
DSM Dutch State Mining 
DSMZ Deutsche Sammlung von Mikroorganismen und Zellkulturen 
dSSM double site saturation mutatgenesis 
DTT dithiothreitol 
E glutamic acid 
E Escherichia 
E. coli Escherichia coli 
EC Enzyme Comission 
EDTA ethyl diamin tretraacetic acid 
ee enantiomeric excess 
epPCR error prone polymerase chain reaction 
F phenylalanine 
FACS fluorescence activated cell sorting 
FDA Food and Drug Association 
FDH formate dehydrogenase 
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Abbreviation Meaning 
Fig Figure 
FPLC fast protein liquid chromatography 
G guanine nucleotide base 
G glycine 
GC gas chromatography 
Gln glutamine 
Glu glutamic acid 
GLUE-IT GLUE including translation 
Gly glycine 
H histidine 
h hour 
His histidine 
HLADH horse liver alcohol dehydrogenase 
HTS high throughput screening 
I isoleucine 
Ile isoleucine 
IPTG isopropyl β-D-1-thiogalactopyranoside 
K lysine 
kb kilobases 
kcat turnover number of an enzyme, first-order rate constant 
kDa kilodalton 
Km affinity constant in Michaelis Menten kinetics 
L leucine 
lac lactose 
LB lysogeny broth 
LbADH Lactobacuillus brevis alcohol dehydrogenase 
LDR long chain dehydrogenase/reductase 
Leu leucine 
LPS lipopolysaccharide 
Lys lysine 
M methionine 
MCS multiple cloning site 
MDR medium-chain dehydrogenases/reductases 
Met methionine 
min minute 
MTBE methyl-tert. butyl ether 
MTP microtiterplate 
N asparagine 
Na sodium 
NAD
+
 nicotinamide adenine dinucleotide, oxidized 
NADH nicotinamide adenine dinucleotide, reduced 
NADPH nicotinamide adenine dinucleotide phosphate 
NDT degenerated nucelotide triplet 
nm nanometer 
NNK degenerated nucelotide triplet 
NNN degenerated nucelotide triplet 
NNS degenerated nucelotide triplet 
OD optical density 
opt optimum 
orf open reading frame 
P proline 
PAGE polyachrylamide gel electrophoresis 
PCR polymerase chain reaction 
PDB/pdb protein data bank 
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Abbreviation Meaning 
PF protein family 
Phe phenylalanine 
Pi inorganic phosphate 
PMSF phenylmethansulfonylfluorid  
Pro proline 
ProSAR Protein Sequence Activity Relationships 
PSI position-specific iterated 
PSSM position-specific scoring matrix 
Q glutamine 
R arginine 
ReADH Rhodococcus erythropolis alcohol dehydrogenase 
RNA ribonucleic acid 
S serine 
SBP substrate binding pocket 
SDM site-directed mutagenesis 
SDR short chain dehydrogenase/reductase 
SDS sodium dodecyl sulfate 
Ser Serine 
SeSaM Sequence Saturation Mutagenesis  
SOC super optimal broth 
sp. species 
SsADH Sulfolobus solfataricusalcohol dehydrogenase 
SSM site saturation mutatgenesis 
StEP staggered extension process 
Strep streptavidin 
T threonine 
T thymine nulceotide base 
Tab Table 
TAE Tris base-acetic acid-EDTA 
TB terrific broth 
TbADH Thermoanaerobacter brockii alcohol dehydrogenase 
TEA triethanolamine 
TEMED N, N, N', N'-tetramethylethylenediamine 
temp temperature 
TeSADH Thermoanaerobacter ethanolicus secondary alcohol dehydrogenase 
TEV tobacco etch virus 
Tris Tris(hydroxymethyl)-aminomethan 
tRNA transfer ribonucleic acid 
Trp tryptophane 
Tyr tyrosine 
U unit 
UV Ultraviolett 
V valine 
Val valine 
W tryptophane 
WT/wt wild type 
X random amino acid 
Y tyrosine 
YADH1 yeast alcohol dehydrogenase 1 
YT yeast extract tryptone 
Z zinc 
Zn zinc 
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